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A B S T R A C T
Background
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide, yet ASCVD risk factor control
and secondary prevention rates remain low. A fixed-dose combination of blood pressure- and cholesterol-lowering and antiplatelet
treatments into a single pill, or polypill, has been proposed as one strategy to reduce the global burden of ASCVD.
Objectives
To determine the effect of fixed-dose combination therapy on all-cause mortality, fatal and non-fatal ASCVD events, and adverse
events. We also sought to determine the effect of fixed-dose combination therapy on blood pressure, lipids, adherence, discontinuation
rates, health-related quality of life, and costs.
Search methods
We updated our previous searches in September 2016 of CENTRAL, MEDLINE, Embase, ISI Web of Science, and DARE, HTA,
and HEED. We also searched two clinical trials registers in September 2016. We used no language restrictions.
Selection criteria
We included randomised controlled trials of a fixed-dose combination therapy including at least one blood pressure-lowering and one
lipid-lowering component versus usual care, placebo, or an active drug comparator for any treatment duration in adults 18 years old
or older, with no restrictions on presence or absence of pre-existing ASCVD.
Data collection and analysis
Three review authors independently selected studies for inclusion and extracted the data for this update. We evaluated risk of bias
using the Cochrane ’Risk of bias’ assessment tool. We calculated risk ratios (RR) for dichotomous data and mean differences (MD) for
continuous data with 95% confidence intervals (CI) using fixed-effect models when heterogeneity was low (I2 < 50%) and random-
effects models when heterogeneity was high (I2 ≥ 50%). We used the GRADE approach to evaluate the quality of evidence.
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Main results
In the initial review, we identified nine randomised controlled trials with a total of 7047 participants and four additional trials (n =
2012 participants; mean age range 62 to 63 years; 30% to 37% women) were included in this update. Eight of the 13 trials evaluated
the effects of fixed-dose combination (FDC) therapy in populations without prevalent ASCVD, and the median follow-up ranged from
six weeks to 23 months. More recent trials were generally larger with longer follow-up and lower risk of bias. The main risk of bias
was related to lack of blinding of participants and personnel, which was inherent to the intervention. Compared with the comparator
groups (placebo, usual care, or active drug comparator), the effects of the fixed-dose combination treatment on mortality (FDC = 1.0%
versus control = 1.0%, RR 1.10, 95% CI 0.64 to 1.89, I2 = 0%, 5 studies, N = 5300) and fatal and non-fatal ASCVD events (FDC =
4.7% versus control = 3.7%, RR 1.26, 95% CI 0.95 to 1.66, I2 = 0%, 6 studies, N = 4517) were uncertain (low-quality evidence). The
low event rates for these outcomes and indirectness of evidence for comparing fixed-dose combination to usual care versus individual
drugs suggest that these results should be viewed with caution. Adverse events were common in both the intervention (32%) and
comparator (27%) groups, with participants randomised to fixed-dose combination therapy being 16% (RR 1.16, 95% CI 1.09 to
1.25, 11 studies, 6906 participants, moderate-quality evidence) more likely to report an adverse event . The mean differences in systolic
blood pressure between the intervention and control arms was -6.34 mmHg (95% CI -9.03 to -3.64, 13 trials, 7638 participants,
moderate-quality evidence). The mean differences (95% CI) in total and LDL cholesterol between the intervention and control arms
were -0.61 mmol/L (95% CI -0.88 to -0.35, 11 trials, 6565 participants, low-quality evidence) and -0.70 mmol/L (95% CI -0.98
to -0.41, 12 trials, 7153 participants, moderate-quality evidence), respectively. There was a high degree of statistical heterogeneity in
comparisons of blood pressure and lipids (I2 ≥ 80% for all) that could not be explained, so these results should be viewed with caution.
Fixed-dose combination therapy improved adherence to a multidrug strategy by 44% (26% to 65%) compared with usual care (4 trials,
3835 participants, moderate-quality evidence).
Authors’ conclusions
The effects of fixed-dose combination therapy on all-cause mortality or ASCVD events are uncertain. A limited number of trials
reported these outcomes, and the included trials were primarily designed to observe changes in ASCVD risk factor levels rather than
clinical events, which may partially explain the observed differences in risk factors that were not translated into differences in clinical
outcomes among the included trials. Fixed-dose combination therapy is associated with modest increases in adverse events compared
with placebo, active comparator, or usual care but may be associated with improved adherence to a multidrug regimen. Ongoing, longer-
term trials of fixed-dose combination therapy will help demonstrate whether short-term changes in risk factors might be maintained
and lead to expected differences in clinical events based on these changes.
P L A I N L A N G U A G E S U M M A R Y
Fixed-dose combination drug therapy for the prevention of heart disease and stroke
Review question:We reviewed the evidence about the effect of fixed-dose combination drug therapy on the prevention of heart attacks
and strokes. We found 13 studies including 9059 participants.
Background:We wanted to discover whether using fixed-dose combination therapy was better or worse than other alternatives, such
as usual care, placebo, or giving drugs separately, for the prevention of heart attacks and strokes. This report represents an update from
a previous review published in 2014.
Study characteristics: The evidence is current to September 2016. Four studies included individuals with a prior heart attack or stroke
or with a high predicted risk for having an initial heart attack and five studies had long-term (12 months or more) follow-up. The
main risk of bias was related to lack of blinding of participants and personnel, which was inherent to the intervention. Most study
participants were middle-aged men with moderate elevations in blood pressure or cholesterol. Two studies specifically included ethnic
Aboriginal or Maori minorities in half of the study participants. The fixed-dose combinations ranged from two to five drugs; all studies
included at least one blood pressure-lowering and one cholesterol-lowering drug.
Key results: The effects of fixed-dose combination drug therapy on all-cause mortality and fatal and non-fatal heart attacks and strokes
are uncertain, primarily due to the low number of participants experiencing these events in these studies (fewer than 5% for both) and
comparisons with usual care (low-quality evidence). Fixed-dose combination drug therapy leads to more adverse events than control
(32% versus 27%), including placebo (moderate-quality evidence). This information is not surprising since aspirin, blood pressure-
lowering drugs and cholesterol drugs are known to increase the risk for side effects compared with placebo. Fixed-dose combination
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therapy may modestly lower blood pressure (~6 mmHg) and cholesterol (-0.6 mmol/L in LDL cholesterol), but these effects were not
consistent (moderate-quality evidence for blood pressure and LDL cholesterol but low-quality evidence of total cholesterol). Fixed-
dose combination therapy appears to improve adherence to medications to prevent ASCVD (moderate-quality evidence).
Quality of the evidence: The quality of evidence from these studies generally ranged from moderate to low. Ongoing trials of fixed-
dose combination drug therapy will likely inform clinical endpoints to guide decision-making.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases (ASCVD)
Patient or population: adults older than 18 years, with no restrict ion regarding presence of ASCVD; part icipants generally had elevated risk of ASCVD (as est imated by the
presence of at least one abnormal cardiovascular risk factor) without prevalent CVD (two studies included > 10% of part icipants with prior ASCVD)
Settings: outpat ient
Intervention: f ixed-dose combinat ion therapy of varying drug combinat ions ranging f rom two to f ive drugs
Comparison: usual care, placebo, or act ive drug therapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk based on
event rates or mean
changes from base-
line in the comparator
group
Corresponding risk
Comparator group, in-
cluding placebo, usual
care, or active drug
comparator
Fixed-dose combina-
tion therapy
All- cause mortality
Median follow-up
range: 9 to 23 months
Total RR = 1.10
(0.64 to 1.89)
5300
(5 studies)
⊕⊕©©
Lowa,b
Low event rates among
trials that were not de-
signed nor powered to
detect dif f erences in
clinical outcomes. Four
of the f ive trials in-
cluded had high-quality
usual care as the com-
parator group
10 per 1000 11 per 1000
(6 to 19)
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ASCVD event, such as
fatal or non-fatal my-
ocardial infarct ion or
stroke
Median follow-
up range: 8 weeks to 23
months
Total RR = 1.26 (0.95 to 1.66) 4517
(6 studies)
⊕⊕©©
Lowa,b
Low event rates among
trials that were not de-
signed nor powered to
detect dif f erences in
clinical outcomes. Four
of the f ive trials in-
cluded had high-quality
usual care as the com-
parator group
37 per 1000 46 per 1000
(35 to 61)
Any investigator-de-
fined adverse event
Median follow-
up range: 6 weeks to 23
months
271 per 1000 314 per 1000
(295 to 339)
RR = 1.16
(1.09 to 1.25)
6906
(11 studies
⊕⊕⊕©
M oderatec
We would expect the
rate of adverse events
to be higher with f ixed-
dose combinat ion com-
pared with placebo, and
the dif ference between
f ixed-dose combinat ion
and usual care depends
on what care is pro-
vided
Systolic blood pres-
sure,
mmHg
Median follow-
up range: 6 weeks to 12
months
The mean change in
systolic blood pressure
ranged across con-
trol groups f rom -17.9
mmHg to 0.9 mmHg
The mean dif ference
in change in sys-
tolic blood pressure be-
tween the intervent ion
and comparator groups
was -6.34 mmHg (95%
CI -9.03 to -3.64)
7638
(13 studies)
⊕⊕⊕©
M oderated
Total cholesterol,
mmol/ L
Median follow-
up range: 6 weeks to 23
months
The mean change in to-
tal cholesterol ranged
across control groups
f rom -1.6 mmol/ L to 0.
2 mmol/ L
The mean dif ference in
change in total choles-
terol between the inter-
vent ion and compara-
tor groups was -0.61
mmol/ L (-0.88 to -0.35)
6565
(11 studies)
⊕⊕©©
Lowd,e
5
F
ix
e
d
-d
o
se
c
o
m
b
in
a
tio
n
th
e
ra
p
y
fo
r
th
e
p
re
v
e
n
tio
n
o
f
a
th
e
ro
sc
le
ro
tic
c
a
rd
io
v
a
sc
u
la
r
d
ise
a
se
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
LDL cholesterol,
mmol/ L
Median follow-
up range: 6 weeks to 23
months
The mean change in
LDL cholesterol ranged
across control groups
f rom
-1.4 mmol/ L to 0.1
mmol/ L
The mean dif ference in
change in LDL choles-
terol between the inter-
vent ion and compara-
tor groups was
-0.70 mmol/ L (95% CI -
0.98 to -0.41)
7153
(12 studies)
⊕⊕⊕©
M oderated
Adherence,
variable definitions
Median follow-up
range: 9 to 23 months
534 per 1000 769 per 1000
(673 to 882)
RR = 1.44 (1.26 to 1.65) 3835
(4 studies)
⊕⊕⊕©
M oderateb
All four trials included
had high-quality com-
parator care as the
comparator group ei-
ther as usual care or
provision of individual
drug components
* The basis for the assumed risk (e.g. the median control group risk across studies) is the outcomes of the study control arms. The corresponding risk (and its 95% conf idence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
ASCVD = atherosclerot ic cardiovascular disease; CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aDowngraded by one level due to imprecision due to low event rates.
bDowngraded one level due to indirectness of evidence, including high quality ’usual care’ as comparator group in four of f ive
trials study lim itat ions, which may not be comparable to sett ings where f ixed-dose combinat ion therapy might be deployed,
including low- and middle-income country sett ings with low treatment rates.
cDowngraded one level due to indirectness of evidence, including dif ferent comparators that could be usual care, placebo, or
act ive comparator.
dDowngraded one level due to heterogeneity likely due to dif ferent part icipants, f ixed-dose combinat ions, and comparator
groups.
eDowngraded one level due to report ing bias demonstrated through funnel plot asymmetry.
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B A C K G R O U N D
Description of the condition
Atherosclerotic cardiovascular disease (ASCVD) is a principal
cause of death worldwide. In 2013, more than 17 million deaths
globally were attributed to ASCVD, over 80% of which occurred
in low- and middle-income countries (Roth 2015). Furthermore,
the situation is not expected to improve, with global ASCVD
mortality estimated to increase, largely because of population
growth and aging (Roth 2015). These trends are largely driven by
atherosclerotic cardiovascular diseases, principally ischaemic heart
disease and cerebrovascular disease. Therefore, preventing deaths
and disease due to ASCVD is a priority for global public health
(WHO 2013).
Optimising modifiable risk factors reduces long-term ASCVD
mortality and morbidity (Berry 2012). Individuals with both hy-
pertension and dyslipidaemia have a greater risk of ASCVD than
those with either hypertension or dyslipidaemia alone (Neaton
1992; Thomas 2002), highlighting the importance of considering
overall ASCVD risk as opposed to individual risk factors (Perk
2012). Therefore, adopting a multifactorial approach to ASCVD
risk management, where multiple risk factors are modified simul-
taneously, is a more effective way of reducing ASCVD events than
focusing on single risk factors in isolation (Gaede 2003).
Current national and international approaches to ASCVD pre-
vention incorporate both primary and secondary prevention (Perk
2012; NICE 2010). Primary prevention aims to prevent ASCVD
events in those who have no clinical evidence of ASCVD who
are considered to be at elevated risk for an ASCVD event. To
achieve this, guidelines recommend intervening usually when five-
or 10-year predicted risk levels exceed thresholds where bene-
fits outweigh risks (NICE 2008; NICE 2010; Perk 2012; Stone
2013). ASCVD incidence and mortality are reduced by antihy-
pertensives (Collins 1990) and statins, which improve the lipid
profile (Taylor 2013). Secondary prevention requires blood pres-
sure control, cholesterol lowering, and use of antiplatelet drugs to
prevent further ASCVD events, which is known to be effective
(ATT-Collaboration 2002; Baigent 2005; Karmali 2016; Rashid
2003).
The same ASCVD risk factors operate globally (O’Donnell 2010;
Yusuf 2004) making multifactorial prevention strategies relevant,
but conventional approaches targeting high risk individuals, con-
ducting investigations, prescribing various medications, regular
monitoring, and drug dose titration to optimise ASCVD risk fac-
tors are difficult to implement. In fact, access, availability, and ad-
herence to medications for the prevention and control of ASCVD
are generally low (Yusuf 2011). In response to this treatment gap,
the World Health Organization has set an 80% availability tar-
get for essential medicines in public and private pharmacies for
the prevention and control of ASCVD and other noncommuni-
cable diseases and a 50% treatment target for eligible individuals
to reduce the risk of premature mortality from noncommunicable
disease by 25% by 2025 (WHO 2013). In collaboration with the
Centers for Disease Control and Prevention, World Heart Feder-
ation, and other organisations, the World Health Organization’s
Global Hearts technical package has also recommended fixed-dose
combination therapy for improving adherence to multidrug ther-
apy (WHO 2016).
Description of the intervention
A fixed-dose combination pill was proposed in 2001 by a World
Health Organization (WHO) and Wellcome Trust expert group
(WHO 2001) and was subsequently specified as a combination of
four drugs (beta-blocker, angiotensin-converting enzyme (ACE)-
inhibitor, aspirin, and statin), which was estimated to reduce AS-
CVD events by 75% in people with clinical evidence of ASCVD
(Yusuf 2002). This concept was followed in 2003 by a proposed
Polypill® (a combination of folic acid, aspirin, three low-dose an-
tihypertensives, and a low-dose statin), which was intended for
both secondary prevention and primary prevention in all people
aged 55 years and over andwas estimated to reduce ASCVDevents
by about 80% (Wald 2003). More contemporary evidence has in-
dicated that the effects of fixed-dose combination treatment may
be less than was initially proposed, but that this strategy may im-
prove the blood pressure and lipid profile to near expected levels
(PILL-collaborative 2011; TIPS 2009). The controversial aspect
of the polypill was that it was intended to be used at a popula-
tion level without screening of blood cholesterol or blood pressure
(Wald 2011) because an age threshold of 55 years and above would
be used to determine eligibility for treatment (Lonn 2010; Wald
2003).
While aspirin is indicated for secondary prevention of ASCVD
(Baigent 2009), the use of aspirin for primary prevention of AS-
CVD is generally indicated when the absolute risk of cardio-
vascular disease outweighs the risk of severe bleeding (Karmali
2016). Also, doubt exists regarding folic acid since recent large
randomised trials have indicated no ASCVD benefit (Armitage
2010; Holmes 2011). On the other hand, statins and antihyper-
tensives as single treatments are known to be relatively safe and in-
dividually beneficial in terms of reducing ASCVDrisk and thereby
cardiovascular events for both secondary prevention and primary
prevention (ALLHAT-investigators 2002; Colhoun 2004; CTT
2012; HPSCG 2002; Julius 2004; Kearney 2008; LaRosa 2005;
Ostergren 2008; Papademetriou 2003; Sever 2003; Taylor 2013;
Turnbull 2003). Therefore, although uncertainty exists regarding
possible components, the consensus is that the minimal fixed-
dose combination for primary and secondary ASCVD prevention
should include at least one antihypertensive and one statin.
There is widespread evidence regarding the efficacy and safety of
antihypertensives and statins when administered concomitantly
(Messerli 2006; Preston 2007), and of multiple antihypertensives
when administered as a single tablet (Bangalore 2007; Gupta
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2010). Clinicians may be wary of combination therapy due to the
potential restrictions on individualised management (Viera 2011);
that is, the ability to amend standard therapy because of medi-
cal history or adverse events, such as avoiding a beta-blocker in a
person with asthma or changing from an ACE-inhibitor due to
cough, and because of the inability to titrate each drug prescribed
according to clinical response (Lonn 2010). It is also unclear if
there are unique adverse events associated with fixed-dose combi-
nation therapy beyond the individual components.
How the intervention might work
The effectiveness of the drugs comprising a fixed-dose combina-
tion is generally well understood, and the principles behind using
pharmacotherapy at a population level are that the drugs them-
selves are inexpensive, simple to administer for easier clinical de-
cision making, might not require a medically trained practitioner,
and may provide a more effective option than the promotion of
lifestyle changes formultiple risk factor control. Yet convincing ev-
idence of the benefits of such interventions has not been achieved
(Beaglehole 2011; Ebrahim 2011; Lonn 2010). Although modi-
fying national health policy has been successful in some high-in-
come countries, such as in Scandinavia (Vartiainen 2010), popula-
tion-level pharmacotherapy can be politically challenging in both
high- and low- to middle-income countries (Lonn 2010; Yusuf
2011) and may not meet with patient approval. However, patient
adherence to the fixed-dose combination therapy is expected to
be better than with multiple tablets, but it has been argued that
they will likely have a greater potential for adverse effects than be-
havioural or lifestyle changes and that a purely biological approach
is too narrow to allow the social, economic, and behavioural com-
plexities of ASCVD prevention to be appreciated and confronted
(Franco 2004).
However, fixed-dose combination therapy still has several un-
knowns. These include (i) the best constituents, whether two or
three or four or five drugs are required; (ii) evidence of safety, ef-
fectiveness, and cost-effectiveness; and (iii) whether increasing the
number of constituents will produce a favourable risk-benefit pro-
file. In particular, the evidence is limited concerning benefits and
risks of fixed-dose combination therapy for primary prevention in
those people with low or intermediate ASCVD risk (event rates at
or below 1% per year).
Why it is important to do this review
Various fixed-dose combination pills are now beingmanufactured,
and there is evidence that physicians are aware of this option and
are potentially willing to prescribe it, though perhaps not without
some reservations (Viera 2011). There is an emerging literature of
randomised controlled trials comparing fixed-dose combination
therapy with placebo or standard practice in both the primary and
secondary prevention of ASCVD, as well as in assessing safety and
tolerability (de Cates 2014; Elley 2012). Since the publication of
these reviews (de Cates 2014; Elley 2012), additional fixed-dose
combination trial data have been published, which provide the ra-
tionale for this update. Also, in 2016, the Sixth Joint Task Force of
the European Society of Cardiology andOther Societies identified
fixed-dose combination therapy as a IIb, level of evidence B rec-
ommendation for improving adherence in the European Guide-
lines on Cardiovascular Disease Prevention in Clinical Practice
(ESC 2016), and the World Health Organization has identified
fixed-dose combination therapy as a strategy to improve adherence
(WHO 2016).
O B J E C T I V E S
To determine the effect of fixed-dose combination therapy on all-
cause mortality, fatal and non-fatal ASCVD events, and adverse
events. We also sought to determine the effect of fixed-dose com-
bination therapy on blood pressure, lipids, adherence, discontin-
uation rates, health-related quality of life, and costs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCT).
Types of participants
Adults 18 years and older with no restriction regarding presence
of ASCVD.
Types of interventions
A fixed-dose combination therapy, a combination of several active
components into a single pill with the aim being to optimise AS-
CVD risk and reduce ASCVD fatal and non-fatal events. At least
one statin and one antihypertensive agent should be included. We
examined different combinations and doses in stratified analyses,
where possible.
Trials were considered where the comparison group was usual care,
placebo, or an active drug comparator.
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Types of outcome measures
Primary outcomes
• Clinical outcomes including mortality (cardiovascular and
all-cause); non-fatal ASCVD endpoints such as myocardial
infarction, coronary artery bypass grafting (CABG),
percutaneous transluminal coronary angioplasty (PTCA), angina
or angiographically-defined ischaemic heart disease, stroke,
transient ischaemic attack (TIA), carotid endarterectomy, or
peripheral arterial disease (PAD). The previous version of the
review included the broader outcome of CVD, but we have
narrowed this definition for this update to include only ASCVD.
• Investigator-defined adverse events including the
proportion of participants experiencing specific symptoms
including: myalgias, cough, elevated liver enzymes, gastric
irritation or dyspepsia.
Secondary outcomes
• Systolic and diastolic blood pressure
• Total and LDL cholesterol
• Adherence
• Discontinuation rates
• Health-related quality of life, measured according to any
well validated and adjusted scale concerning quality of life
• Costs of fixed-dose combination therapy
Search methods for identification of studies
Electronic searches
We searched the following electronic databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL, Issue 8, 2016) in the Cochrane Library;
• MEDLINE (Ovid) (1946 to 19 September 2016);
• Embase (Ovid) (1980 to Week 38, September 2016);
• ISI Web of Science (1970 to 19 September 2016);
• Database of Abstracts of Reviews of Effects (DARE),
Health Technology Assessment Database (HTA), and Health
Economics Evaluations Database (HEED) in the Cochrane
Library (2016, Issue 8).
The searches were limited to records published since 2000. The
fixed-dose combination therapy was conceptualised in 2001, so
relevant trials will only appear after this date. The searches were
initially run in January 2012 (Appendix 1) and updated in July
2013 (Appendix 2), January 2015, February 2016, and September
2016 (Appendix 3).We used the Cochrane sensitivity-maximising
RCT filter (Lefebvre 2011) for MEDLINE and adaptations of it
were used for Embase and Web of Science.
Searching other resources
We searched the metaRegister of
controlled trials (mRCT) (www.controlled-trials.com/mrct), clin-
icaltrials.gov (www.clinicaltrials.gov), and the World Health Or-
ganization (WHO) International Clinical Trials Registry Platform
(ICTRP) (apps.who.int/trialsearch/) for ongoing trials on 24 De-
cember 2011 and the latter two registers on 27 September 2016
for this update to review existing ongoing studies that had been
identified and to find any recent registrations. In addition, we
checked reference lists of reviews and retrieved articles for addi-
tional studies and performed citation searches on key articles. We
contacted experts in the field for unpublished and ongoing trials
and study authors where necessary for additional information.
Data collection and analysis
Selection of studies
From the searches, three review authors (EB, MP, MH) reviewed
the title and abstract of each paper for this update and retrieved
potentially relevant references. Following this initial screening, we
obtained the full-text reports of potentially relevant studies, and
three authors (EB, MP, MH) independently selected studies to be
included in the review using predetermined inclusion criteria. In
all cases we resolved disagreements about any study inclusions by
consensus.
Data extraction and management
Two review authors (EB,MH) independently extracted data using
a proforma, and contacted principal investigators to provide addi-
tional relevant informationwhere necessary. EB andMHextracted
details of the study design, participant characteristics, study set-
ting, intervention and comparator, and outcome data including
details of outcome assessment, adverse effects, and methodologi-
cal quality (randomisation, blinding, attrition) from each of the
included studies. We resolved disagreements about extracted data
by consensus.
Assessment of risk of bias in included studies
We assessed risk of bias according to the Cochrane ’Risk of bias’
assessment tool, including examining the quality of the random
sequence generation and allocation concealment, description of
dropouts and withdrawals (including intention-to-treat analysis),
blinding (participants, personnel, and outcome assessment), and
selective outcome reporting (Higgins 2011a). For cluster-ran-
domised trials, we have followed the Cochrane Handbook for Sys-
tematic Reviews of Interventions’ recommendations for assessing
risk of bias, with particular attention across the domains of: re-
cruitment; baseline imbalances; loss of clusters; incorrect analyses;
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and comparability with individually randomised trials (Higgins
2011b). Two review authors (EB,MH) independently assessed the
risk of bias in the included studies.
One author (MDH) evaluated the quality of evidence using the
GRADE approach for this update using the checklist outlined by
Meader 2014. We have reported the rationale for downgrading
the quality of evidence for each of our included outcomes: im-
precision due to low event rates; indirectness of evidence; includ-
ing high quality ’usual care’ as comparator group, which may not
be comparable to settings where fixed-dose combination therapy
might be deployed (including low- and middle-income country
settings with low treatment rates), as well as different comparators
that could be usual care, placebo or active comparator. Additional
reasons for downgrading the overall quality of evidence include
heterogeneity likely due to different participants, fixed-dose com-
binations, and comparator groups and reporting bias. We have
reported the absolute and relative effects, quality of evidence, and
specific reason(s) applied for downgrading the overall quality of
evidence for each listed outcome in our Summary of findings for
the main comparison.
Measures of treatment effect
We processed data in accordance with the Cochrane Handbook
for Systematic Reviews of Interventions (Deeks 2011). We expressed
dichotomous outcomes as risk ratios (RR), and calculated 95%
confidence intervals (CI) for each study. For continuous variables,
we compared net changes (that is intervention group minus con-
trol group differences) and calculated mean difference (MD) and
95% CI for each study. For TIPS 2009, we compared the effects
of fixed-dose combination therapy on mean (standard deviation
(SD)) levels of blood pressure and cholesterol against the study
arms without active components as reported by the study authors.
Where SDs were not reported in the outcomes of interest (TIPS
2009), we used baseline SDs per Elley 2012 and Furukawa 2006.
Unit of analysis issues
One trial was a cross-over trial (Wald 2012), and the fixed-dose
combination was unlikely to have a cross-over effect on the mea-
sured risk factors. Thus, we analysed the treatment effect as a par-
allel-group trial (Deeks 2011). No trials were cluster-randomised
trials.
Dealing with missing data
We sought missing data from investigators to obtain key informa-
tion or missing numerical outcome data where possible. We ob-
tained updated data from two trials (Malekzadeh 2010; Soliman
2009) in the initial version of this review and none for this update.
We investigated attrition rates, losses to follow-up, withdrawals,
and critically appraised methods for handling missing data and
imputation methods. If SDs for outcomes were not reported and
were not provided by study authors, then we imputed these values
from data within the trial using methods outlined in the Cochrane
Handbook for Systematic Reviews of Interventions, Chapter 16.1.3
(Higgins 2011b).
Assessment of heterogeneity
For each outcome, we carried out tests of heterogeneity using the
Chi2 test of heterogeneity and the I2 statistic (Higgins 2003).
Where no or minimal heterogeneity was present, we performed
fixed-effect model meta-analyses. Where substantial heterogene-
ity was detected (I2 ≥ 50%), we evaluated the results for possi-
ble explanations (for example participants and interventions) and
performed random-effects model meta-analyses with cautious in-
terpretation.
Assessment of reporting biases
We evaluated reporting bias by creating funnel plots for outcomes
with at least 10 trials to evaluate for asymmetry which could rep-
resent true heterogeneity, poor methodological design leading to
small study bias, publication bias or a combination thereof.
Data synthesis
We synthesised our results through fixed-effect or random-effects
meta-analyses based on heterogeneity identified for each outcome.
We have reported RRs or MDs with corresponding 95% CIs.
To evaluate the quality of evidence for each outcome, we used
the GRADE approach (GRADE 2013) and the ’Checklist to aid
consistency and reproducibility of GRADE assessments’ (Meader
2014) for these assessments, which we included in the ’Summary
of findings’ table.
Subgroup analysis and investigation of heterogeneity
If there were sufficient studies, we aimed to conduct the following
subgroup analyses.
• Age
• Sex
• Primary prevention (populations where 10% or less had
pre-existing ASCVD) versus secondary prevention (population
where > 10% had pre-existing ASCVD)
• Two-drug versus three-drug or more fixed-dose
combination therapies
• Comparator group as usual care versus placebo or inactive
control
Data were available to perform subgroup analyses on the latter
three analyses.
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Sensitivity analysis
We performed sensitivity analyses by excluding studies at high risk
of bias. We created funnel plots and performed tests of asymmetry
(Egger 1997) according to the available outcomes of systolic blood
pressure and total cholesterol to assess possible publication bias
through funnel plot asymmetry.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies; Characteristics of
studies awaiting classification.
Results of the search
We have presented the PRISMA flowchart in Figure 1 (Moher
2009). The 2014 review included 14 reports of nine trials
(CRUCIAL 2011; CUSP 2009; Malekzadeh 2010; PILL 2011;
Soliman 2009; TIPS 2009; TOGETHER 2010; UMPIRE 2013;
Wald 2012). Our updated search identified 5629 reports, and we
identified five reports through handsearching and 16 trials through
trials register searches. After de-duplication, we screened 4376
records and excluded 4236 records based on review of the title
or abstract. After full-text review of the remaining 140 reports,
we excluded 96 records and included 22 reports of eight trials.
This included eight additional reports of four trials included in
the 2014 systematic review and 14 reports of four new trials.
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Figure 1. Flow diagram
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Overall, we have included 36 reports of 13 trials in this
update (CRUCIAL 2011; CUSP 2009; FOCUS 2014;
IMPACT 2014; Kanyini GAP 2014; Malekzadeh 2010;
OLSTA 2016; PILL 2011; Soliman 2009; TIPS 2009;
TOGETHER 2010; UMPIRE 2013; Wald 2012), as well
as 10 reports of six ongoing trials (NCT01826019;
INTEGRATE; PolyIran; NCT02278471; NCT02596126;
NCT01646437) and 12 reports of 12 trials awaiting clas-
sification (Fommei 2015; NCT00530946; NCT01004705;
NCT01005290; NCT01362218; NCT01406431;
NCT01764178; NCT02075619; NCT02569814;
NCT02662894; NCT02791958; NCT02842359).
Included studies
Details of the methods, participants, intervention, comparison
group andoutcomemeasures for each of the studies included in the
review are shown in the Characteristics of included studies table.
We included nine trials with 7047 participants randomised in the
initial review, with four additional trials (FOCUS 2014; IMPACT
2014;KanyiniGAP2014;OLSTA2016; n=2012participants) in
this update. The six largest trials (CRUCIAL 2011; FOCUS2014;
IMPACT 2014; Kanyini GAP 2014; TIPS 2009; UMPIRE 2013)
randomized 7349 (81%) of all participants. The duration of the
intervention and follow-up periods was generally short-term (six
weeks in one study (TOGETHER 2010), eight weeks in two stud-
ies (CUSP 2009, OLSTA 2016), 12 weeks in four studies (PILL
2011; Soliman 2009; TIPS 2009; Wald 2012)) or medium-term
(nine months in one study (FOCUS 2014)); however, five studies
had amedian follow-up period of 12 months or more (CRUCIAL
2011; IMPACT 2014; Kanyini GAP 2014; Malekzadeh 2010;
UMPIRE 2013). All trials reported changes in blood pressure
and cholesterol, whereas mortality was only reported in five trials
(CRUCIAL 2011; FOCUS 2014; IMPACT 2014; Kanyini GAP
2014; UMPIRE 2013). Five trials (CRUCIAL 2011; IMPACT
2014; Kanyini GAP 2014; Soliman 2009; UMPIRE 2013) com-
pared fixed-dose combination therapy against usual care, whereas
the other trials compared combination therapy against either ac-
tive control or placebo. One trial (TIPS 2009) included nine arms
with different drug combinations, which led to restricting our
analyses to comparisons between fixed-dose combination therapy
and groups without either blood pressure- or cholesterol-lowering
drugs (depending upon the analysis) and lowered the sample sizes
in these analyses.
The included studies frequently had complex inclusion and exclu-
sion criteria that were generally based upon freedom from prior
cardiovascular disease, an age threshold ranging from older than
21 years to older than 55 years in women, a composite measure of
short-term (10-year) risk (5-year predicted Framingham ASCVD
risk≥ 7.5% in PILL 2011), or one to three elevated cardiovascular
disease risk factors. FOCUS 2014, IMPACT 2014, Kanyini GAP
2014 and UMPIRE 2013 specifically enrolled participants with
established ASCVD or an elevated risk of ASCVD (≥ 15% pre-
dicted risk over five years), while CRUCIAL 2011 included more
than 18% of participants with peripheral artery disease (PAD) and
more than 14% with prior transient ischaemic attack (TIA) or
stroke. The participants were generally middle-aged with a mean
(SD) age ranging from 52.6 (9.6) years (CUSP 2009) to 63.7
(12.7) years (Kanyini GAP 2014). The majority of trials enrolled
predominantly men, with two trials randomising more than 80%
men (PILL 2011; UMPIRE 2013) compared with one trial that
enrolled only 27% men (Soliman 2009). Two trials enrolled 50%
ethnic Aboriginal/Torres Strait Islander (Kanyini GAP 2014) or
Maori (IMPACT 2014) individuals by design. Baseline systolic
blood pressure ranged from 125 mmHg to 166 mmHg, and base-
line total cholesterol ranged from 4.2 mmol/L to 6.1 mmol/L.
The drugs included in the various fixed-dose combination pills
varied (Table 1), with four studies including twodrugs (CRUCIAL
2011;CUSP2009;OLSTA2016;TOGETHER2010), one study
including three drugs (FOCUS 2014), seven studies including
four drugs (IMPACT 2014; Kanyini GAP 2014; Malekzadeh
2010; PILL 2011; Soliman 2009; UMPIRE 2013; Wald 2012),
and one study including five drugs (TIPS 2009). Eight studies
included aspirin (FOCUS 2014; IMPACT 2014; Kanyini GAP
2014; Malekzadeh 2010; PILL 2011; Soliman 2009; TIPS 2009;
UMPIRE 2013), and blood pressure- and cholesterol-lowering
drugs were included, by definition, in all 13 studies. The blood
pressure components included either a calcium channel blocker,
thiazide diuretic, beta-blocker, ACE-inhibitor, or angiotensin re-
ceptor blocker (ARB), or a combination thereof. In terms of
lipid-lowering drugs, simvastatin was used in eight trials (FOCUS
2014; IMPACT 2014; Kanyini GAP 2014; PILL 2011; Soliman
2009; TIPS 2009; UMPIRE 2013; Wald 2012), atorvastatin was
used in four trials (CRUCIAL 2011; CUSP 2009; Malekzadeh
2010; TOGETHER 2010), and rosuvastatin was used in one trial
(OLSTA 2016).
Excluded studies
Details and reasons for exclusion for the studies that underwent
full-text review are presented in the Characteristics of excluded
studies table. The majority of excluded studies were not RCTs.
Risk of bias in included studies
Details are provided for each of the included studies in the risk of
bias tables in Characteristics of included studies and in Figure 2
and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
Allocation
The methods of random sequence generation or allocation con-
cealment were unclear in four of the included studies (CRUCIAL
2011; CUSP 2009;Malekzadeh 2010; Soliman 2009). In the nine
studies where randomisation and allocation concealment were
clear, we judged the methods used to have a low risk of bias
(FOCUS 2014; IMPACT 2014; Kanyini GAP 2014; OLSTA
2016; PILL 2011; TIPS 2009; TOGETHER 2010; UMPIRE
2013; Wald 2012).
Blinding
Five of the 13 included studies had a high risk for performance bias
because the comparator group was usual care (CRUCIAL 2011;
IMPACT 2014; Kanyini GAP 2014; Soliman 2009; UMPIRE
2013). However, three of these studies included blinded outcome
assessment (IMPACT 2014; Kanyini GAP 2014; UMPIRE 2013)
andhad low risk of detectionbias except for self-reported outcomes
(e.g. self-reported adherence). One trial did not report whether or
not the outcome assessment committee was blinded for adjudicat-
ing clinical events (FOCUS 2014), but the participants and per-
sonnel were not blinded to group allocation. The remaining seven
trials stated that they were double-blinded (participants and study
personnel, including outcome assessors, were blinded to treatment
allocation) and were regarded as having low risk of bias in this
domain.
Incomplete outcome data
Most studies reported losses to follow-up, but there were gener-
ally minimal differences in the proportion of losses to follow-up
between the intervention and control arms. Four studies had a
high risk of attrition bias (CRUCIAL 2011; Malekzadeh 2010;
OLSTA 2016; TOGETHER 2010), including use of last observa-
tion carried forward for missing continuous variables. Four stud-
ies had an unclear risk of attrition bias (CUSP 2009; FOCUS
2014; Soliman 2009; TIPS 2009), and five studies had low risk of
attrition bias (IMPACT 2014; Kanyini GAP 2014; PILL 2011;
UMPIRE 2013; Wald 2012).
Selective reporting
The risk of bias associated with selective reporting was low
in eight studies (CUSP 2009; IMPACT 2014; Kanyini GAP
2014; Malekzadeh 2010; PILL 2011; Soliman 2009; TIPS 2009;
UMPIRE 2013), unclear in four studies (CRUCIAL 2011;
FOCUS 2014; TOGETHER 2010; Wald 2012), and high in one
study (OLSTA 2016).
Other potential sources of bias
Malekzadeh 2010 used a run-in period to exclude potential partic-
ipants who had adherence rates less than 70%. In Soliman 2009,
participants had varying degrees of background blood pressure and
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lipid-lowering therapies between groups. In other cases there was
insufficient information to judge the risk of bias in other sources of
bias not covered above, and we categorised them all as unclear. In
UMPIRE 2013, participants randomised to the intervention arm
received fixed-dose combination therapy at no cost compared with
participants randomised to usual care who were responsible for
their drug costs, which may have led to increased adherence in the
intervention arm. In FOCUS 2014, the threshold of adherence
using the Morisky-Green Questionnaire was changed from 16 or
more to 20 during the study, which has uncertain effects on this
outcome. OLSTA 2016 was funded, executed, and monitored by
the manufacturing company of the fixed-dose combination that
was studied.
Effects of interventions
See: Summary of findings for the main comparison Fixed-
dose combination therapy for the prevention of atherosclerotic
cardiovascular diseases (ASCVD)
Primary outcomes
All-cause mortality
Five secondary prevention trials, including 5300 participants, re-
ported all-cause mortality rates at the end of the study period with
median follow-up ranging from9 to 23months (CRUCIAL 2011;
FOCUS 2014; IMPACT 2014; Kanyini GAP 2014; UMPIRE
2013). Mortality rates were low in both groups (1% in the inter-
vention group compared with 1% in the comparator group; only
53 total deaths), and participants randomised to the intervention
had no evidence of increased mortality compared with the com-
parator group (RR 1.10, 95% CI 0.64 to 1.89, I2 = 0%, Analysis
1.1) in the context of relatively few events. There were no differ-
ences among subgroups related to type of comparator (Analysis
1.2; Analysis 1.3) or number of drugs in the intervention (Analysis
1.4; Analysis 1.5).
Major ASCVD events
Only six out of 13 studies, including 4517 participants, reported
rates of ASCVD events (FOCUS 2014; IMPACT 2014; Kanyini
GAP 2014; Malekzadeh 2010; OLSTA 2016; UMPIRE 2013).
ASCVD events were uncommon in both groups (4.7% rate in
the intervention group compared with 3.7% in the comparator
group; only 188 total ASCVD events), resulting in uncertainty
of the effect of fixed-dose combination therapy on this outcome
(RR 1.26, 95% CI 0.95 to 1.66, I2 = 0%, Analysis 1.6). This
uncertainty remained when evaluating subgroups of primary or
secondary prevention trials (Analysis 1.7; Analysis 1.8), type of
comparator (Analysis 1.9; Analysis 1.10), or number of drugs in
the intervention (Analysis 1.11; Analysis 1.12).
Adverse events
We included 11 trials including 6906 participants reporting aggre-
gated rates of adverse events in both groups in the meta-analysis.
The risk for adverse events was higher in participants in the inter-
vention arm compared with participants in the control arm (32%
versus 27%, RR 1.16, 95% CI 1.09 to 1.25, I2 = 0%, Analysis
2.1). There was a trend toward higher rate of adverse events in
primary prevention trials (RR 1.37, 95%CI 1.17 to 1.60, Analysis
2.2) compared with secondary prevention trials (RR 1.11, 95%
CI 1.03 to 1.20, Analysis 2.3) but there were no differences among
other subgroups. Specific side effects that were evaluated included
myalgias (8 studies, 4% versus 3%, RR 1.11, 95% CI 0.84 to
1.48, Analysis 2.8), increased liver enzymes (4 studies, 7% versus
6%, RR 1.04, 95% CI 0.74 to 1.47, I2 = 0%, Analysis 2.9), cough
(5 studies, 5% versus 3%, RR 1.86, 95% CI 0.75 to 4.59, I2 =
76%, Analysis 2.10), gastric irritation and dyspepsia (4 studies,
3% versus 2%, RR 1.33, 95% CI 0.64 to 2.74, I2 = 67%, Analysis
2.11), and bleeding (2 studies, 2% versus 0.2%, RR 5.68, 95%
CI 1.01 to 32.03, I2 = 0%, Analysis 2.12).
Secondary outcomes
Blood pressure
All 13 trials reported changes in systolic and diastolic blood pres-
sure in 7638 participants. There was a large degree of hetero-
geneity among the trials for both systolic blood pressure (I2 =
92%) and diastolic blood pressure (I2 = 91%). No single trial ex-
plained this heterogeneity, nor was it explained by primary ver-
sus secondary prevention trials nor two-drug versus three or more
drug combinations. Using a random-effects model, the MD in
systolic blood pressure between the intervention and control arms
was -6.34 mmHg (95% CI -9.03 to -3.64, Analysis 3.1), and
the MD in diastolic blood pressure between the intervention and
control arms was -3.33 mmHg (95% CI -4.86 to -1.79, Analysis
3.2). Trials that included usual care in the comparator group
(CRUCIAL 2011; CUSP 2009; IMPACT 2014; Kanyini GAP
2014; UMPIRE 2013) did not have as large reductions in sys-
tolic blood pressure (MD -3.44 mmHg, 95% CI -7.61 to 0.74)
compared with other trials (Analysis 3.5), but the direction of ef-
fect was similar. These results should be interpreted with caution
given the degree of heterogeneity. There was no evidence of funnel
plot asymmetry for systolic blood pressure. There were no differ-
ences in subgroup analyses evaluating the effect on systolic blood
pressure by primary or secondary prevention trials (Analysis 3.3;
Analysis 3.4). The effects were lower in trials that included usual
care as the comparator (MD -3.44 mmHg, 95% CI -7.61 to 0.74,
Analysis 3.5) compared with trials that used a placebo as the com-
parator (MD -10.77 mmHg, 95% CI -12.72 to -8.81, Analysis
3.6). There were no differences between trials with 3+ drugs or 2
drugs (Analysis 3.7; Analysis 3.8).
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Lipids
Eleven trials reported changes in total cholesterol in 6565 partici-
pants, and 12 trials reported changes in LDL cholesterol in 7153
participants. There was a large degree of heterogeneity among the
trials for both total cholesterol (I2 = 98%) and LDL cholesterol
(I2 = 98%). No single trial explained this heterogeneity. Using a
random-effects model, the MD in total cholesterol between the
intervention and control arm was -0.61mmol/L (95%CI -0.88 to
-0.35, Analysis 4.1). Using a random-effects model, MD in LDL
cholesterol between the intervention and control arms was -0.70
mmol/L (95%CI -0.98 to -0.41, Analysis 4.2). Trials that included
usual care in the comparator group (CRUCIAL 2011; CUSP
2009; IMPACT 2014; Kanyini GAP 2014; UMPIRE 2013) did
not have as large reductions in total cholesterol (MD -0.16 mmol/
L, 95% CI -0.44 to 0.12) compared with other trials (Analysis
4.5), but the direction of effect was similar. These results should be
interpreted with caution given the degree of heterogeneity. There
was evidence of funnel plot asymmetry for total cholesterol (Figure
4). The effects of fixed-dose combination therapy on total choles-
terol were greater in the seven primary prevention trials (MD -
0.92 mmol/L, 95%CI -1.18 to 0.65, Analysis 4.3) compared with
the four secondary prevention trials (MD -0.16 mmol/L, 95%
CI -0.49 to 0.17, Analysis 4.4), which may have been due to the
higher use of placebo control in primary prevention trials. The
effects were lower in trials that included usual care as the com-
parator (MD -0.16 mmol/L, 95% CI -0.44 to 0.12, Analysis 4.5)
compared with trials that used a placebo as the comparator (MD
-0.83 mmol/L, 95% CI -0.99 to -0.67, Analysis 4.6). There were
no differences in the effect among trials that included 3+ drugs
(MD -0.48 mmol/L, 95% CI -0.80 to -0.16, Analysis 4.7) com-
pared with 2 drugs (MD -0.94 mmol/L, 95% CI -1.50 to -0.38,
Analysis 4.8), which is expected because of the use of statin ther-
apy in all fixed-dose combinations.
Figure 4. Funnel plot of comparison: 3 Cholesterol, outcome: 3.1 Total cholesterol.
Adherence
Four trials reported adherence in 3835 participants (FOCUS
2014, IMPACT 2014, Kanyini GAP 2014, UMPIRE 2013; all
secondary prevention trials and all combinations included 3+
drugs), and in three of these trials (IMPACT 2014, Kanyini GAP
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2014, UMPIRE 2013) adherence was defined as taking aspirin,
statin, and two or more blood pressure-lowering drugs. Adherence
was assessed through self-report (FOCUS 2014, IMPACT 2014,
Kanyini GAP 2014, UMPIRE 2013), pill count (FOCUS 2014),
and linkage to pharmacy data (IMPACT 2014). Adherence was
higher in the intervention group comparedwith the control groups
(74% versus 53%, RR 1.44, 95%CI 1.26 to 1.65, I2 = 80%, mod-
erate-quality evidence, Analysis 5.1). The heterogeneity of effect
was largely explained by IMPACT 2014, but the magnitude and
direction of effect was similar after excluding this trial (post-hoc
analysis: RR 1.35 95% CI 1.25 to 1.46, I2 = 34%). The effect of
fixed-dose combination therapy was similar in the three trials that
used usual care as the comparator (Analysis 5.2) compared with
the one trial with the comparator of providing individual drugs
(Analysis 5.3).
Discontinuation
Rates of discontinuation were reported in both groups in seven
trials including 3118 participants with active control or placebo as
the comparator (CUSP 2009; FOCUS 2014; Malekzadeh 2010;
PILL 2011; TIPS 2009; TOGETHER 2010; Wald 2012). Dis-
continuation rates were higher in individuals randomized to fixed-
dose combination therapy (12% versus 10%, RR 1.24, 95% CI
1.01 to 1.51, I2 = 0%, Analysis 6.1).
Health-related quality of life
Three trials including 3009 participants (IMPACT 2014, Kanyini
GAP 2014, UMPIRE 2013) reported health-related quality-of-
life measures at the end of the study period using the EQ-5D
instrument. Mean (SD) summary index scores demonstrated no
effect of fixed-dose combination on EQ-5D scores compared with
usual care (MD 0.22, 95% CI -1.02 to 1.46, I2 = 0%, Analysis
7.1).
Costs
One study (Kanyini GAP 2014) reported direct Medicare benefit
costs (n = 551 participants) and pharmacy benefit costs (n = 458
participants) among a sub-sample of individuals randomised to
fixed-dose combination therapy or usual care who agreed to have
their records linked to Medicare benefits. As part of the trial de-
sign, individuals randomised to the fixed-dose combination ther-
apy arm incurred out-of-pocket costs typical for the Pharmaceuti-
cal Benefits Scheme, ranging from AUS 0 to AUS 35 per month.
Unadjusted Medicare costs were similar (MD AUS 12, 95% CI -
259 to 235) but unadjusted pharmacy costs appeared lowered in
participants randomised to fixed-dose combination therapy (MD
AUS 995, 95% CI -1366 to -624).
D I S C U S S I O N
Summary of main results
This systematic review demonstrates that the effects of fixed-dose
combination therapy on all-cause mortality or ASCVD events are
uncertain. However, the event rates for these outcomes were very
low, only five (all-cause mortality) and six (ASCVD) events out
of 13 trials reported these outcomes, respectively, and these trials
used usual care as their comparator. The uncertainty from this up-
date suggests that future research will likely change this estimate.
The trend toward greater number of ASCVD events in the group
randomised to fixed-dose combination may be due to chance, per-
formance bias due to lack blinding of the study personnel and
participants, or the effects of switching or initiating the fixed-dose
combination, butmerits further investigation. Adverse events were
common in both the intervention (30%) and comparator (24%)
groups, with participants randomised to fixed-dose combination
therapy being 20% more likely to report an adverse event. No-
tably, no serious adverse events were reported. The trials reported
reductions in systolic and diastolic blood pressure and total and
LDL cholesterol. These risk factor changes would have been ex-
pected to result in a reduction in ASCVD events if sustained, but
the trials reporting changes in risk factors were generally too short
to detect a potential difference by their design. There was also
substantial heterogeneity in these estimates, so these effects on risk
factors should be interpreted with caution.
The trials demonstrated a 26% (95% CI 2% to 55%) increased
risk of discontinuing the study medication (discontinuation rate
range 10% to 23%) compared with either usual care, placebo,
or an active drug (aspirin, statin, or thiazide in the case of TIPS
2009). We were unable to explain the heterogeneity of effects on
blood pressure or lipids in terms of primary versus secondary pre-
vention trials, the number of drugs in the fixed-dose combination
pills, or the comparator group being active control, placebo or
usual care. It is possible that the heterogeneity is due to the char-
acteristics of the participants studied, differences in the potency
of the antihypertensives and statins used, and the differences in
treatments used in the comparison groups. The apparent paradox
of the intervention leading to higher discontinuation rates and
higher adherence is largely dependent on the comparator group.
For example, in trials that included usual care as the comparator,
the trials were not able to measure and thus report discontinuation
rates.
Overall completeness and applicability of
evidence
The included trials used five different polypills: three of the stud-
ies (CRUCIAL 2011; CUSP 2009; TOGETHER 2010) included
polypills with only two drugs (one blood pressure-lowering drug
(amlodipine) and one statin (atorvastatin)); three studies (PILL
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2011; Soliman 2009; UMPIRE 2013) used the Dr Reddy’s Lab
Red Heart Pill that includes four drugs (aspirin, lisinopril, sim-
vastatin, and hydrochlorothiazide), and the remaining studies in-
cluded different four-drug (Malekzadeh 2010;Wald 2012) or five-
drug combinations (TIPS 2009). These trials were performed in
32 countries, including 19 low- and middle-income countries,
where the burden of ASCVD is greater than in high-income coun-
tries (Roth 2015). However, the provision of usual care in trials
led to far higher adherence rates than have been reported in com-
munity-based studies evaluating multidrug adherence in low- and
middle-income countries (Yusuf 2011).
The decision to combine the estimates of these different drug com-
binations and different comparators was made, and meta-analysis
for this review was performed to evaluate the estimated effect size
of fixed-dose combination therapy. A rationale for fixed-dose com-
bination therapy is that it is more likely to be taken than multiple
dose regimens. However, we found a higher likelihood of discon-
tinuation for fixed-dose treatment than for placebo. Comparisons
of adherence across trials are hampered by differing definitions,
which should be standardised in future reporting of these trials.
Trials using ’usual care’ comparison groups reported reasonably
high levels of adherence and low levels of discontinuation, but
these may be misleading as there is no relevant comparison.
There are six ongoing trials (NCT01826019; INTEGRATE;
PolyIran;NCT02278471;NCT02596126;NCT01646437), and
12 trials that await classification (Fommei 2015; NCT00530946;
NCT01004705; NCT01005290; NCT01362218;
NCT01406431; NCT01764178; NCT02075619;
NCT02569814;
NCT02662894; NCT02791958; NCT02842359). The results
of these trials are likely to have an important impact on our confi-
dence in the estimates of effect andmay change the estimates given
the number of trials, number of participants, length of follow-up,
and estimated number of events relative to the current evidence
base. These trials evaluate the effects of combinations in various
settings, including among older individuals (NCT02596126) and
within complex health system interventions that incorporate clin-
ician decision support (INTEGRATE) and non-physician health
workers (NCT01826019).
Quality of the evidence
The main risk of bias was related to lack of blinding of partici-
pants and personnel, which was inherent to the intervention. Us-
ing other GRADE domains, we judged the quality of evidence
of fixed-dose combination therapy for all-cause mortality and AS-
CVD events to be low, whichwas driven by imprecision (low event
rates) and indirectness of evidence. The comparator of usual care
was of a higher standard than might be expected outside of the
research setting and particularly higher than has been reported
in low- and middle-income countries based on previous research
(Yusuf 2011). This observation is further supported by the SPACE
collaboration demonstrating a differential effect of the interven-
tion on adherence among individuals with low baseline treatment,
suggesting that individuals who have low treatment rates at base-
line are more likely to benefit (Webster 2016a). We judged the
quality of evidence for fixed-dose combination therapy on adverse
events to be moderate, due to indirectness of evidence, because
the comparator group included individuals receiving usual care,
which included drug prescription rates that were higher than those
seen in non-research settings, as well as placebo, which would not
be an expected comparator for fixed-dose combinations in clinical
settings. We judged the quality of evidence for the effect of fixed-
dose combination therapy on systolic blood pressure and LDL
cholesterol to be moderate, due to unexplained heterogeneity that
was likely driven by differences in populations, fixed-dose com-
binations, and comparator groups. We judged the quality of evi-
dence for fixed-dose combination on total cholesterol as low be-
cause of unexplained heterogeneity as outlined for systolic blood
pressure and LDL cholesterol; we further downgraded the quality
of evidence for total cholesterol for reporting bias due to funnel
plot asymmetry. We judged the quality of evidence for fixed-dose
combination therapy on adherence to be moderate due to indi-
rectness of evidence based on the high quality care provided in the
comparator of usual care (IMPACT 2014; Kanyini GAP 2014;
UMPIRE 2013) or active drug comparator provided to these par-
ticipants (FOCUS 2014).
Potential biases in the review process
For the TIPS 2009 and Wald 2012 studies, we relied upon the
point estimates and standard deviations extracted by Elley 2012,
since these data points were not specifically provided in the text
of the manuscripts. Elley and colleagues estimated the outcome
standard deviations using baseline standard deviations as reported
by Furukawa and colleagues (Furukawa 2006).
Agreements and disagreements with other
studies or reviews
Our results demonstrated modestly lower reductions in systolic (-
6.34 mmHg versus -9.20 mmHg) and diastolic blood pressure (-
3.33 mmHg versus -5.00 mmHg) and lower total (-0.61 mmol/L
versus -1.22 mmol/L) and LDL cholesterol (-0.70 mmol/L versus
-1.02 mmol/L) compared with an earlier systematic review (Elley
2012). The absolute and relative adverse event rates were similar
to those reported by Elley 2012, but the absolute and relative
discontinuation rates were lower in our review. These differences
are accounted for by our inclusion of seven additional studies
(CRUCIAL 2011; FOCUS 2014; IMPACT 2014; Kanyini GAP
2014; OLSTA 2016; Soliman 2009; UMPIRE 2013).
The changes in blood pressure were lower than those predicted by
Wald and Law (diastolic blood pressure: -3.33 mmHg versus -11
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mmHg, Wald 2003), which may be due to the number of blood
pressure-lowering drugs, baseline blood pressures, or comparison
to usual care groups that received very high-quality care demon-
strated by adherence rates in the comparator groups, which would
not be typical in most communities (Yusuf 2011). The changes
in LDL cholesterol were also lower than those predicted by Wald
and Law (-0.70 mmol/L versus 1.8 mmol/L) for similar reasons
to those outlined above.
We have reported a similar direction and magnitude of effects
that were reported in the individual participant data meta-anal-
ysis performed by the Single Pill to Avert Cardiovascular Events
(SPACE) collaboration (Webster 2016a), which included data
from IMPACT 2014; Kanyini GAP 2014; UMPIRE 2013. In the
SPACE collaboration meta-analysis, the relative effect on adher-
ence was larger (80% versus 50%, RR 1.58, 95% CI 1.32 to 1.90)
but the effect on systolic blood pressure (SBP) (−2.5mmHg; 95%
CI −4.5 to −0.4) and LDL cholesterol (−0.1 mmol/L; 95% CI
−0.2 to 0.0) were lower but with greater precision. These inves-
tigators evaluated the interaction between baseline treatment and
adherence and SBP and demonstrated a greater effect of fixed-dose
combination therapy on adherence and SBP among individuals
with low baseline treatment compared with individuals with high
baseline treatment.
Bangalore 2007 have previously performed a systematic review
and meta-analysis of the effect of fixed-dose combination ther-
apy on adherence for chronic conditions including hypertension,
diabetes, and HIV and reported a 24% (95% CI 19% to 29%)
lower rate of discontinuation comparedwith control. These results
were similar to those reported by Gupta 2010, who reported an
increased odds of adherence with fixed-dose combination therapy
for blood pressure compared with usual care (OR 1.21, 95% CI
1.03 to 1.43). Gupta and colleagues demonstrated trends toward
improved blood pressure control and side effects (Gupta 2010).
The differences in discontinuation rates and adherence between
these studies and our study may be due to the fact that participants
in the Bangalore and Gupta meta-analyses received active drug
in either arm compared with our meta-analysis where compara-
tor group participants received either usual care (and possibly no
drugs), placebo, or alternative drugs with potentially lower rates
of side effects (TIPS 2009).
Virdee 2013 interviewed 11 primary care physicians and five prac-
tice nurses in nine Birmingham, UK practices about their knowl-
edge and attitudes toward fixed-dose combination therapy. The
majority of respondents were uncertain about how they would
incorporate fixed-dose combination therapy in their practice and
whether it was designed for primary or secondary ASCVDpreven-
tion. Most felt reluctant about using a specific age cut-off to ini-
tiate therapy, despite acknowledging potential advantages to this
approach. Most respondents felt unease at the concept of minimal
or nomonitoring of patients taking a fixed-dose combination ther-
apy, despite the proposal byWald and Law (Wald 2003). InMarch
2010, Viera and colleagues surveyed US physicians about their
willingness to prescribe fixed-dose combination therapy. Nearly
two out of every three physicians reported that they would pre-
scribe fixed-dose combination therapy for people at moderate risk
for ASCVD and more than four out of every five physicians re-
ported that they would prescribe fixed-dose combination therapy
for people at high risk for ASCVD. These disparate data using
different methods of data collection suggest varying potential for
uptake among physicians.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The effects of fixed-dose combination therapy on all-cause mor-
tality or atherosclerotic cardiovascular disease (ASCVD) events are
uncertain. A limited number of trials reported these outcomes,
and the included trials were primarily designed to observe changes
in ASCVD risk factor levels rather than clinical events, which
may partially explain the observed differences in risk factors that
were not translated into differences in clinical outcomes among
the included trials. Fixed-dose combination therapy is associated
with modest increases in adverse events compared with placebo,
active comparators, or usual care which may result from improved
adherence to a multidrug regimen. Ongoing, longer-term trials
of fixed-dose combination therapy will help demonstrate whether
short-term changes in risk factors might be maintained and lead
to expected differences in clinical events based on these changes.
Implications for research
High-quality randomised controlled trials are needed to evaluate
if the effect of fixed-dose combination therapies on risk factor lev-
els translates into improvements in fatal and non-fatal events in
both primary and secondary ASCVD-prevention settings. Ongo-
ing trials will be informative; studies awaiting classification may
be as well. The certainty of effect following the inclusion of these
trials relies, at least in part, on their conduct and event rates. Some
of these trials will also help demonstrate the effectiveness of fixed-
dose combination therapy in conjunction with other health sys-
tem interventions. Larger studies are also needed to evaluate the
risk of serious adverse events in varied populations.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
CRUCIAL 2011
Methods Open label, cluster-randomised trial
Participants 136 clusters; 1461 total participants (779 intervention; 682 comparator participants)
from 19 countries (Costa Rica, Croatia, Czech Republic, Dominican Republic, Indone-
sia, Jordan, Kuwait, Lebanon, Malaysia, Mexico, Panama, Philippines, South Korea,
Russia, Taiwan, Thailand, Turkey, United Arab Emirates, Venezuela)
Men and women aged 35-79 years with hypertension and total cholesterol < 250 mg/
dL plus 3 or more risk factors (current smoker, peripheral artery disease, type 2 diabetes,
family history of early CHD before aged 55 years in first-degree relative; left ventricular
hypertrophy on ECG; history of transient ischaemic attack or stroke three or more
months prior to screening; ECG abnormalities; age > 55 years (men) or > 65 years
(women), total cholesterol > 250mg/dL, or HDL < 40mg/dL)
Interventions Intervention: single pill amlodipine/atorvastatin (5 mg/10 mg-10 mg/10 mg; site inves-
tigators could request dosages of 5/20 mg and 10/20 mg) in addition to other hyperten-
sive/lipid-lowering therapy as required, as well as therapeutic lifestyle counselling change
Comparator: usual care, including therapeutic lifestyle counselling change
Outcomes SBP, DBP, LDL-C, total cholesterol; all-cause mortality reported
Notes Comparator: inactive/usual care
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Investigators - randomly assigned”, “randomi-
sation was stratified”, “investigator as unit of ran-
domisation”
Allocation concealment (selection bias) Unclear risk Due to cluster randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
High risk 93/779 (11.9%) discontinued intervention; 44/
682 (6.5%) discontinued in usual care arm
Selective reporting (reporting bias) Unclear risk Not all outcomes available for meta-analysis
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CRUCIAL 2011 (Continued)
Other bias Unclear risk Differences between two arms in terms of base-
line blood pressure, ECG abnormalities, PVD
CUSP 2009
Methods Individual-level RCT
Participants 130 participants (66 intervention; 64 comparator) from the USA with coexisting, un-
treated hypertension (SBP = 140 mmHg-169 mmHg or DBP = 90 mmHg-105 mmHg)
and dyslipidaemia (LDL-C = 110 mg/dL-160 mg/dL) but without a history of cardio-
vascular disease; age > 21 years
Interventions Intervention: single pill amlodipine/atorvastatin (5 mg/20 mg) + therapeutic lifestyle
changes
Comparator: therapeutic lifestyle changes
Outcomes Target for BP < 140/90 mm Hg and LDL-C < 100 mg/dL (2.59 mmol L) at week 4
and week 8: the percentage of participants in whom the single LDL-C goal was reached
at weeks 4 and 8; mean changes from baseline in SBP and DBP at weeks 4 and 8; mean
changes from baseline in LDL-C at weeks 4 and 8; 10-year Framingham risk of CHD
at weeks 4 and 8
Notes Comparator: inactive/usual care
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specifically stated: “Patients were randomised in a double-
blind manner”
Allocation concealment (selection bias) Unclear risk Not specifically stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not specifically stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not specifically stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how data from participants lost to follow-up were han-
dled
Selective reporting (reporting bias) Low risk Primary outcomes reported (week 4 blood pressure and LDL
targets)
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CUSP 2009 (Continued)
Other bias Low risk No other sources of bias are identifiable
FOCUS 2014
Methods ”randomized, open-label, active-controlled, piggyback, 2-group parallel trial“
Participants 695 participants (350 polypill; 345 comparator) across 63 sites in 4 countries (Argentina,
Italy, Paraguay, Spain)
Details about Phase 2 participants (age, sex) not provided in the primary manuscript
Inclusion criteria: “The study population included men and women age > 40 years with
a history of acute MI within the last 2 years...Due to slow recruitment, after the initial
591 participants had been included, an amendment to the initial protocol was approved
to allow for the inclusion of patients with any past history of an acute MI, regardless of
duration from enrollment.”
Exclusion criteria: ”secondary dyslipidemia, contraindication to any of the components
of the polypill, participation in another trial, previous percutaneous transluminal coro-
nary angioplasty with a drug-eluting stent within the previous year, severe congestive
heart failure (New York Heart Association functional class III to IV), serum creatinine
> 2 mg/dL, any condition limiting life expectancy < 2 years, and pregnancy or pre-
menopause.”
Interventions Intervention: “aspirin (100mg), simvastatin (40mg), and ramipril at 3 different doses (2.
5 mg, 5 mg, or 10 mg, which allowed for up-titration at the discretion of the physician)
” in hard-shell gelatin capsule
Comparator: aspirin, simvastatin, and ramipril provided separately
Drugs were provided free of cost for both arms
Outcomes Primary
• Medication adherence assessed by attendance at the final 9-month visit and the
MAQ and pill count methods, simultaneously. ”Participants lost for follow-up and
those discontinuing medication due to adverse effects were also considered to be
nonadherent for this analysis”. Definition: “Pill count was calculated as: (no. of pills
dispensed - no. of pills returned)/number of pills prescribed X 100. A pill count
between 80% and 110% was considered good adherence.”
• Blood pressure
• LDL cholesterol
Secondary
• Incidence of adverse events including death, reinfarction, and rehospitalisation for
any CV cause
• Rate of treatment withdrawal
• Tolerability
• Quality of life
• “Economic endpoints”
Outcomes measured at 1, 4, and 9 months
Follow-up: 9 months
Notes Comparator: individual drugs (aspirin, simvastatin, ramipril) provided separately
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FOCUS 2014 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”a central electronic randomization service
assigned participants to 1 of 2 arms”
Allocation concealment (selection bias) Low risk “a central electronic randomization service
assigned participants to 1 of 2 arms”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Open label trial; no evidence of blinded
outcome assessment committee
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Similar loss to follow-up between groups
(intervention 12.3%; comparator 10.1%,
Table 2) but could influence primary out-
come
Selective reporting (reporting bias) Unclear risk Primary outcome was reported, but the
threshold for defining adherence was
changed from 16-20 during the trial. The
effects of this change are uncertain
Data on 4-month outcomes not reported
but not likely different than longer term
trends
Other bias Unclear risk Relatively small study to detect any differ-
ences in clinical outcomes; could be con-
sidered low risk of small study bias for ad-
herence
IMPACT 2014
Methods ”Open label randomised control trial“
Participants 513 participants (from 91 General Practitioners); target = 600 participants in New
Zealand
256 polypill; 257 comparator
Mean (SD) age: 62 (8) years for both arms
Maori ethnicity: 50% for both arms
Women: 39% intervention; 34% comparator
CAD: 35% intervention; 38% comparator
DM: 44% intervention; 41% comparator
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IMPACT 2014 (Continued)
Employed: 46% intervention; 44% comparator
“Given the available funding resources, the recruitment target was revised down to 500,
which provided 89-93% power to detect the same differences between risk factors and
92% power to detect a 30% relative improvement in adherence.”
Inclusion criteria: ”Adults aged 18-79 years at high risk of cardiovascular disease (based
on either established disease (coronary, cerebrovascular, or peripheral vascular) or≥15%
five year risk of a cardiovascular event); patient’s general practitioner considered all the
drugs in at least one of the two versions of the fixed-dose combination treatment available
were recommended and was uncertain if treatment was best provided as fixed-dose
combination based treatment or as usual care“
Exclusion criteria: ”contraindications to any of the components of the fixed dose combi-
nation, congestive heart failure, haemorrhagic stroke, active stomach or duodenal ulcer,
receipt of an oral anticoagulant, concerns by the general practitioner about the risk to
a patient of changing his or her cardiovascular disease drugs, impending alteration of a
drug regimen for an important length of time (for example, planned coronary bypass
graft operation), or the participant was unlikely to complete the trial or trial procedures“
Interventions Intervention:
• Aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, atenolol 50 mg or
• Aspirin 75 mg, simvastatin 40 mg, and lisinopril 10 mg, hydrochlorothiazide 12.
5 mg
Comparator: ”The control is usual management. Physicians in both groups are encour-
aged to prescribe in line with New Zealand CVD risk assessment and management
guidelines.”
“both trial drugs and usual drugs were dispensed through community pharmacies.”
“Participants were required to pay what they would normally pay to receive a single
government subsidised drug”
“Standard patient co-payments of NZ$5 (£2.6; EURO3.1; $4.3) for each item every
three months”
Outcomes Primary:
• Adherence (self-reported current use of antiplatelet, statin, and at least two blood
pressure-lowering drugs) at 12 months
• Change in blood pressure between baseline and 12 months
• Change in LDL-C between baseline and 12 months
Secondary:
• Serious adverse events
• Cardiovascular events
• Health-related quality of life (EuroQol EQ-5D)
Outcomes measured: baseline, 1, 6, 12 months, end of trial
Follow-up: median of 23 months in both arms
Notes Comparator: usual care
Risk of bias
Bias Authors’ judgement Support for judgement
37Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
IMPACT 2014 (Continued)
Random sequence generation (selection
bias)
Low risk “A central randomisation service randomly as-
signed (1:1) participants to fixed dose combi-
nation based treatment or usual care.”
Allocation concealment (selection bias) Low risk “A central randomisation service randomly as-
signed (1:1) participants to fixed dose combi-
nation based treatment or usual care.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Adherence: self-report but corroborated by
pharmacy claims data but definition favours
intervention (requiring second BP lowering
drug, though sensitivity analyses showed simi-
lar direction of effect)
LDL/SBP objectively measured and not likely
too susceptible to bias
SAE/CV events self-reported but objective and
reviewed by endpoints committee
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up rates low and balanced
Selective reporting (reporting bias) Low risk Outcome reporting largely matches protocol;
6-month data may not have been reported but
not likely different than longer term outcome
trends
Other bias Unclear risk Small study bias to evaluate differences in clin-
ical outcomes
Kanyini GAP 2014
Methods “randomized, open-label trial”
Participants 623 participants (311 polypill, 312 comparator) from 33 centres (12 Aboriginal Medical
Services); target = 1000 participants in Australia
Mean (SD) age: 63.4 (12.5) years intervention; 63.7 (12.7) years comparator
Women: 37% intervention; 37% comparator
Indigenous: 51% overall (not reported by group)
CVD: 59% intervention; 63% comparator
CHD: 52% intervention; 54% comparator
CM: 60% intervention; 55% comparator
Inclusion criteria: “18 years or over and able to give informed consent, have a history
of coronary heart disease (myocardial infarction, stable or unstable angina pectoris, or
coronary revascularization procedure), and/ or ischaemic cerebrovascular disease, and/
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Kanyini GAP 2014 (Continued)
or peripheral vascular disease; or a calculated 5-year CVD risk of 15% or greater*...Each
participant had to have, in their doctor’s view, indications for all and no contraindications
to any component of at least one of two polypills”
*including a 5% increment for Aboriginal or Torres Strait Islander identification
Exclusion criteria: “Participants were excluded if it was felt clinically inappropriate to
alter medications.”
Interventions Intervention
• Aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, atenolol 50 mg
• Aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12.5 mg
Comparator: “usual care”
“Out-of-pocket expenses for the polypill were incurred identically to those for any other
drug listed in the Pharmaceutical Benefits Scheme, which is the government subsidy
programme through which most drugs are obtained in Australia.”
Outcomes Primary
• Self-reported use of all medications was assessed at each visit, recorded as the
number of days on which medication was taken in the immediately preceding week…
antiplatelet, statin and >2 BP lowering therapies for >4 of the previous seven days)”
• Blood pressure (SBP, DBP)
• Lipids (total cholesterol, LDL cholesterol)
Secondary
• Barriers to adherence
• Health-related quality of life (EQ-5D questionnaire)
• Cardiovascular, renal and other serious adverse events
• Reasons for stopping cardiovascular medications
Time points measured: baseline, 1 month, and q6 month through 24 months
Follow-up: intervention: median 20.7 months, comparator: median 18.1 months
Notes Comparator: usual care
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Central, computer-based randomization to polypill-
based strategy or usual care was stratified by primary
healthcare centre, type of indication (established CVD
versus high risk), Indigenous identification and level
of preventive treatment at baseline.”
Allocation concealment (selection bias) Low risk “Central, computer-based randomization to polypill-
based strategy or usual care was stratified by primary
healthcare centre, type of indication (established CVD
versus high risk), Indigenous identification and level
of preventive treatment at baseline.”
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Kanyini GAP 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Adherence: high risk of bias because it was self reported
SBP/TC/events: low risk of bias because these are ob-
jective measures, and the latter was adjudicated by a
blinded outcome assessment committee
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low rates of losses to follow-up and missingness, with
rates balanced between the groups
Selective reporting (reporting bias) Low risk No differences between primary reports and protocol
Other bias Unclear risk Small study bias for events but low risk of bias for
adherence and change in risk factors
Malekzadeh 2010
Methods Individual-level, blocked RCT
Participants 475 participants (241 polypill; 234 control) from Golestan, Iran without CVD, hyper-
tension, or hyperlipidaemia aged 50-79 years (men) and 55-79 years (women)
Interventions Intervention: polypill (aspirin 81 mg, enalapril 2.5 mg, atorvastatin 20 mg and hy-
drochlorothiazide 12.5 mg)
Comparator: placebo
Outcomes Hospital admissions/major cardiovascular events/seated and standing BP, LDL-C, total
cholesterol, triglycerides, HDL-C and fasting glucose
Notes Comparator: inactive/placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block randomisation
Allocation concealment (selection bias) Unclear risk Computer generation allocation to numbered list of
blister packs manufactured by Alborz Darou, but dif-
ferences between intervention and comparator groups
for baseline gender (38% versus 28%), systolic (125
mmHg vs 130 mmHg) and diastolic blood pressure
(78 mmHg vs 81 mmHg) were seen
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Malekzadeh 2010 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical blister packs used for participant blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors (clinicians) blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk High rate of loss to follow-up at 12 months (experi-
mental 32%; control 22%)
Selective reporting (reporting bias) Low risk Primary outcome reported (changes in blood pressure
and LDL cholesterol)
Other bias High risk Run-in period excluded participants with low (< 70%)
adherence; large differences in baseline characteristics
between intervention and control groups
OLSTA 2016
Methods Individual-level RCT, 2:1:1:1 design with triple dummy
Participants 181 “Korean patients with mild to moderate hypertension and dyslipidemia” defined by
JNC VII and ATP III. Participants underwent 4 week run-in period and were recruited
from 25 centres in Korea
Exclusion criteria:
• Secondary hypertension
• HbA1c > 9%
• CVD event within 6 months; NYHA FC III or IV heart failure
• TSH, serum creatinine, liver chemistries > 1.5 times upper limit of normal
• Any condition that might influence the study results
FDC: 71 participants, mean (SD) age 61.9 (8.1) years; 44% women; 44% diabetes; 0%
CHD
Olmesartan: 38participants,mean (SD) age 59.5 (6.9) years; 33%women; 39%diabetes;
0% CHD
Rosuvastatin: 38 participants, mean (SD) age 61.8 (8.0) years; 31% women; 22% dia-
betes; 0% CHD
Placebo: 34 participants, mean (SD) age 62.5 (8.2) years; 28% women; 31% DM; 0%
CHD
Interventions Intervention: fixed-dose combination of olmesartan medoxomil 40 mg + rosuvastatin
20 mg
Comparator 1: Olmesartan medoxomil 40 mg
Comparator 2: Rosuvastatin 20 mg
Comparator 3: Placebo
Outcomes Primary
• Percentage change from baseline in the LDL-C at week 8
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OLSTA 2016 (Continued)
• Percentage change from baseline in DBP at week 8
Secondary
• Percentage change from baseline in total cholesterol, triglycerides, and HDL-C at
week 4 and week 8
• Percentage change from baseline in SBP at week 4 and week 8
• Percentage of participants who achieved treatment goals
• Adverse events
Notes Reported differences in baseline characteristics, which may or may not be due to chance:
3.3 mm SBP difference between rosuvastatin and placebo arms (but only those who
completed follow-up had baseline data reported); 3.3-year difference in age between
olmesartan and placebo group; 16% difference in women between FDC and placebo;
22% difference in DM between FDC and rosuvastatin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralized, computer generator random
sequence
Allocation concealment (selection bias) Low risk Centralized, computer generator random
sequence
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, triple dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded study staff
Incomplete outcome data (attrition bias)
All outcomes
High risk High loss to follow-up rate in intervention
group with complete case analysis only (no
imputation)
FDC: 10/71 (14%)
Olmesartan: 2/38 (5%)
Rosuvastatin: 2/38 (5%)
Placebo: 5/34 (15%)
Selective reporting (reporting bias) High risk Protocol (NCT01764295) published in
January 2013, after trial initiation
Other bias High risk Small study bias with short follow-up;
sponsored by Daewoong Pharmaceutical,
which also performed trial execution and
monitoring
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PILL 2011
Methods Individual-level RCT
Participants 378 participants (189 intervention; 189 comparator) from 7 countries (Australia, Brazil,
India, Netherlands, New Zealand, UK, USA) with 5-year Framingham coronary heart
disease risk ≥ 7.5% or if Framingham risk was between 5% and 7.5%, two or more
additional untreated risk factors were needed (body mass index > 30 kg/m2, waist cir-
cumference > 102 cm in men or > 88 cm in women; heart rate > 80 bpm; fasting glucose
5.6 mmol/L-7 mmol/L, triglycerides > 1.7 mmol/L; family history of first degree relative
with premature ischaemic heart disease or stroke (men < 55 years; women: < 65 years),
or glomerular filtration rate < 60mL/min
Interventions Intervention: Red heart pill (aspirin 75 mg, lisinopril 10 mg, hydrochlorothiazide 12.5
mg and simvastatin 20 mg)
Comparator: placebo
Outcomes Change in SBP; change in LDL-C; tolerability; secondary outcomes included discon-
tinuation, DBP, total cholesterol, HDL-C, total cholesterol:HDL cholesterol ratio, non-
HDL cholesterol, triglycerides, frequency of switching/adding open-label treatment, es-
timated effects on CVD risk
Notes Comparator: inactive/placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-based randomisation
Allocation concealment (selection bias) Low risk Central computer-based randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Specifically reported and use of placebo control
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors and study staff all blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low rates of loss to follow-up (experimental 2%; control 1%)
; however, last observation carried forward method used for
missing continuous data at week 12
Selective reporting (reporting bias) Low risk Outcomes outlined in methods paper were reported in the pri-
mary manuscript
Other bias Low risk No other sources of bias are identifiable
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Soliman 2009
Methods Open label, parallel-group RCT
Participants 216 participants (105 polypill; 111 comparator); ≥ 40 years for men and ≥ 50 years for
women; estimated 10-year World Health Organization total cardiovascular risk score ≥
20% without established cardiovascular disease
Interventions Intervention: Red Heart pill 2b (75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and
12.5 mg hydrochlorothiazide)
Comparator: standard practice defined by the study investigators
Outcomes SBP, total cholesterol, 10-year cardiovascular disease risk, adherence, fasting glucose,
creatinine, potassium, and liver enzymes
Notes Comparator: inactive/usual care
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No method of randomisation stated
Allocation concealment (selection bias) Unclear risk No method of randomisation stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how missing data were handled
Selective reporting (reporting bias) Low risk Primary outcomes (blood pressure, cholesterol, ten
year CVD risk) all reported
Other bias High risk Use of non-study antihypertensives and statins very
different between centres
TIPS 2009
Methods Individual-level RCT
Participants 2053 participants (205 aspirin; 205 thiazide; 209 thiazide + ramipril; 207 thiazide +
atenolol; 205 ramipril + atenolol; 204 thiazde + ramipril + atenolol; 204 thiazide +
ramipril + atenolol + aspirin; 202 simvastatin; 412 Polycap [thiazide + ramipril + atenolol
+ simvastatin + aspirin); 45-80 years old without prior cardiovascular disease but with
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TIPS 2009 (Continued)
at least one risk factor: type 2 diabetes; blood pressure > 140/90 mmHg but < 160/100
mmHg; smoker within the past five years; waist-to-hip ratio > 0.85 for women and 0.
90 for men; LDL cholesterol > 3.1 mmol/L but less 4.5 mmol/L or HDL cholesterol <
1.04 mmol/L
Interventions Intervention: Polycap (thiazide 12.5 mg, atenolol 50 mg, ramipril 5 mg, simvastatin 20
mg, aspirin 100 mg)
Comparator: 8 other drug/drug combination groups listed above
Outcomes LDL for the effect of lipid-lowering drugs, BP for antihypertensive drugs, heart rate for
the effects of atenolol, urinary 11-dehydrothromboxane B2 for the antiplatelet effects of
aspirin, rates of discontinuation of drugs for safety
Notes Comparator: active
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer randomisation
Allocation concealment (selection bias) Low risk Central computer randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo control using identical capsule
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinding reported; probably occurred given research
team’s prior studies
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how missing SBP and LDL-C data at week 12 follow-
up were handled
Selective reporting (reporting bias) Low risk Primary outcomes reported
Other bias Low risk No other sources of bias are identifiable
TOGETHER 2010
Methods Individual-level randomised, double dummy controlled trial
Participants 244 participants (122 intervention; 122 control) from the USA with history of hyper-
tension but no history of CVD or diabetes with ≥ 2 risk factors: age ≥ 45 years for
men;≥ 55 years for women; current smoker; family history of premature coronary heart
disease in first degree relative; HDL cholesterol < 40 mg/dl; waist circumference > 102
cm in men and > 88 cm in women
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TOGETHER 2010 (Continued)
Interventions Intervention: single pill amlodipine (5/10 mg) plus atorvastatin 20 mg + therapeutic
lifestyle changes
Comparator: amlodipine (5/10 mg) + therapeutic lifestyle changes
Outcomes Proportion achieving a BP goal < 140/90 mmHg and LDL-C < 100 mg/dl at week 6;
BP and LDL-C goal at week 4; BP goal at weeks 4 and 6; change in SBP, DBP, LDL-C,
total cholesterol, HDL-C, triglycerides at weeks 4 and 6; predicted 10-year Framingham
coronary heart disease risk score, adverse events
Notes Comparator: active
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central, computer-based telerandomisa-
tion
Allocation concealment (selection bias) Low risk Central, computer-based telerandomisa-
tion
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind labelled bottles and double
dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reportedly double blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Last observation carried forward used for
non-completers for final analysis
Selective reporting (reporting bias) Unclear risk Primary outcomes reported
Other bias Low risk No other sources of bias are identifiable
UMPIRE 2013
Methods Randomised, open label, blinded endpoint clinical trial of an FDC-based treatment
strategy compared with usual care
Participants ≥18 years old and established CVD or an estimated 5-year CVD risk of 15% or greater
in India and 3 European countries (England, Ireland, and the Netherlands)
Interventions Intervention: one of two versions of the fixed-dose combination ((1) aspirin 75 mg,
simvastatin 40 mg, lisinopril 10 mg, atenolol 50 mg or (2) aspirin 75 mg, simvastatin
40 mg, lisinopril 10 mg, hydrochlorothiazide 12.5 mg)
Comparator: usual care
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UMPIRE 2013 (Continued)
Outcomes Primary: adherence to indicated medications (self-reported current use of antiplatelet,
statin, and≥ 2 BP-lowering therapies, defined as taking themedication for at least 4 days
during the week preceding the visit) at baseline and at the end of the trial and changes
in SBP and LDL-C from baseline to the end of the trial
Secondary: adherence at 12 months, reasons for stopping cardiovascular medications,
quality of life, serious adverse events, and changes in total cholesterol, HDL-C, triglyc-
erides, and creatinine from baseline to 12 months and end of study and cardiovascular
events (including coronary heart disease, heart failure leading to death or hospital ad-
mission, and cerebrovascular or peripheral arterial disease events)
Notes Comparator: inactive/usual care
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation occurred through web-
based clinical data management system
Allocation concealment (selection bias) Low risk Randomisation occurred through web-
based clinical data management system
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk At the end of the study, data on self-re-
ported adherence, systolic BP, and LDL-C
were available for 1921 (96%), 1849 (92%)
, and1807 (90%) randomizedparticipants,
respectively
Selective reporting (reporting bias) Low risk All primary and secondary outcomes re-
ported
Other bias Unclear risk Participants randomized to the interven-
tion arm received fixed-dose combination
therapy at no cost compared with partici-
pants randomized to usual care who were
responsible for their drug costs
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Wald 2012
Methods Individual-level randomised double-blind placebo-controlled cross-over trial
Participants 86 individuals (43 Polypill then placebo; 43 placebo then Polypill) aged 50 years or over
without history of cardiovascular disease who were previously taking simvastatin and
blood pressure-lowering drugs; limited to participants living in London or could travel
easily to London
Interventions Intervention: fixed-dose combination (amlodipine 2.5mg, losartan 25mg, hy-
drochlorothiazide 12.5mg, simvastatin 40mg) daily for 12 weeks
Comparator: placebo
Outcomes SBP, DBP, total cholesterol, LDL-C, HDL-C, triglycerides, apoB, adherence (pill counts
of fixed-dose combination compared with placebo), adverse events
Notes Comparator: inactive/placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block randomisation
Allocation concealment (selection bias) Low risk Computer-generated block randomisation
with sequential identical blister packs
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo controlled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors reported as being
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary outcomes reported
Selective reporting (reporting bias) Unclear risk Adverse event data not clearly described;
only proportion of individuals with “symp-
tom”, which was assumed to be an adverse
event
Other bias Low risk No need for intention-to-treat analysis as
cross-over design. Any losses to follow-up
clear
apoB: apolipoprotein B
CHD: coronary heart disease
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CVD: cardiovascular disease
DBP: diastolic blood pressure
ECG: electrocardiogram
HDL-C: high-density lipoprotein cholesterol
LDL-C: low-density lipoprotein cholesterol
PVD: peripheral vascular disease
RCT: randomised controlled trial
SBP: systolic blood pressure
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdellatif 2012 Wrong intervention
Agabiti Rosei 2014 Wrong intervention
Agarwal 2013 Wrong intervention
Anonymous 2010 Wrong study design
Anonymous 2011 Wrong study design
Anonymous 2012a Wrong study design
Anonymous 2012b Wrong intervention
Anonymous 2013a Review
Anonymous 2013b Wrong intervention
Athyros 2013 Wrong study design
Athyros 2014 Wrong study design
Bashir 2011 Wrong study design
Becerra 2015 Wrong study design
Bittencourt 2013 Wrong study design
Bittencourt 2014 Wrong study design
Blank 2007 Review
Briasoulis 2013 Wrong intervention
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(Continued)
Bryant 2013 Wrong study design
Carey 2012 Review
Cass 2013 Duplicate
Castellano 2014a Wrong study design
Castellano 2014b Wrong study design
Castellano 2015 Wrong study design
Chae 2015 Wrong comparator
ChineseExpert 2013 Wrong study design
Chrysant 2014 Wrong study design
Crunkhorn 2012 Wrong intervention
Dabhadkar 2013 Wrong study design
deCates 2014 Meta-analysis
Delgado Montero 2012 Wrong study design
Dimitrov 2012 Wrong intervention
Dresser 2012 Wrong intervention
Dresser 2013 Wrong comparator
Elley 2012 Meta-analysis
Fedacko 2013 noncomparative design
Feldman 2012 Wrong study design
Feldman 2014 Wrong study design
Feng 2012 Wrong intervention
Galindo Ocana 2012 Wrong study design
Gaziano 2013 Wrong study design
50Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Holzgreve 2014 Review
Huang 2016 Wrong study design
Huffman 2012 Wrong study design
Huffman 2014 Wrong study design
Ito 2012 Wrong study design
Ivanovic 2013 Wrong study design
Jadhav 2014 Wrong intervention
Jang 2015 Wrong intervention
Jaques 2011 Wrong study design
Kawashiri 2015 Wrong intervention
Kereiakes 2012 Wrong intervention
Khaled 2015 Wrong study design
Laba 2014a Wrong intervention
Laba 2014b Abstract
Lafeber 2011 Wrong study design
Lafeber 2012 Wrong study design
Lafeber 2013a Wrong study design
Lafeber 2013b Wrong study design
Lafeber 2014a Wrong study design
Lafeber 2014b Abstract
Lafeber 2014c Wrong outcomes
Lafeber 2014d Wrong comparator
Lafeber 2015 Wrong comparator
Lafeber 2016 Wrong study design
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(Continued)
Law 2006 Wrong study design
Liu 2014 Abstract
Liu 2015 Duplicate
Marazzi 2016 Wrong intervention
Mishchenko 2014 Abstract
Mossello 2015 Wrong study design
Neutel 2009 Duplicate
Nguyen 2013 Wrong study design
OliverasVila 2014 Wrong study design
Reiner 2013 Review
Selak 2013 Wrong comparator
Selak 2016 Meta-analysis
Sepanlou 2012 Wrong intervention
Sigamani 2012 Wrong comparator
Simonyi 2016 Wrong study design
Son 2013 Wrong comparator
Tanaka 2014 Noncomparative design
Truelove 2014 Abstract
Wald 2016 Wrong study design
Wang 2012 Abstract
Webster 2013 Protocol
Webster 2014 Wrong study design
Webster 2015a Wrong study design
Webster 2015b Meta-analysis
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Webster 2016a Meta-analysis
Webster 2016b Wrong study design
Wei 2013 Protocol
Wijns 2014 Wrong study design
Wiley 2014 Wrong study design
Xing 2013 Meta-analysis
Zeng 2016 Wrong study design
Zomer 2013 Wrong study design
Characteristics of studies awaiting assessment [ordered by study ID]
Fommei 2015
Methods Randomised cross-over trial
Participants Well-controlled non-complicated hypertensive outpatients under multiple therapy with at least one hypertensive
drug and/or a statin and/or aspirin
Interventions Single once-a-day administration (mono-administration) with at least one hypertensive drug and/or a statin and/or
aspirin
Comparator: usual care (multiple administration with at least one hypertensive drug and/or a statin and/or aspirin
Outcomes Adherence to treatment, adverse events, ambulatory blood pressure monitoring and lipid profile
Notes
NCT00530946
Methods Randomised open-label, parallel trial
Participants The outpatient with concurrent hypertension and hyper-LDL-cholesterolemia is a male or female >= 20 to < 80 years
of age at Visit 1.The SBP at Visit 4 (Week -1) and Visit 5 (Week 0) is continuously SBP >= 140 mmHg and < 180
mmHg, LDL-C >= 140 mg/dL and < 250 mg/dL at Visit 3 (Week -2) and 4 (Week -1)
Interventions Drug: amlodipine 2.5 mg/atorvastatin 5 mg (single pill combination, dosed once daily for 8 weeks)
Drug: amlodipine 2.5mg/atorvastatin 10mg (single pill combination, dosed once daily for 8 weeks)
Drug: amlodipine 5 mg/atorvastatin 5 mg (single pill combination, dosed once daily for 8 weeks)
Drug: amlodipine 5 mg/atorvastatin 10 mg (single pill combination, dosed once daily for 8 weeks)
Comparator:
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active comparator: CI-1038 2.5 mg/5 mg (intervention: drug: amlodipine 2.5 mg/atorvastatin 5 mg)
active comparator: CI-1038 2.5 mg/10 mg (intervention: drug: amlodipine 2.5 mg/atorvastatin 10 mg)
active comparator: CI-1038 5 mg/5 mg (intervention: drug: amlodipine 5 mg/atorvastatin 5 mg)
active comparator: CI-1038 5 mg/10 mg (intervention: drug: amlodipine 5 mg/atorvastatin 10 mg)
Outcomes Primary outcomes:
• Change in SBP, Percent Change in LDL
Secondary outcomes:
• Change in SBP from baseline to each observation point (4 weeks and 8weeks)
• Change in DBP from baseline to each observation point (4 weeks, 8 weeks)
• Percent change in LDL, total cholesterol, HDL, triglycerides, from baseline to each observation point
• Change in LDL/HDL ratio (timeframe 2 weeks, 4 weeks, 8 weeks), change in total cholesterol/HDL
(timeframe 2 weeks, 4 weeks, 8 weeks)
• -Change in apolipoprotein B From baseline to each observation point ((timeframe 2 weeks, 4 weeks, 8 weeks)
Notes
NCT01004705
Methods Randomised open-label cross-over trial
Participants Male or female participants ≥18 years of age
Previously untreated LDL cholesterol ≥ 100 mg/dL and ≤ 180 mg/dL
Interventions Once-daily oral dose of combinationof acetylsalicylic acid, simvastatin, and ramipril (containing100mgacetylsalicylic
acid, 40 mg simvastatin, and 5 or 10 mg ramipril)
Comparator: once-daily oral dose of Simvastatin 40 mg
Outcomes Primary outcomes
• The difference in LDL cholesterol levels between the basal and the final visit of each treatment period
• Change from baseline in LDL cholesterol level following each treatment period was defined as the difference
between the measurements from the baseline visit
Secondary outcomes
• The difference in mean total cholesterol between the basal and the final visit of each treatment period
• Change from baseline in mean total cholesterol level following each treatment period was defined as the
difference between the measurements from the baseline visit
Notes
NCT01005290
Methods Randomised open-label, cross-over trial
Participants Participants will be ≥ 18 years old. Previously untreated systolic pressure result of ≥ 120 < 160 mmHg and diastolic
pressure result of ≥ 80 < 100 mmHg
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Interventions A once-daily oral dose of the cardiovascular fixed-dose combination pill (containing 100 mg acetylsalicylic acid, 40
mg simvastatin, and 5 mg ramipril) for 1 week followed by a once-daily oral dose of the cardiovascular fixed-dose
combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks
Comparator: a once-daily oral dose of 5 mg ramipril for 1 week followed by a once-daily oral dose of 10 mg ramipril
for 4 weeks
Outcomes Primary outcomes
• Difference in the adjusted mean 24-h systolic pressure results (using ABPM (ambulatory blood pressure
monitoring)) between the basal and the final visit of each treatment period. (Time frame: days 7 and 36 of period 1
and days 49 and 85 of period 2.) (Designated as safety issue: no)
• Difference in the adjusted mean 24-h systolic pressure results using ABPM in the PP population
Secondary outcomes
• Difference in the adjusted mean 24-h diastolic pressure results between the basal and the final visit of each
treatment period. (Time frame: days 7 and 36 of period 1 and days 49 and 85 of period 2.) (Designated as safety
issue: no)
• Difference in the adjusted mean 24-h diastolic pressure results (using ABPM) between the basal and the final
visit of each treatment period
Notes
NCT01362218
Methods Randomised open-label, parallel assignment
Participants Male or female participants aged ≥ 18 and < 75 years
Previously untreated or not treated with fibrates during the last 6 weeks or with any other lipid-lowering drug for
the last 4 weeks
LDL-cholesterol ≥ 130 and ≤ 220 mg/dL
Systolic blood pressure ≥ 120 and < 160 mmHg and diastolic blood pressure ≥ 70 and < 100 mmHg
Interventions Drug: cardiovascular fixed-dose combination pill (acetylsalicylic acid, simvastatin and ramipril)
Comparator: simvastatin given together with the reference drugs ramipril and acetylsalicylic acid
Outcomes Primary outcomes
• Difference in LDL-cholesterol levels between the basal and the final visit of treatment period
Secondary outcomes
• Difference in VLDL-cholesterol levels between the basal and the final visit of treatment period
• Difference in HDL-cholesterol levels between the basal and the final visit of treatment period
• Difference in total cholesterol levels between the basal and the final visit of treatment period
• Difference in triglyceride levels between the basal and the final visit of treatment period
Notes
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NCT01406431
Methods Randomised, open-label, cross-over assignment
Participants Healthy male volunteers
Age 20-55 years at the time of screening
BMI 19-26 kg/m2 at the time of screening
Interventions Pitavastatin 4 mg (2 tablets), valsartan 160 mg (1 tablet). Other name: Livalo, Diovan
Comparator drug: pitavastatin, valsartan
Outcomes Primary Outcomes:
-Cmax of study drugs after single oral administration
-AUClast of study drugs after single oral administration
Secondary Outcomes
-AUCinf, Tmax and t1/2β of study drugs after single oral administration
Notes
NCT01764178
Methods Randomised, open-label, cross-over trial
Participants Healthy male volunteers
Age 20-55 years at the time of screening
BMI 19-26 kg/m2 at the time of screening
Interventions Livalo fixed combination drug (pitavastatin + valsartan)
Comparator: pitavastatin, valsartan
Outcomes Primary outcomes:
• Cmax and AUC of study drugs after single oral administration
Secondary outcomes:
• AUCinf of study drugs after single oral administration
• t1/2β of study drugs after single oral administration
• Tmax of study drugs after single oral administration
Notes
NCT02075619
Methods Open-label, single-centre, randomised, single-dose, three-way cross-over, six-sequence study
Participants • Male or female 21-65 years of age inclusive, at the time of signing the informed consent
• Alanine transaminase, alkaline phosphatase and total bilirubin <= 1.5 x upper limit of normal (ULN) (isolated
bilirubin > 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%)
• Normal electrocardiogram (ECG) morphology and measurements. Single corrected QT interval (QTc) < 450
ms. In particular QTc < 450 msec or QT < 480 ms in subjects with Bundle Branch Block based on an average from
three ECGs obtained over a brief recording period
• Female participants eligible if of non-childbearing potential. Female participants must agree to use
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contraception until 14 days after last dose of amlodipine/rosuvastatin, i.e. after single dose of treatment period 3
• Male participants with female partners of child-bearing potential must agree to use one of the contraceptive
methods and not to donate sperm.
• Chinese or white self-reported by the participants for both parents and all 4 grandparents. The ethnic group is
as defined by National Registration Identity Cards provided additional confirmation of ethnicity
Interventions Experimental: Sequence 1
Four participants (2 Chinese and 2 white) will receive 1 amlodipine 10 mg tablet and 1 rosuvastatin 20 mg tablet in
Period 1; 1 GSK3074477 fixed-dose combination (FDC) formulation-1 tablet in Period 2 and 1 GSK3074477 FDC
formulation-2 tablet in Period 3; all treatments will be administered orally in fasted state. The 3 treatment periods
will be separated by a washout period of between 12-17 days
Experimental: Sequence 2
Four participants (2 Chinese and 2 white) will receive 1 amlodipine 10 mg tablet and 1 rosuvastatin 20 mg tablet
in Period 1; 1 GSK3074477 FDC formulation-2 tablet in Period 2 and 1 GSK3074477 FDC formulation-1 tablet
in Period 3; all treatments will be administered orally in fasted state. The 3 treatment periods will be separated by a
washout period of between 12-17 days
Experimental: Sequence 3
Four participants (2 Chinese and 2 white) will receive 1 GSK3074477 FDC formulation-1 tablet in Period 1, 1
amlodipine 10 mg tablet and 1 rosuvastatin 20 mg tablet in Period 2; and 1 GSK3074477 FDC formulation-2 tablet
in Period 3; all treatments will be administered orally in fasted state. The 3 treatment periods will be separated by a
washout period of between 12-17 days
Experimental: Sequence 4
Four participants (2 Chinese and 2 white) will receive 1 GSK3074477 FDC formulation-1 tablet in Period 1; 1
GSK3074477 FDC formulation-2 tablet in Period 2; and 1 amlodipine 10 mg tablet and 1 rosuvastatin 20 mg tablet
in Period 3; all treatments will be administered orally in fasted state. The 3 treatment periods will be separated by a
washout period of between 12-17 days
Experimental: Sequence 5
Four participants (2 Chinese and 2 white) will receive 1 GSK3074477 FDC formulation-2 tablet in Period 1; 1
amlodipine 10 mg tablet and 1 rosuvastatin 20 mg tablet in Period 2; and 1 GSK3074477 FDC formulation-1 tablet
in Period 3; all treatments will be administered orally in fasted state. The 3 treatment periods will be separated by a
washout period of between 12-17 days
Experimental: Sequence 6
Four participants (2 Chinese and 2 white) will receive 1 GSK3074477 FDC formulation-2 tablet in Period 1; 1
GSK3074477 FDC formulation-1 tablet in Period 2; and 1 amlodipine 10 mg tablet and 1 rosuvastatin 20 mg tablet
in Period 3; all treatments will be administered orally in fasted state. The 3 treatment periods will be separated by a
washout period of between 12-17 days
Outcomes Primary outcomes:
• Plasma pharmacokinetics (PK) parameters of amlodipine and rosuvastatin following single dose administration
Secondary outcomes:
• Safety as assessed by adverse events
• Safety as assessed by vital signs
• Safety as assessed by clinical laboratory safety data
• Safety as assessed by Electrocardiogram (ECG) parameters
Notes
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NCT02569814
Methods Randomised, open-label, cross-over assignment trial
Participants Healthy men, aged 19-50 years
Interventions Group1
Fimasartan/amlodipine combination tablet and rosuvastatin individual tablets at 1st day as period I. And then, after
wash out for 2 weeks, as period II, Group 1 participants take a fimasartan/amlodipine/rosuvastatin combination
tablet at 15th day
Group 2
A fimasartan/amlodipine/rosuvastatin combination tablet at 1st day as period I. And then, after wash out for 2 weeks,
as period II, Group 2 participants take fimasartan/amlodipine combination tablet and rosuvastatin individual tablets
at 15th day
Outcomes Primary outcome
-Cmax of fimasartan, amlodipine and rosuvastatin
Secondary outcome
-AUCt (Area Under the Curve) of fimasartan, amlodipine and rosuvastatin
Notes
NCT02662894
Methods Randomised parallel-assignment, open-label trial
Participants Participants of both sexes aged 18-65 years
Participants diagnosed with uncontrolled hypertension
Participants with intermediate and high risk dyslipidaemia, according to the V Brazilian Guidelines on Dyslipidemia
and Prevention of Atherosclerosis
Ability to understand and consent to participate in this clinical study, manifested by signing the Informed Consent
Interventions Valsartan + rosuvastatin FDC
Fixed-dose combination of valsartan (160 mg or 320 mg) + rosuvastatin (20 mg), once daily for 4 weeks
Comparator: separate tablets of valsartan (160 mg or 320 mg) + rosuvastatin (20 mg), once daily for 4 weeks
Outcomes Primary outcomes:
• Reduction of systemic blood pressure measured between the first visit and last visit.
• Percentage of participants who reach the goal of LDL-C according to intermediate risk rating (LDLc < 100
mg/dL ) and high risk (LDLc < 70 mg/dL)
Secondary outcomes:
• Incidence and severity of adverse events recorded after the signing of the Informed Consent and until the end
of the study
Notes
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Methods Randomised, open-label, parallel-assignment trial
Participants Men or women aged ≥ 18 and < 75 years
People with Stage 1 (SBP/DBP: 140-159/90-99 mmHg) or Stage 2 (SBP/DBP:≥ 160/≥ 100 mmHg) hypertension,
either untreated or after a wash out period
LDL cholesterol level of ≥ 100 mg/dL and, either untreated or after the wash out period
Untreated with BP-lowering and/or lipid-lowering medication
Treatedwith BP-lowering and/or lipid-loweringmedication can be included if themedication can be safely withdrawn
as per physician’s judgment
Interventions A once-daily oral dose of the Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, ator-
vastatin 40 mg and ramipril 10 mg) for 4 weeks
Comparator
• Atorvastatin 40 mg: a once-daily oral dose of atorvastatin 40 mg (Lipitor®) for 4 weeks
• A once-daily oral dose of ramipril 10 mg (Altace®) for 4 weeks
Outcomes Primary outcomes
• Difference in the adjusted mean 24-h systolic blood pressure results using ABPM between the baseline (week
0) and the final visit (week 8)
• Difference in LDL cholesterol levels between the baseline (week 4) and the final visit (week 8)
Secondary outcome measures
• Difference in the adjusted mean 24-h diastolic blood pressure results (using ABPM) between the basal and the
final visits
• Difference in the adjusted mean 24-h mean arterial pressure results (using ABPM) between the basal and the
final visits
• Difference in the adjusted mean 24-h heart rate results (using ABPM) between the basal and the final visits
• Difference in very low-density lipoprotein (VLDL) cholesterol levels between the basal and the final visits
• Difference in HDL cholesterol levels between the basal and the final visits
• Difference in total cholesterol levels between the basal and the final visits
• Difference in triglyceride levels between the basal and the final visits
• Incidence of treatment-emergent adverse events (safety and tolerability)
Notes
NCT02842359
Methods Randomised, open-label, parallel-assignment trial
Participants Aged ≥ 19 years to < 75 years
No medication history of hyperlipidaemia and hypertension within 3 months following registration, among people
with type 2 diabetes diagnosed with hyperlipidaemia and stage I hypertension (systolic blood pressure:≥ 140 mmHg,
≤ 159 mmHg or diastolic blood pressure: ≥ 90 mmHg, ≤ 99 mmHg), with adequately controlled haemoglobin
levels
Diagnosis of diabetes: haemoglobin A1c ≥ 6.5% or; fasting plasma glucose level above 8 hour ≥ 126 mg/dL or
plasma glucose ≥ 200 mg/dL ( 11.1 mmol/l) 2 h after a 75 g glucose load or symptoms (such as polyuria, polydipsia,
unexplained weight loss) and a random plasma glucose ≥ 200 mg/dL (11.1 mmol/L)
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Interventions Irbesartan/atorvastatin fixed-dose combination: pharmaceutical form: tablet; route of administration: oral; other
name: Rovelito
Comparators
Irbesartan SR47436: pharmaceutical form: tablet; route of administration: oral; other name: Aprovel
Atorvastatin: pharmaceutical form: tablet; route of administration: oral; other name: Newvast
Outcomes Primary outcomes: (time frame: 4 weeks-maximum 5 weeks)
• Change from baseline in flow mediated dilatation
Secondary outcomes: (Time frame: 4 weeks up to maximum 5 weeks)
• Rate of change from baseline in nytrotyrosine marker
• Rate of change from baseline in Intercellular Adhesion Molecule-1
• Rate of change from baseline in interleukin-6
• Rate of change from baseline in C-reactive protein
• Change from baseline in blood pressure (irbesartan/atorvastatin fixed-dose combination group and irbesartan
group)
• Change from baseline in low density lipoprotein-C (irbesartan/atorvastatin fixed-dose combination group and
atorvastatin group)
• Change from baseline in total cholesterol (irbesartan/atorvastatin fixed-dose combination group and
atorvastatin group)
• Change from baseline in high density lipoprotein-C (irbesartan/atorvastatin fixed-dose combination group
and atorvastatin group)
• Change from baseline in triglycerides (irbesartan/atorvastatin fixed-dose combination group and atorvastatin
group)
• Change from baseline in apolipoprotein-A1 (irbesartan/atorvastatin fixed-dose combination group and
atorvastatin group)
• Change from baseline in apolipoprotein-B (irbesartan/atorvastatin fixed-dose combination group and
atorvastatin group) -Percentage of participants with decreased level of blood pressure (irbesartan/atorvastatin fixed-
dose combination group and irbesartan group)]
• Rate of change from baseline in immunosenescence T cell fractionation
• Rate of change from baseline in T-cell induced inflammatory factors
Notes
Characteristics of ongoing studies [ordered by study ID]
INTEGRATE
Trial name or title INTEGRATE Study: A pragmatic cluster randomised controlled trial of an integrated general practice and
pharmacy-based intervention to promote the prescription and use of appropriate preventive medications
among individuals at high cardiovascular risk
Methods Cluster-randomized control, open-label, parallel-assignment
Participants All adult patients (18 years) attending the GP will be potentially be eligible to receive the HealthTracker
intervention. All adult patients who are recommended for the component medications according to current
guidelines are eligible to be prescribed the polypill therapy. All adult patients attending the paired pharmacy
with a new prescription for a CVDpreventionmedication will be eligible to receive the pharmacy intervention
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Interventions The integrated intervention comprises the following three elements: (1) HealthTracker, (2) availability of the
Polypills and (3) Pharmacy Adherence Support Service (PASS)
** Eight CVD polypills will be available and they are:
• Name: PolyPill Hydroirb; components: hydrochlorothiazide (12.5 mg) + irbesartan (150 mg) +
atorvastatin (40 mg)
• Name: PolyPill Hydroirb Asp; components: hydrochlorothiazide (12.5 mg) + irbesartan (150 mg) +
atorvastatin (40 mg) + 100 mg aspirin
• Name: PolyPill Amloirb; components: amlodipine (5 mg) + irbesartan (150 mg) + atorvastatin (40 mg)
• Name: PolyPill Amloirb Asp; components: amlodipine (5 mg) + irbesartan (150 mg) + atorvastatin (40
mg) + aspirin (100 mg)
• Name: PolyPill Perindap; components: perindopril (4 mg) + indapamide (1.25 mg) + atorvastatin (40
mg)
• Name: PolyPill Perindap Asp; components: perindopril (4 mg) + indapamide (1.25 mg) + atorvastatin
(40 mg) + aspirin (100 mg)
• Name: PolyPill Peramlo; components: perindopril (4 mg) + amlodipine (5 mg) + atorvastatin (40 mg)
• Name: PolyPill Peramlo Asp; components: perindopril (4 mg) + amlodipine (5 mg) + atorvastatin (40
mg) + aspirin (100 mg)
Outcomes Primary Outcomes
• Proportion of high-risk participants who were not on full treatment at baseline achieving
recommended target (i) BP and (ii) LDL-C target levels, at the end of the study. This is a composite primary
outcome. These levels will be extracted from the general practice software systems using a general practice
data auditing tool known as Clinical Audit Tool (CAT). Data is de-identified prior to extraction
Secondary Outcomes
• Proportion of high-risk participants who were not on full treatment at baseline achieving
recommended target BP levels at study end
• Proportion of under-treated high-risk participants achieving recommended BP or LDL-C targets.
Note: not composite. Data will be extracted from the general practice software systems using CAT. Under-
treated includes participants at high risk of a CV event, not on full treatment at baseline. Full treatment: at
least 1 BP-lowering drug and a statin for participants without established CVD; for those with CVD, full
treatment will additionally require at least 1 antiplatelet drug
• Proportion of all high-risk participants achieving BP and LDL-C targets. Data will be extracted from
the general practice software systems using CAT.
• Proportion of participants achieving BP and LDL-C targets and prescribed antiplatelet (if relevant).
Data will be extracted from the general practice software systems using CAT
• Risk factor measurement and mean levels. Data will be extracted from the general practice software
systems using CAT. Risk factor measurement is calculated by HealthTracker
• Treatment intensity in high-risk participants. Proportion of high-risk participants who receive a dose
escalation or addition to their prescribed medication during the intervention period. De-identified data will
be extracted from the general practice software systems using CAT
• Polypill prescriptions - will be assessed from the number of consent forms signed for the polypill and
the supply of polypills
• Participation in pharmacy adherence support programmes. Will be assessed from the number of
consent forms for the PASS
• Proportion of non-high risk participants receiving either BP lowering or statin and or anti-platelet
therapy (looking at all the therapies individually and combined)
Starting date 1 March 2016
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INTEGRATE (Continued)
Contact information Prof Anushka Patel, apatel@georgeinstitute.org
Notes
NCT01646437
Trial name or title The International Polycap Study-3
Methods 2 x 2 x 2 randomised controlled trial, factorial design (3 arms: Polycap, aspirin, vitamin D)
Participants 5000 participants (women 60 years or older and men 55 years or older) without known heart disease or prior
stroke and without a clear indication or contraindication to any of the study medications and INTERHEART
risk score of 10 or greater
Interventions Polycap vs. placebo; embedded in trial comparing enteric coated aspirin vs. placebo and vitamin D vs. placebo
Outcomes Composite of major CVD (CV death, non-fatal stroke, non-fatal MI), plus heart failure, resuscitated cardiac
arrest, or revascularisation with evidence of ischaemia in participants taking Polycap versus placebo
Starting date June 2012; protocol updated on clinicaltrials.gov onMay 2015 (ClinicalTrials.gov Identifier: NCT01646437)
Contact information Dr. Salim Yusuf, Population Health Research Institute
Notes
NCT01826019
Trial name or title Heart Outcomes Prevention and Evaluation 4 (HOPE-4)
Methods Open-label, parallel, cluster-randomised controlled trial design
Participants HT Phase: at least 50 urban and rural communities in Canada, Colombia and Malaysia will be randomised
to participate in an intensive CV risk detection and control program by NPHW or to care as usual for 12
months
CVD Phase: continuation and expansion of HT Phase to include at least 190 urban and rural communities
in countries within Asia, South America, Sub-Saharan Africa, and Canada that will be allocated to participate
in an intensive CV risk detection and control programme supported by NPHWs or to care as usual for up to
6 years
Inclusion criteria
Individuals (≥ 50 years) with at least ONE of the following criteria:
• SBP ≥ 160 mmHg in one visit
• SBP 140-159 mmHg in one visit AND participant-reported medical diagnosis of hypertension
• SBP 140-159 mmHg in one visit AND participant taking anti-HT medication
• SBP ≥ 130 mmHg in one visit AND participant-reported medical diagnosis of diabetes
• SBP ≥ 130 mmHg in one visit AND participant taking medication for diabetes
• Participants that do not meet criteria 1-5 AND SBP 140-159 mmHg in one visit AND SBP ≥ 140
mmHg in a second visit ≥ 24 h apart
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Interventions Intensive CV risk detection, counselling and follow-up programme by NPHW; recommended CV medi-
cations will include combinations of anti-hypertensive medications (both low and high doses) and a lipid-
lowering agent (e.g. statin) in accordance with treatment algorithm (precise formulations used may differ in
each country); use of treatment supporters to reinforce adherence
Comparator: usual care. Participants in control communities will be referred to usual care
Outcomes Primary outcomes
• Change in systolic BP (SBP) between the intervention and control communities at 6 and 12 months
(time frame: baseline to 6 months and 12 months (HT phase))
• Proportion of participants with well-controlled blood pressure at 6 and 12 months (SBP < 140 mmHg
in non-diabetics and SBP < 130 mmHg in diabetics (time frame: baseline to 6 months and 12 months (HT
phase))
• Change in HDL, LDL, total cholesterol, triglycerides, and glucose levels at 12 months (time frame:
baseline to 1 year (HT phase))
• Change in smoking status at 6 and 12 months(time frame: baseline to 6 months and 12 months (HT
phase))
• Change in IHRS at 6 and 12 months and ChRS at 12 months (time frame: baseline to 6 months and
12 months (HT phase))
• Number of participants receiving prescriptions for (or taking) anti-hypertensive medications (as an
indication of physician adherence to treatment guidelines) at 6 and 12 months (time frame: baseline to 6
months and 12 months (HT phase))
• Medication adherence measures at 6 and 12 months (time frame: baseline to 6 months and 12 months
(HT phase))
• Clinical events (e.g. death, CVD development, hospitalisations) at 6 and 12 months (time frame:
baseline to 6 months and 12 months (HT phase))
• Country-specific process outcomes at 6 and 12 months (time frame: baseline to 6 months and 12
months (HT phase))
• Change in individual components of the primary outcomes in the HT phase (time frame: baseline to 6
years (CVD phase))
• Secondary outcomes from the HT phase (time frame: baseline to 6 years (CVD phase))
Secondary outcomes
• A descriptive analysis of the processes involved in the intervention (time frame: baseline to 6 years)
• Qualitative feedback from participants, NPHWs, and supervising physicians (time frame: baseline to 6
years)
• Health economic and quality-of-life evaluations (as available and appropriate). (Time frame: baseline
to 6 years)
• We will collect data that will allow us to determine the costs of the suggested programmes (i.e.
intervention package) and the costs of what is being provided currently for CVD assessment and
management in the communities studied (i.e. control)
Starting date August 2014
Contact information Contact: Patricio Lopez-Jaramillo, MD
jplopezj@gmail.com
Notes
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NCT02278471
Trial name or title The SCCS Polypill Pilot Trial
Methods Randomised, parallel-assignment, open-label trial
Participants Enrolled at the SCCS site in Mobile, Alabama, obtain care at Franklin Primary Health Center, or live in the
surrounding area
Aged 45-75 years
Baseline systolic blood pressure ≥ 120 mm Hg
Interventions The study medication will be a fixed-dose combination pill (polypill) containing: atorvastatin 10 mg, am-
lodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg. Once daily medication
Comparator: usual care: they will remain on the same care that they are used to receiving
Outcomes Primary outcomes
• Systolic blood pressure (time frame: 12 months) polypill versus usual care
• Medication adherence (time frame: 12 months) polypill arm-evaluation via pill counts
• LDL cholesterol (time frame: 12 months)
Secondary outcome measures
• Systolic blood pressure (time frame: 2 months)
• Medication adherence (time frame: 2 months)
• Medication adherence (time Frame: 12 months)
• LC/MS/MS-based drug metabolite profile assay screen in the polypill arm
• LDL cholesterol (time frame: 2 months)
Starting date December 2015
Contact information Judy P. Mitchell 251-436-7631 judy.mitchell@franklinprimary.org
Notes
NCT02596126
Trial name or title Secondary Prevention of Cardiovascular Disease in the Elderly Trial (SECURE)
Methods Randomised, open-label, parallel-assignment
Participants A total number of 3206 participants will be randomized (1:1) to treatment arms. Participants will be recruited
across seven countries in Europe (Spain, Italy, Germany, France, Hungary, Poland, and Czech Republic)
• Participants will be ≥ 65 years old and diagnosed with a type 1 myocardial infarction within 8 weeks
prior to study enrolment
Inclusion criteria
• Participants diagnosed with a type 1 myocardial infarction within the previous 8 weeks.
• Participants must be ≥ 65 years old, presenting with at least one of the following additional conditions:
Documented diabetes mellitus or previous treatment with oral hypoglycemic drugs or insulin
Mild to moderate renal dysfunction: creatinine clearance 60-30 mL/min/1.73 m2
Prior myocardial infarction: defined as an AMI occurring before the index event documented in a medical
report
Prior coronary revascularization: coronary artery bypass grafting (CABG) or percutaneous coronary interven-
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NCT02596126 (Continued)
tion (PCI)
Prior stroke: history of a documented stroke, defined as an acute episode of focal cerebral, spinal, or retinal
dysfunction caused by infarction of central nervous system tissue, not resulting in death
Age ≥ 75 years.
Interventions (A) aspirin 100 mg, atorvastatin 40 mg, and ramipril (2.5 mg, or 5 mg, or 10mg)
or
(B) aspirin 100 mg, atorvastatin 20 mg, and ramipril (2.5 mg, or 5 mg, or 10mg)
Other name: Polypill
Comparator: participants allocated to the usual care arm will receive standard of care therapies for secondary
prevention according to the ESC guidelines. Drugs and doses will be left at the discretion of the treating
physicians
Outcomes Primary outcome measures
• Major adverse cardiovascular events
• Cardiovascular death
• Any nonfatal type 1 myocardial infarction
• Any nonfatal ischaemic stroke
• Any urgent coronary revascularisation not resulting in death
Secondary Outcomes
• Evaluate the efficacy of treatment: incidence of the first occurrence of any component of the following
composite endpoint:
◦ CV death
◦ MI
◦ stroke
• Evaluate the first occurrence of the individual components of the primary endpoint:
◦ CV death
◦ Nonfatal type 1 myocardial infarction
◦ Nonfatal ischaemic stroke
◦ Urgent coronary revascularisation
• Change in treatment adherence: the Morisky-Medication Adherence Scale (8 item) Questionnaire will
be administered
• Change in Patient Satisfaction: the Treatment Satisfaction Questionnaire for Medication (TSQM) will
be administered
• Change in systolic and diastolic blood pressure (SBP and DBP): systolic and diastolic blood pressure
will be collected and summarised at each time point
• Change in LDL cholesterol level: non-fasting blood analysis will be collected and LDL cholesterol level
evaluated at each time point
• Regional differences in performance of the polypill in the previous endpoints
• Health economic evaluation comparing intervention and usual care arm
• Cost differences and Incremental Cost-Effectiveness Ratio (ICER) will be assessed at each time point
• Change in quality of life: the European Quality of Life- 5 Dimensions (EQ-5D) Questionnaire will be
administered at each time point to evaluate change in quality of life.
• Incidence of treatment-emergent adverse events (safety and tolerability) (time frame: 24 months)
• All-cause mortality and adverse events (bleeding, renal dysfunction, drug, allergies, and refractory
cough leading to drug discontinuation)
Starting date January 2016
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NCT02596126 (Continued)
Contact information Jose Maria Castellano Vazquez, MD, PhD, josemaria.castellano@cnic.es
Notes
PolyIran
Trial name or title PolyIran
Methods Zelen design, randomised controlled trial nested within the Golestan cohort study (110:90 ratio)
Participants 7000 (2400 in related PolyIran Liver trial) cohort participants over 50 years in Iran followed for 5 years
Interventions Fixed-combination therapy (aspirin 80 mg, hydrochlorthiazide 12.5 mg, valsartan 40 mg, and atorvastatin
20 mg (PolyPill 4-2, Alborz-Darou, Ghazvin, Iran),) + usual care versus usual care alone
Outcomes Primary outcome
• major cardiovascular events (non-fatal myocardial infarction and unstable angina)
• fatal myocardial infarction
• sudden death
• new-onset heart failure
• coronary artery revascularization procedures
• stroke (fatal or non-fatal)
• Secondary outcomes
• all-cause mortality
• individual components of the primary outcome
• liver-related secondary outcomes: changes in liver stiffness, liver enzyme levels, Visceral Adipose Tissue
thickness (VAT), Subcutaneous Adipose Tissue thickness (SAT) and carotid Intima-media thickness (IMT).
• Additional secondary outcomes include the proportion of patients with pNASH and pNAFLD.
Compliance and adverse events will also be assessed
Measured at 2.5 years and 5 years
Starting date October 2011
Contact information Reza Malekzadeh MD, Digestive Disease Research Institute, Tehran University of Medical Sciences,
Shariati Hospital, 1411713135, Tehran, Iran. Tel: +98 (21) 8241-5000, Fax: +98 (21) 8241-5400, E-mail:
malek@tums.ac.ir
TomMarshall MD, School of Health and Population Sciences, University of Birmingham, Edgbaston, Birm-
ingham B15 2TT, UK. Tel: 44 (0)121 414 7832, Fax: 44 (0)121 414 7878, E-mail: T.P.Marshall@bham.ac.
uk
Notes PolyIran protocol: Eur J Prev Cardiol. 2015; 22(12) 1609-1617.
PolyIran Liver protocol: Arch Iran Med. 2015; 18(8): 515 - 523.
Registriations: NCT00603590, NCT01245608, NCT01271985
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D A T A A N D A N A L Y S E S
Comparison 1. Mortality and cardiovascular events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 5 5300 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.64, 1.89]
2 All-cause mortality: comparator
as usual care
4 4601 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.64, 1.91]
3 All-cause mortality: comparator
provision of individual drugs
1 699 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.06, 15.88]
4 All-cause mortality: 3+ drugs 4 3839 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.56, 1.78]
5 All-cause mortality: 2+ drugs 1 1461 Risk Ratio (M-H, Fixed, 95% CI) 2.19 [0.43, 11.24]
6 Fatal or non-fatal ASCVD events 6 4517 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.95, 1.66]
7 Fatal and non-fatal ASCVD
events: primary prevention
trials
2 686 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.04, 3.23]
8 Fatal and non-fatal ASCVD
events: secondary prevention
trials
4 3831 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.97, 1.72]
9 Fatal and non-fatal ASCVD
events: comparator provision of
individual drugs
2 906 Risk Ratio (M-H, Fixed, 95% CI) 1.63 [0.66, 3.98]
10 Fatal and non-fatal ASCVD
events: comparator as usual
care
4 3611 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.91, 1.64]
11 Fatal and non-fatal ASCVD
events: 3+ drugs
5 4306 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.96, 1.69]
12 Fatal and non-fatal ASCVD
events: 2 drugs
1 211 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.02, 8.05]
Comparison 2. Adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Any adverse event 11 6906 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [1.09, 1.25]
2 Any adverse event: primary
prevention trials
6 1610 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [1.17, 1.60]
3 Any adverse event: secondary
prevention trial
5 5296 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [1.03, 1.20]
4 Any adverse event: comparator
as usual care
4 4601 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [1.03, 1.21]
5 Adverse event: comparator as
placebo or inactive control
7 2305 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [1.12, 1.43]
6 Adverse event: 3+ drugs only 7 4860 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [1.08, 1.30]
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7 Adverse events: 2 drugs 4 2046 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [1.01, 1.25]
8 Myalgias 8 4745 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.84, 1.48]
9 Increased liver enzymes 4 1638 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.74, 1.47]
10 Cough 5 2788 Risk Ratio (M-H, Random, 95% CI) 1.86 [0.75, 4.59]
11 Dyspepsia/gastrointestinal
irritation
4 3417 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.64, 2.74]
12 Bleeding 2 891 Risk Ratio (M-H, Fixed, 95% CI) 5.68 [1.01, 32.03]
Comparison 3. Blood pressure
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Systolic blood pressure 13 7638 Mean Difference (IV, Random, 95% CI) -6.34 [-9.03, -3.64]
2 Diastolic blood pressure 13 7628 Mean Difference (IV, Random, 95% CI) -3.33 [-4.86, -1.79]
3 Systolic blood pressure: primary
prevention trials
8 2463 Mean Difference (IV, Random, 95% CI) -8.67 [-12.41, -4.94]
4 Systolic blood pressure:
secondary prevention trial
5 5175 Mean Difference (IV, Random, 95% CI) -3.20 [-6.98, 0.59]
5 Systolic blood pressure:
comparator as usual care
5 4673 Mean Difference (IV, Random, 95% CI) -3.44 [-7.61, 0.74]
6 Systolic blood pressure: placebo
or inactive control
5 1245 Mean Difference (IV, Fixed, 95% CI) -10.77 [-12.72, -8.
81]
7 Systolic blood pressure: 3+ drugs
only
9 5758 Mean Difference (IV, Random, 95% CI) -5.03 [-8.13, -1.93]
8 Systolic blood pressure: 2 drugs 4 1870 Mean Difference (IV, Random, 95% CI) -9.56 [-14.75, -4.38]
Comparison 4. Lipids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total cholesterol 11 6565 Mean Difference (IV, Random, 95% CI) -0.61 [-0.88, -0.35]
2 LDL cholesterol 12 7153 Mean Difference (IV, Random, 95% CI) -0.70 [-0.98, -0.41]
3 Total cholesterol: primary
prevention trials
7 2147 Mean Difference (IV, Random, 95% CI) -0.92 [-1.18, -0.65]
4 Total cholesterol: secondary
prevention trials
4 4417 Mean Difference (IV, Random, 95% CI) -0.16 [-0.49, 0.17]
5 Total cholesterol: comparator as
usual care
5 4620 Mean Difference (IV, Random, 95% CI) -0.16 [-0.44, 0.12]
6 Total cholesterol: placebo or
inactive control
4 1148 Mean Difference (IV, Random, 95% CI) -0.83 [-0.99, -0.67]
7 Total cholesterol: 3+ drugs only 8 4792 Mean Difference (IV, Random, 95% CI) -0.48 [-0.80, -0.16]
8 Total cholesterol: 2 drugs 3 1773 Mean Difference (IV, Random, 95% CI) -0.94 [-1.50, -0.38]
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Comparison 5. Adherence
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adherence 4 3835 Risk Ratio (M-H, Random, 95% CI) 1.44 [1.26, 1.65]
2 Adherence: usual care as
comparator
3 3140 Risk Ratio (M-H, Fixed, 95% CI) 1.42 [1.35, 1.49]
3 Adherence: comparator
provision of individual drugs
1 695 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [1.06, 1.47]
Comparison 6. Discontinuation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Discontinuation 7 3118 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [1.01, 1.51]
Comparison 7. Health-related quality of life
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 EQ-5D health state 3 3009 Mean Difference (IV, Fixed, 95% CI) 0.22 [-1.02, 1.46]
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Analysis 1.1. Comparison 1 Mortality and cardiovascular events, Outcome 1 All-cause mortality.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 1 Mortality and cardiovascular events
Outcome: 1 All-cause mortality
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CRUCIAL 2011 5/779 2/682 8.5 % 2.19 [ 0.43, 11.24 ]
FOCUS 2014 1/350 1/349 4.0 % 1.00 [ 0.06, 15.88 ]
IMPACT 2014 4/256 6/257 23.8 % 0.67 [ 0.19, 2.34 ]
Kanyini GAP 2014 1/311 1/312 4.0 % 1.00 [ 0.06, 15.97 ]
UMPIRE 2013 17/1002 15/1002 59.7 % 1.13 [ 0.57, 2.26 ]
Total (95% CI) 2698 2602 100.0 % 1.10 [ 0.64, 1.89 ]
Total events: 28 (FDC), 25 (Comparator)
Heterogeneity: Chi2 = 1.30, df = 4 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Comparator Fixed-dose combination
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Analysis 1.2. Comparison 1 Mortality and cardiovascular events, Outcome 2 All-cause mortality:
comparator as usual care.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 1 Mortality and cardiovascular events
Outcome: 2 All-cause mortality: comparator as usual care
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CRUCIAL 2011 5/779 2/682 8.8 % 2.19 [ 0.43, 11.24 ]
IMPACT 2014 4/256 6/257 24.8 % 0.67 [ 0.19, 2.34 ]
Kanyini GAP 2014 1/311 1/312 4.1 % 1.00 [ 0.06, 15.97 ]
UMPIRE 2013 17/1002 15/1002 62.2 % 1.13 [ 0.57, 2.26 ]
Total (95% CI) 2348 2253 100.0 % 1.11 [ 0.64, 1.91 ]
Total events: 27 (FDC), 24 (Comparator)
Heterogeneity: Chi2 = 1.29, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Comparator Fixed-dose combination
Analysis 1.3. Comparison 1 Mortality and cardiovascular events, Outcome 3 All-cause mortality:
comparator provision of individual drugs.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 1 Mortality and cardiovascular events
Outcome: 3 All-cause mortality: comparator provision of individual drugs
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
FOCUS 2014 1/350 1/349 100.0 % 1.00 [ 0.06, 15.88 ]
Total (95% CI) 350 349 100.0 % 1.00 [ 0.06, 15.88 ]
Total events: 1 (FDC), 1 (Comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Comparator Fixed-dose combination
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Analysis 1.4. Comparison 1 Mortality and cardiovascular events, Outcome 4 All-cause mortality: 3+ drugs.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 1 Mortality and cardiovascular events
Outcome: 4 All-cause mortality: 3+ drugs
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
FOCUS 2014 1/350 1/349 4.4 % 1.00 [ 0.06, 15.88 ]
IMPACT 2014 4/256 6/257 26.0 % 0.67 [ 0.19, 2.34 ]
Kanyini GAP 2014 1/311 1/312 4.3 % 1.00 [ 0.06, 15.97 ]
UMPIRE 2013 17/1002 15/1002 65.3 % 1.13 [ 0.57, 2.26 ]
Total (95% CI) 1919 1920 100.0 % 1.00 [ 0.56, 1.78 ]
Total events: 23 (FDC), 23 (Comparator)
Heterogeneity: Chi2 = 0.52, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Comparator Fixed-dose combination
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Analysis 1.5. Comparison 1 Mortality and cardiovascular events, Outcome 5 All-cause mortality: 2+ drugs.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 1 Mortality and cardiovascular events
Outcome: 5 All-cause mortality: 2+ drugs
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CRUCIAL 2011 5/779 2/682 100.0 % 2.19 [ 0.43, 11.24 ]
Total (95% CI) 779 682 100.0 % 2.19 [ 0.43, 11.24 ]
Total events: 5 (FDC), 2 (Comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Comparator Fixed-dose combination
Analysis 1.6. Comparison 1 Mortality and cardiovascular events, Outcome 6 Fatal or non-fatal ASCVD
events.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 1 Mortality and cardiovascular events
Outcome: 6 Fatal or non-fatal ASCVD events
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
FOCUS 2014 12/350 6/345 7.2 % 1.97 [ 0.75, 5.19 ]
IMPACT 2014 16/256 18/267 21.0 % 0.93 [ 0.48, 1.78 ]
Kanyini GAP 2014 26/304 22/305 26.2 % 1.19 [ 0.69, 2.05 ]
Malekzadeh 2010 0/241 1/234 1.8 % 0.32 [ 0.01, 7.91 ]
OLSTA 2016 0/71 2/140 2.0 % 0.39 [ 0.02, 8.05 ]
UMPIRE 2013 50/1002 35/1002 41.7 % 1.43 [ 0.94, 2.18 ]
Total (95% CI) 2224 2293 100.0 % 1.26 [ 0.95, 1.66 ]
Total events: 104 (FDC), 84 (Comparator)
0.5 0.7 1 1.5 2
Comparator Fixed-dose combination
(Continued . . . )
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(. . . Continued)
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 3.33, df = 5 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Comparator Fixed-dose combination
Analysis 1.7. Comparison 1 Mortality and cardiovascular events, Outcome 7 Fatal and non-fatal ASCVD
events: primary prevention trials.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 1 Mortality and cardiovascular events
Outcome: 7 Fatal and non-fatal ASCVD events: primary prevention trials
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Malekzadeh 2010 0/241 1/234 47.4 % 0.32 [ 0.01, 7.91 ]
OLSTA 2016 0/71 2/140 52.6 % 0.39 [ 0.02, 8.05 ]
Total (95% CI) 312 374 100.0 % 0.36 [ 0.04, 3.23 ]
Total events: 0 (FDC), 3 (Comparator)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Comparator Fixed-dose combination
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Analysis 1.8. Comparison 1 Mortality and cardiovascular events, Outcome 8 Fatal and non-fatal ASCVD
events: secondary prevention trials.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 1 Mortality and cardiovascular events
Outcome: 8 Fatal and non-fatal ASCVD events: secondary prevention trials
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
FOCUS 2014 12/350 6/345 7.5 % 1.97 [ 0.75, 5.19 ]
IMPACT 2014 16/256 18/267 21.9 % 0.93 [ 0.48, 1.78 ]
Kanyini GAP 2014 26/304 22/305 27.2 % 1.19 [ 0.69, 2.05 ]
UMPIRE 2013 50/1002 35/1002 43.4 % 1.43 [ 0.94, 2.18 ]
Total (95% CI) 1912 1919 100.0 % 1.29 [ 0.97, 1.72 ]
Total events: 104 (FDC), 81 (Comparator)
Heterogeneity: Chi2 = 2.04, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Comparator Fixed-dose combination
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Analysis 1.9. Comparison 1 Mortality and cardiovascular events, Outcome 9 Fatal and non-fatal ASCVD
events: comparator provision of individual drugs.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 1 Mortality and cardiovascular events
Outcome: 9 Fatal and non-fatal ASCVD events: comparator provision of individual drugs
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
FOCUS 2014 12/350 6/345 78.1 % 1.97 [ 0.75, 5.19 ]
OLSTA 2016 0/71 2/140 21.9 % 0.39 [ 0.02, 8.05 ]
Total (95% CI) 421 485 100.0 % 1.63 [ 0.66, 3.98 ]
Total events: 12 (FDC), 8 (Comparator)
Heterogeneity: Chi2 = 1.00, df = 1 (P = 0.32); I2 =0%
Test for overall effect: Z = 1.07 (P = 0.29)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Comparator Fixed-dose combination
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Analysis 1.10. Comparison 1 Mortality and cardiovascular events, Outcome 10 Fatal and non-fatal ASCVD
events: comparator as usual care.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 1 Mortality and cardiovascular events
Outcome: 10 Fatal and non-fatal ASCVD events: comparator as usual care
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
IMPACT 2014 16/256 18/267 23.2 % 0.93 [ 0.48, 1.78 ]
Kanyini GAP 2014 26/304 22/305 28.9 % 1.19 [ 0.69, 2.05 ]
Malekzadeh 2010 0/241 1/234 2.0 % 0.32 [ 0.01, 7.91 ]
UMPIRE 2013 50/1002 35/1002 46.0 % 1.43 [ 0.94, 2.18 ]
Total (95% CI) 1803 1808 100.0 % 1.22 [ 0.91, 1.64 ]
Total events: 92 (FDC), 76 (Comparator)
Heterogeneity: Chi2 = 1.89, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.19)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Comparator Fixed-dose combination
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Analysis 1.11. Comparison 1 Mortality and cardiovascular events, Outcome 11 Fatal and non-fatal ASCVD
events: 3+ drugs.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 1 Mortality and cardiovascular events
Outcome: 11 Fatal and non-fatal ASCVD events: 3+ drugs
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
FOCUS 2014 12/350 6/345 7.4 % 1.97 [ 0.75, 5.19 ]
IMPACT 2014 16/256 18/267 21.5 % 0.93 [ 0.48, 1.78 ]
Kanyini GAP 2014 26/304 22/305 26.7 % 1.19 [ 0.69, 2.05 ]
Malekzadeh 2010 0/241 1/234 1.9 % 0.32 [ 0.01, 7.91 ]
UMPIRE 2013 50/1002 35/1002 42.6 % 1.43 [ 0.94, 2.18 ]
Total (95% CI) 2153 2153 100.0 % 1.28 [ 0.96, 1.69 ]
Total events: 104 (FDC), 82 (Comparator)
Heterogeneity: Chi2 = 2.75, df = 4 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.090)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Mortality and cardiovascular events, Outcome 12 Fatal and non-fatal ASCVD
events: 2 drugs.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 1 Mortality and cardiovascular events
Outcome: 12 Fatal and non-fatal ASCVD events: 2 drugs
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
OLSTA 2016 0/71 2/140 100.0 % 0.39 [ 0.02, 8.05 ]
Total (95% CI) 71 140 100.0 % 0.39 [ 0.02, 8.05 ]
Total events: 0 (FDC), 2 (Comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Comparator Fixed-dose combination
79Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Adverse events, Outcome 1 Any adverse event.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 2 Adverse events
Outcome: 1 Any adverse event
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CRUCIAL 2011 380/779 300/682 33.8 % 1.11 [ 0.99, 1.24 ]
CUSP 2009 21/66 22/64 2.4 % 0.93 [ 0.57, 1.51 ]
FOCUS 2014 124/350 112/345 11.9 % 1.09 [ 0.89, 1.34 ]
IMPACT 2014 99/256 93/257 9.8 % 1.07 [ 0.85, 1.34 ]
Kanyini GAP 2014 144/311 127/312 13.4 % 1.14 [ 0.95, 1.36 ]
Malekzadeh 2010 97/241 71/234 7.6 % 1.33 [ 1.04, 1.70 ]
OLSTA 2016 17/71 24/140 1.7 % 1.40 [ 0.80, 2.43 ]
PILL 2011 81/189 59/189 6.2 % 1.37 [ 1.05, 1.80 ]
TOGETHER 2010 18/122 11/122 1.2 % 1.64 [ 0.81, 3.32 ]
UMPIRE 2013 118/1002 102/1002 10.8 % 1.16 [ 0.90, 1.49 ]
Wald 2012 24/86 11/86 1.2 % 2.18 [ 1.14, 4.17 ]
Total (95% CI) 3473 3433 100.0 % 1.16 [ 1.09, 1.25 ]
Total events: 1123 (FDC), 932 (Comparator)
Heterogeneity: Chi2 = 10.02, df = 10 (P = 0.44); I2 =0%
Test for overall effect: Z = 4.30 (P = 0.000017)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Adverse events, Outcome 2 Any adverse event: primary prevention trials.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 2 Adverse events
Outcome: 2 Any adverse event: primary prevention trials
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CUSP 2009 21/66 22/64 11.7 % 0.93 [ 0.57, 1.51 ]
Malekzadeh 2010 97/241 71/234 37.6 % 1.33 [ 1.04, 1.70 ]
OLSTA 2016 17/71 24/140 8.4 % 1.40 [ 0.80, 2.43 ]
PILL 2011 81/189 59/189 30.8 % 1.37 [ 1.05, 1.80 ]
TOGETHER 2010 18/122 11/122 5.7 % 1.64 [ 0.81, 3.32 ]
Wald 2012 24/86 11/86 5.7 % 2.18 [ 1.14, 4.17 ]
Total (95% CI) 775 835 100.0 % 1.37 [ 1.17, 1.60 ]
Total events: 258 (FDC), 198 (Comparator)
Heterogeneity: Chi2 = 4.75, df = 5 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 3.96 (P = 0.000074)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Adverse events, Outcome 3 Any adverse event: secondary prevention trial.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 2 Adverse events
Outcome: 3 Any adverse event: secondary prevention trial
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CRUCIAL 2011 380/779 300/682 42.4 % 1.11 [ 0.99, 1.24 ]
FOCUS 2014 124/350 112/345 15.0 % 1.09 [ 0.89, 1.34 ]
IMPACT 2014 99/256 93/257 12.3 % 1.07 [ 0.85, 1.34 ]
Kanyini GAP 2014 144/311 127/312 16.8 % 1.14 [ 0.95, 1.36 ]
UMPIRE 2013 118/1002 102/1002 13.5 % 1.16 [ 0.90, 1.49 ]
Total (95% CI) 2698 2598 100.0 % 1.11 [ 1.03, 1.20 ]
Total events: 865 (FDC), 734 (Comparator)
Heterogeneity: Chi2 = 0.31, df = 4 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 2.70 (P = 0.0070)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Adverse events, Outcome 4 Any adverse event: comparator as usual care.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 2 Adverse events
Outcome: 4 Any adverse event: comparator as usual care
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CRUCIAL 2011 380/779 300/682 49.9 % 1.11 [ 0.99, 1.24 ]
IMPACT 2014 99/256 93/257 14.5 % 1.07 [ 0.85, 1.34 ]
Kanyini GAP 2014 144/311 127/312 19.8 % 1.14 [ 0.95, 1.36 ]
UMPIRE 2013 118/1002 102/1002 15.9 % 1.16 [ 0.90, 1.49 ]
Total (95% CI) 2348 2253 100.0 % 1.12 [ 1.03, 1.21 ]
Total events: 741 (FDC), 622 (Comparator)
Heterogeneity: Chi2 = 0.28, df = 3 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 2.58 (P = 0.0098)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Adverse events, Outcome 5 Adverse event: comparator as placebo or inactive
control.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 2 Adverse events
Outcome: 5 Adverse event: comparator as placebo or inactive control
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CUSP 2009 21/66 22/64 7.3 % 0.93 [ 0.57, 1.51 ]
FOCUS 2014 124/350 112/345 37.1 % 1.09 [ 0.89, 1.34 ]
Malekzadeh 2010 97/241 71/234 23.7 % 1.33 [ 1.04, 1.70 ]
OLSTA 2016 17/71 24/140 5.3 % 1.40 [ 0.80, 2.43 ]
PILL 2011 81/189 59/189 19.4 % 1.37 [ 1.05, 1.80 ]
TOGETHER 2010 18/122 11/122 3.6 % 1.64 [ 0.81, 3.32 ]
Wald 2012 24/86 11/86 3.6 % 2.18 [ 1.14, 4.17 ]
Total (95% CI) 1125 1180 100.0 % 1.26 [ 1.12, 1.43 ]
Total events: 382 (FDC), 310 (Comparator)
Heterogeneity: Chi2 = 7.36, df = 6 (P = 0.29); I2 =18%
Test for overall effect: Z = 3.72 (P = 0.00020)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Adverse events, Outcome 6 Adverse event: 3+ drugs only.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 2 Adverse events
Outcome: 6 Adverse event: 3+ drugs only
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
FOCUS 2014 124/350 112/345 19.6 % 1.09 [ 0.89, 1.34 ]
IMPACT 2014 99/256 93/257 16.1 % 1.07 [ 0.85, 1.34 ]
Kanyini GAP 2014 144/311 127/312 22.0 % 1.14 [ 0.95, 1.36 ]
Malekzadeh 2010 97/241 71/234 12.5 % 1.33 [ 1.04, 1.70 ]
PILL 2011 81/189 59/189 10.2 % 1.37 [ 1.05, 1.80 ]
UMPIRE 2013 118/1002 102/1002 17.7 % 1.16 [ 0.90, 1.49 ]
Wald 2012 24/86 11/86 1.9 % 2.18 [ 1.14, 4.17 ]
Total (95% CI) 2435 2425 100.0 % 1.19 [ 1.08, 1.30 ]
Total events: 687 (FDC), 575 (Comparator)
Heterogeneity: Chi2 = 7.03, df = 6 (P = 0.32); I2 =15%
Test for overall effect: Z = 3.71 (P = 0.00021)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Adverse events, Outcome 7 Adverse events: 2 drugs.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 2 Adverse events
Outcome: 7 Adverse events: 2 drugs
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CRUCIAL 2011 380/779 300/682 86.6 % 1.11 [ 0.99, 1.24 ]
CUSP 2009 21/66 22/64 6.0 % 0.93 [ 0.57, 1.51 ]
OLSTA 2016 17/71 24/140 4.4 % 1.40 [ 0.80, 2.43 ]
TOGETHER 2010 18/122 11/122 3.0 % 1.64 [ 0.81, 3.32 ]
Total (95% CI) 1038 1008 100.0 % 1.13 [ 1.01, 1.25 ]
Total events: 436 (FDC), 357 (Comparator)
Heterogeneity: Chi2 = 2.35, df = 3 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Adverse events, Outcome 8 Myalgias.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 2 Adverse events
Outcome: 8 Myalgias
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
FOCUS 2014 5/250 10/345 10.4 % 0.69 [ 0.24, 1.99 ]
IMPACT 2014 14/256 10/257 12.4 % 1.41 [ 0.64, 3.11 ]
Kanyini GAP 2014 9/311 9/312 11.1 % 1.00 [ 0.40, 2.49 ]
PILL 2011 13/189 14/189 17.4 % 0.93 [ 0.45, 1.92 ]
Soliman 2009 29/105 26/111 31.3 % 1.18 [ 0.75, 1.86 ]
TOGETHER 2010 6/122 7/122 8.7 % 0.86 [ 0.30, 2.48 ]
UMPIRE 2013 3/1002 6/1002 7.4 % 0.50 [ 0.13, 1.99 ]
Wald 2012 9/86 1/86 1.2 % 9.00 [ 1.17, 69.51 ]
Total (95% CI) 2321 2424 100.0 % 1.11 [ 0.84, 1.48 ]
Total events: 88 (FDC), 83 (Comparator)
Heterogeneity: Chi2 = 6.99, df = 7 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Adverse events, Outcome 9 Increased liver enzymes.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 2 Adverse events
Outcome: 9 Increased liver enzymes
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CUSP 2009 1/66 0/64 0.9 % 2.91 [ 0.12, 70.15 ]
Malekzadeh 2010 43/241 38/234 69.5 % 1.10 [ 0.74, 1.64 ]
OLSTA 2016 1/71 0/140 0.6 % 5.88 [ 0.24, 142.41 ]
TIPS 2009 12/412 16/410 28.9 % 0.75 [ 0.36, 1.56 ]
Total (95% CI) 790 848 100.0 % 1.04 [ 0.74, 1.47 ]
Total events: 57 (FDC), 54 (Comparator)
Heterogeneity: Chi2 = 2.39, df = 3 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Adverse events, Outcome 10 Cough.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 2 Adverse events
Outcome: 10 Cough
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FOCUS 2014 5/350 6/345 20.1 % 0.82 [ 0.25, 2.67 ]
Malekzadeh 2010 2/241 0/234 6.9 % 4.86 [ 0.23, 100.60 ]
PILL 2011 19/189 3/189 19.8 % 6.33 [ 1.91, 21.05 ]
Soliman 2009 22/412 12/612 25.8 % 2.72 [ 1.36, 5.44 ]
TIPS 2009 18/105 25/111 27.4 % 0.76 [ 0.44, 1.31 ]
Total (95% CI) 1297 1491 100.0 % 1.86 [ 0.75, 4.59 ]
Total events: 66 (FDC), 46 (Comparator)
Heterogeneity: Tau2 = 0.70; Chi2 = 16.38, df = 4 (P = 0.003); I2 =76%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 Adverse events, Outcome 11 Dyspepsia/gastrointestinal irritation.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 2 Adverse events
Outcome: 11 Dyspepsia/gastrointestinal irritation
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
PILL 2011 23/189 6/189 24.5 % 3.83 [ 1.60, 9.20 ]
Soliman 2009 20/105 15/111 30.0 % 1.41 [ 0.76, 2.60 ]
TIPS 2009 5/412 9/407 20.6 % 0.55 [ 0.19, 1.62 ]
UMPIRE 2013 10/1002 11/1002 25.0 % 0.91 [ 0.39, 2.13 ]
Total (95% CI) 1708 1709 100.0 % 1.33 [ 0.64, 2.74 ]
Total events: 58 (FDC), 41 (Comparator)
Heterogeneity: Tau2 = 0.36; Chi2 = 8.97, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 2.12. Comparison 2 Adverse events, Outcome 12 Bleeding.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 2 Adverse events
Outcome: 12 Bleeding
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
IMPACT 2014 4/256 0/257 33.3 % 9.04 [ 0.49, 166.96 ]
PILL 2011 4/189 1/189 66.7 % 4.00 [ 0.45, 35.46 ]
Total (95% CI) 445 446 100.0 % 5.68 [ 1.01, 32.03 ]
Total events: 8 (FDC), 1 (Comparator)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Blood pressure, Outcome 1 Systolic blood pressure.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 3 Blood pressure
Outcome: 1 Systolic blood pressure
Study or subgroup FDC Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CRUCIAL 2011 760 -19.8 (17.1) 657 -10 (16.4) 8.8 % -9.80 [ -11.55, -8.05 ]
CUSP 2009 63 -13.4 (12.6) 60 -5.1 (15.5) 6.9 % -8.30 [ -13.31, -3.29 ]
FOCUS 2014 350 -0.32 (16.2) 345 0.88 (15.5) 8.5 % -1.20 [ -3.56, 1.16 ]
IMPACT 2014 242 -5.9 (20.6) 249 -4.6 (20.9) 7.8 % -1.30 [ -4.97, 2.37 ]
Kanyini GAP 2014 283 139 (15.2) 285 140.5 (15.2) 8.4 % -1.50 [ -4.00, 1.00 ]
Malekzadeh 2010 241 -3.7 (23.9) 234 -1.3 (25.1) 7.3 % -2.40 [ -6.81, 2.01 ]
OLSTA 2016 61 132.6 (17.9) 36 153.4 (19.1) 5.2 % -20.80 [ -28.49, -13.11 ]
PILL 2011 189 -16.7 (16.2) 189 -6.8 (16.5) 8.0 % -9.90 [ -13.20, -6.60 ]
Soliman 2009 99 -28.8 (24.9) 104 -26.9 (25.7) 5.7 % -1.90 [ -8.86, 5.06 ]
TIPS 2009 392 -12.4 (12.3) 390 -5 (12.3) 8.8 % -7.40 [ -9.12, -5.68 ]
TOGETHER 2010 118 -4 (11) 115 -1 (12.5) 8.2 % -3.00 [ -6.03, 0.03 ]
UMPIRE 2013 1002 -7.8 (17.7) 1002 -6 (16.1) 8.9 % -1.80 [ -3.28, -0.32 ]
Wald 2012 86 -17.9 (10.4) 86 0 (16) 7.6 % -17.90 [ -21.93, -13.87 ]
Total (95% CI) 3886 3752 100.0 % -6.34 [ -9.03, -3.64 ]
Heterogeneity: Tau2 = 20.83; Chi2 = 144.46, df = 12 (P<0.00001); I2 =92%
Test for overall effect: Z = 4.60 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Blood pressure, Outcome 2 Diastolic blood pressure.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 3 Blood pressure
Outcome: 2 Diastolic blood pressure
Study or subgroup FDC Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CRUCIAL 2011 760 -10.5 (10.2) 657 -5.3 (9.5) 8.8 % -5.20 [ -6.23, -4.17 ]
CUSP 2009 63 -9.1 (8.5) 60 -5.8 (10.9) 6.3 % -3.30 [ -6.77, 0.17 ]
FOCUS 2014 350 -0.11 (9.7) 345 0.38 (10.1) 8.5 % -0.49 [ -1.96, 0.98 ]
IMPACT 2014 242 -2.5 (11.9) 239 -1.9 (12.2) 7.8 % -0.60 [ -2.75, 1.55 ]
Kanyini GAP 2014 283 79 (8.5) 285 79.9 (8.5) 8.5 % -0.90 [ -2.30, 0.50 ]
Malekzadeh 2010 241 -0.8 (14.8) 234 -0.1 (14.4) 7.2 % -0.70 [ -3.33, 1.93 ]
OLSTA 2016 61 82.1 (9.8) 36 93 (9.2) 5.8 % -10.90 [ -14.78, -7.02 ]
PILL 2011 189 -8.1 (10.2) 189 -2.9 (10.3) 7.9 % -5.20 [ -7.27, -3.13 ]
Soliman 2009 99 -11.3 (12.3) 104 -10.8 (12) 6.4 % -0.50 [ -3.85, 2.85 ]
TIPS 2009 392 -8.1 (8.1) 390 -2.5 (8.1) 8.7 % -5.60 [ -6.74, -4.46 ]
TOGETHER 2010 118 -1.7 (8.2) 115 -1.1 (7) 8.0 % -0.60 [ -2.56, 1.36 ]
UMPIRE 2013 1002 -4.6 (9.14) 1002 -3.1 (9.13) 9.0 % -1.50 [ -2.30, -0.70 ]
Wald 2012 86 -9.8 (8) 86 0 (10) 7.1 % -9.80 [ -12.51, -7.09 ]
Total (95% CI) 3886 3742 100.0 % -3.33 [ -4.86, -1.79 ]
Heterogeneity: Tau2 = 6.68; Chi2 = 131.28, df = 12 (P<0.00001); I2 =91%
Test for overall effect: Z = 4.24 (P = 0.000022)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Blood pressure, Outcome 3 Systolic blood pressure: primary prevention trials.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 3 Blood pressure
Outcome: 3 Systolic blood pressure: primary prevention trials
Study or subgroup FDC Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CUSP 2009 63 -13.4 (12.6) 60 -5.1 (15.5) 12.1 % -8.30 [ -13.31, -3.29 ]
Malekzadeh 2010 241 -3.7 (23.9) 234 -1.3 (25.1) 12.7 % -2.40 [ -6.81, 2.01 ]
OLSTA 2016 61 132.6 (17.9) 36 153.4 (19.1) 9.3 % -20.80 [ -28.49, -13.11 ]
PILL 2011 189 -16.7 (16.2) 189 -6.8 (16.5) 13.8 % -9.90 [ -13.20, -6.60 ]
Soliman 2009 99 -28.8 (24.9) 104 -26.9 (25.7) 10.0 % -1.90 [ -8.86, 5.06 ]
TIPS 2009 392 -12.4 (12.3) 390 -5 (12.3) 14.9 % -7.40 [ -9.12, -5.68 ]
TOGETHER 2010 118 -4 (11) 115 -1 (12.5) 14.0 % -3.00 [ -6.03, 0.03 ]
Wald 2012 86 -17.9 (10.4) 86 0 (16) 13.1 % -17.90 [ -21.93, -13.87 ]
Total (95% CI) 1249 1214 100.0 % -8.67 [ -12.41, -4.94 ]
Heterogeneity: Tau2 = 23.50; Chi2 = 55.06, df = 7 (P<0.00001); I2 =87%
Test for overall effect: Z = 4.55 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Blood pressure, Outcome 4 Systolic blood pressure: secondary prevention trial.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 3 Blood pressure
Outcome: 4 Systolic blood pressure: secondary prevention trial
Study or subgroup FDC Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CRUCIAL 2011 760 -19.8 (17.1) 657 -10 (16.4) 20.8 % -9.80 [ -11.55, -8.05 ]
FOCUS 2014 350 -0.32 (16.2) 345 0.88 (15.5) 20.1 % -1.20 [ -3.56, 1.16 ]
IMPACT 2014 242 -5.9 (20.6) 249 -4.6 (20.9) 18.1 % -1.30 [ -4.97, 2.37 ]
Kanyini GAP 2014 283 139 (15.2) 285 140.5 (15.2) 19.9 % -1.50 [ -4.00, 1.00 ]
UMPIRE 2013 1002 -7.8 (17.7) 1002 -6 (16.1) 21.1 % -1.80 [ -3.28, -0.32 ]
Total (95% CI) 2637 2538 100.0 % -3.20 [ -6.98, 0.59 ]
Heterogeneity: Tau2 = 17.14; Chi2 = 62.04, df = 4 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.65 (P = 0.098)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Blood pressure, Outcome 5 Systolic blood pressure: comparator as usual care.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 3 Blood pressure
Outcome: 5 Systolic blood pressure: comparator as usual care
Study or subgroup FDC Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CRUCIAL 2011 760 -19.8 (17.1) 657 -10 (16.4) 22.3 % -9.80 [ -11.55, -8.05 ]
IMPACT 2014 242 -5.9 (20.6) 239 -4.6 (20.9) 19.6 % -1.30 [ -5.01, 2.41 ]
Kanyini GAP 2014 283 139 (15.2) 285 140.5 (15.2) 21.4 % -1.50 [ -4.00, 1.00 ]
Soliman 2009 99 -28.8 (24.9) 104 -26.9 (25.7) 14.1 % -1.90 [ -8.86, 5.06 ]
UMPIRE 2013 1002 -7.8 (17.7) 1002 -6 (16.1) 22.5 % -1.80 [ -3.28, -0.32 ]
Total (95% CI) 2386 2287 100.0 % -3.44 [ -7.61, 0.74 ]
Heterogeneity: Tau2 = 19.56; Chi2 = 56.81, df = 4 (P<0.00001); I2 =93%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Blood pressure, Outcome 6 Systolic blood pressure: placebo or inactive control.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 3 Blood pressure
Outcome: 6 Systolic blood pressure: placebo or inactive control
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
CUSP 2009 63 -13.4 (12.6) 60 -5.1 (15.5) 15.2 % -8.30 [ -13.31, -3.29 ]
Malekzadeh 2010 241 -3.7 (23.9) 234 -1.3 (25.1) 19.6 % -2.40 [ -6.81, 2.01 ]
OLSTA 2016 61 132.6 (17.9) 36 153.4 (19.1) 6.5 % -20.80 [ -28.49, -13.11 ]
PILL 2011 189 -16.7 (16.2) 189 -6.8 (16.5) 35.2 % -9.90 [ -13.20, -6.60 ]
Wald 2012 86 -17.9 (10.4) 86 0 (16) 23.5 % -17.90 [ -21.93, -13.87 ]
Total (95% CI) 640 605 100.0 % -10.77 [ -12.72, -8.81 ]
Heterogeneity: Chi2 = 33.59, df = 4 (P<0.00001); I2 =88%
Test for overall effect: Z = 10.80 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Blood pressure, Outcome 7 Systolic blood pressure: 3+ drugs only.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 3 Blood pressure
Outcome: 7 Systolic blood pressure: 3+ drugs only
Study or subgroup FDC Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
FOCUS 2014 350 -0.32 (16.2) 345 0.88 (15.5) 12.1 % -1.20 [ -3.56, 1.16 ]
IMPACT 2014 242 -5.9 (20.6) 239 -4.6 (20.9) 10.9 % -1.30 [ -5.01, 2.41 ]
Kanyini GAP 2014 283 139 (15.2) 285 140.5 (15.2) 12.0 % -1.50 [ -4.00, 1.00 ]
Malekzadeh 2010 241 -3.7 (23.9) 234 -1.3 (25.1) 10.3 % -2.40 [ -6.81, 2.01 ]
PILL 2011 189 -16.7 (16.2) 189 -6.8 (16.5) 11.3 % -9.90 [ -13.20, -6.60 ]
Soliman 2009 99 -28.8 (24.9) 104 -26.9 (25.7) 7.8 % -1.90 [ -8.86, 5.06 ]
TIPS 2009 392 -12.4 (12.3) 390 -5 (12.3) 12.5 % -7.40 [ -9.12, -5.68 ]
UMPIRE 2013 1002 -7.8 (17.7) 1002 -6 (16.1) 12.6 % -1.80 [ -3.28, -0.32 ]
Wald 2012 86 -17.9 (10.4) 86 0 (16) 10.6 % -17.90 [ -21.93, -13.87 ]
Total (95% CI) 2884 2874 100.0 % -5.03 [ -8.13, -1.93 ]
Heterogeneity: Tau2 = 19.28; Chi2 = 93.23, df = 8 (P<0.00001); I2 =91%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Fixed-dose combination Comparator
98Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.8. Comparison 3 Blood pressure, Outcome 8 Systolic blood pressure: 2 drugs.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 3 Blood pressure
Outcome: 8 Systolic blood pressure: 2 drugs
Study or subgroup FDC Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CRUCIAL 2011 760 -19.8 (17.1) 657 -10 (16.4) 29.8 % -9.80 [ -11.55, -8.05 ]
CUSP 2009 63 -13.4 (12.6) 60 -5.1 (15.5) 23.9 % -8.30 [ -13.31, -3.29 ]
OLSTA 2016 61 132.6 (17.9) 36 153.4 (19.1) 18.4 % -20.80 [ -28.49, -13.11 ]
TOGETHER 2010 118 -4 (11) 115 -1 (12.5) 27.9 % -3.00 [ -6.03, 0.03 ]
Total (95% CI) 1002 868 100.0 % -9.56 [ -14.75, -4.38 ]
Heterogeneity: Tau2 = 22.70; Chi2 = 24.65, df = 3 (P = 0.00002); I2 =88%
Test for overall effect: Z = 3.62 (P = 0.00030)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Fixed-dose combination Comparator
99Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.1. Comparison 4 Lipids, Outcome 1 Total cholesterol.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 4 Lipids
Outcome: 1 Total cholesterol
Study or subgroup FDC Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CRUCIAL 2011 760 -0.45 (0.48) 657 0.02 (0.47) 9.6 % -0.47 [ -0.52, -0.42 ]
CUSP 2009 63 -0.72 (0.32) 60 0.09 (0.37) 9.4 % -0.81 [ -0.93, -0.69 ]
IMPACT 2014 242 -0.18 (0.8) 239 -0.11 (0.79) 9.4 % -0.07 [ -0.21, 0.07 ]
Kanyini GAP 2014 261 4.39 (0.81) 254 4.31 (0.81) 9.4 % 0.08 [ -0.06, 0.22 ]
Malekzadeh 2010 241 -0.89 (1.53) 234 -0.27 (1.39) 8.8 % -0.62 [ -0.88, -0.36 ]
PILL 2011 189 -0.99 (1.24) 189 -0.15 (0.96) 9.0 % -0.84 [ -1.06, -0.62 ]
Soliman 2009 99 -1.4 (1.2) 104 -1 (1.6) 8.0 % -0.40 [ -0.79, -0.01 ]
TIPS 2009 375 -0.75 (0.9) 189 0.18 (0.9) 9.3 % -0.93 [ -1.09, -0.77 ]
TOGETHER 2010 118 -1.47 (0.71) 115 0.1 (0.63) 9.2 % -1.57 [ -1.74, -1.40 ]
UMPIRE 2013 1002 -0.1 (1.03) 1002 -0.1 (1.03) 9.5 % 0.0 [ -0.09, 0.09 ]
Wald 2012 86 -1.16 (1.18) 86 0 (1) 8.4 % -1.16 [ -1.49, -0.83 ]
Total (95% CI) 3436 3129 100.0 % -0.61 [ -0.88, -0.35 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 441.55, df = 10 (P<0.00001); I2 =98%
Test for overall effect: Z = 4.51 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Lipids, Outcome 2 LDL cholesterol.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 4 Lipids
Outcome: 2 LDL cholesterol
Study or subgroup FDC Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CRUCIAL 2011 760 -0.66 (0.71) 657 0.07 (0.81) 8.6 % -0.73 [ -0.81, -0.65 ]
CUSP 2009 63 -1.03 (0.44) 59 0.13 (0.69) 8.3 % -1.16 [ -1.37, -0.95 ]
FOCUS 2014 350 0.14 (1.43) 345 0.06 (0.76) 8.4 % 0.08 [ -0.09, 0.25 ]
IMPACT 2014 242 -0.21 (0.68) 239 -0.16 (0.64) 8.5 % -0.05 [ -0.17, 0.07 ]
Kanyini GAP 2014 261 2.23 (0.69) 254 2.23 (0.69) 8.5 % 0.0 [ -0.12, 0.12 ]
Malekzadeh 2010 241 -0.6 (0.56) 234 -0.15 (0.96) 8.5 % -0.45 [ -0.59, -0.31 ]
OLSTA 2016 61 1.9 (0.7) 36 4 (1.1) 7.4 % -2.10 [ -2.50, -1.70 ]
PILL 2011 189 -0.93 (0.96) 189 -0.18 (0.96) 8.3 % -0.75 [ -0.94, -0.56 ]
TIPS 2009 375 -0.7 (0.79) 189 0.02 (0.8) 8.5 % -0.72 [ -0.86, -0.58 ]
TOGETHER 2010 118 -1.27 (0.6) 115 0.01 (0.65) 8.4 % -1.28 [ -1.44, -1.12 ]
UMPIRE 2013 1002 -0.15 (1.49) 1002 -0.11 (1.48) 8.5 % -0.04 [ -0.17, 0.09 ]
Wald 2012 86 -1.4 (0.95) 86 0 (0.9) 8.0 % -1.40 [ -1.68, -1.12 ]
Total (95% CI) 3748 3405 100.0 % -0.70 [ -0.98, -0.41 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 496.20, df = 11 (P<0.00001); I2 =98%
Test for overall effect: Z = 4.82 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Lipids, Outcome 3 Total cholesterol: primary prevention trials.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 4 Lipids
Outcome: 3 Total cholesterol: primary prevention trials
Study or subgroup FDC Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CUSP 2009 63 -0.72 (0.32) 59 0.09 (0.37) 15.7 % -0.81 [ -0.93, -0.69 ]
Malekzadeh 2010 241 -0.89 (1.53) 234 -0.27 (1.39) 14.0 % -0.62 [ -0.88, -0.36 ]
PILL 2011 189 -0.99 (1.24) 189 -0.15 (0.96) 14.6 % -0.84 [ -1.06, -0.62 ]
Soliman 2009 99 -1.4 (1.2) 104 -1 (1.6) 12.1 % -0.40 [ -0.79, -0.01 ]
TIPS 2009 375 -0.75 (0.9) 189 0.18 (0.9) 15.4 % -0.93 [ -1.09, -0.77 ]
TOGETHER 2010 118 -1.47 (0.71) 115 0.1 (0.63) 15.2 % -1.57 [ -1.74, -1.40 ]
Wald 2012 86 -1.16 (1.18) 86 0 (1) 13.0 % -1.16 [ -1.49, -0.83 ]
Total (95% CI) 1171 976 100.0 % -0.92 [ -1.18, -0.65 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 71.00, df = 6 (P<0.00001); I2 =92%
Test for overall effect: Z = 6.76 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Lipids, Outcome 4 Total cholesterol: secondary prevention trials.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 4 Lipids
Outcome: 4 Total cholesterol: secondary prevention trials
Study or subgroup FDC Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CRUCIAL 2011 760 -0.45 (0.48) 657 0.02 (0.47) 31.2 % -0.47 [ -0.52, -0.42 ]
IMPACT 2014 242 -0.18 (0.8) 239 -0.11 (0.79) 29.7 % -0.07 [ -0.21, 0.07 ]
Kanyini GAP 2014 261 4.39 (8.1) 254 4.31 (0.81) 8.3 % 0.08 [ -0.91, 1.07 ]
UMPIRE 2013 1002 -0.1 (1.03) 1002 -0.1 (1.03) 30.7 % 0.0 [ -0.09, 0.09 ]
Total (95% CI) 2265 2152 100.0 % -0.16 [ -0.49, 0.17 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 95.54, df = 3 (P<0.00001); I2 =97%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Lipids, Outcome 5 Total cholesterol: comparator as usual care.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 4 Lipids
Outcome: 5 Total cholesterol: comparator as usual care
Study or subgroup FDC Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CRUCIAL 2011 760 -0.45 (0.48) 657 0.02 (0.47) 21.7 % -0.47 [ -0.52, -0.42 ]
IMPACT 2014 242 -0.18 (0.8) 239 -0.11 (0.79) 20.7 % -0.07 [ -0.21, 0.07 ]
Kanyini GAP 2014 261 4.39 (0.81) 254 4.31 (0.81) 20.8 % 0.08 [ -0.06, 0.22 ]
Soliman 2009 99 -1.4 (1.2) 104 -1 (1.6) 15.4 % -0.40 [ -0.79, -0.01 ]
UMPIRE 2013 1002 -0.1 (1.03) 1002 -0.1 (1.03) 21.4 % 0.0 [ -0.09, 0.09 ]
Total (95% CI) 2364 2256 100.0 % -0.16 [ -0.44, 0.12 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 126.32, df = 4 (P<0.00001); I2 =97%
Test for overall effect: Z = 1.14 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 Lipids, Outcome 6 Total cholesterol: placebo or inactive control.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 4 Lipids
Outcome: 6 Total cholesterol: placebo or inactive control
Study or subgroup FDC Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CUSP 2009 63 -0.72 (0.32) 60 0.09 (0.37) 37.7 % -0.81 [ -0.93, -0.69 ]
Malekzadeh 2010 241 -0.89 (1.53) 234 -0.27 (1.39) 21.1 % -0.62 [ -0.88, -0.36 ]
PILL 2011 189 -0.99 (1.24) 189 -0.15 (0.96) 25.0 % -0.84 [ -1.06, -0.62 ]
Wald 2012 86 -1.16 (1.18) 86 0 (1) 16.1 % -1.16 [ -1.49, -0.83 ]
Total (95% CI) 579 569 100.0 % -0.83 [ -0.99, -0.67 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.44, df = 3 (P = 0.09); I2 =53%
Test for overall effect: Z = 10.15 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 Lipids, Outcome 7 Total cholesterol: 3+ drugs only.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 4 Lipids
Outcome: 7 Total cholesterol: 3+ drugs only
Study or subgroup FDC Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
IMPACT 2014 242 -0.18 (0.8) 239 -0.11 (0.79) 13.0 % -0.07 [ -0.21, 0.07 ]
Kanyini GAP 2014 261 4.39 (0.81) 254 4.31 (0.81) 13.0 % 0.08 [ -0.06, 0.22 ]
Malekzadeh 2010 241 -0.89 (1.53) 234 -0.27 (1.39) 12.3 % -0.62 [ -0.88, -0.36 ]
PILL 2011 189 -0.99 (1.24) 189 -0.15 (0.96) 12.6 % -0.84 [ -1.06, -0.62 ]
Soliman 2009 99 -1.4 (1.2) 104 -1 (1.6) 11.2 % -0.40 [ -0.79, -0.01 ]
TIPS 2009 375 -0.75 (0.9) 189 0.18 (0.9) 13.0 % -0.93 [ -1.09, -0.77 ]
UMPIRE 2013 1002 -0.1 (1.03) 1002 -0.1 (1.03) 13.2 % 0.0 [ -0.09, 0.09 ]
Wald 2012 86 -1.16 (1.18) 86 0 (1) 11.7 % -1.16 [ -1.49, -0.83 ]
Total (95% CI) 2495 2297 100.0 % -0.48 [ -0.80, -0.16 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 193.43, df = 7 (P<0.00001); I2 =96%
Test for overall effect: Z = 2.95 (P = 0.0032)
Test for subgroup differences: Not applicable
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Analysis 4.8. Comparison 4 Lipids, Outcome 8 Total cholesterol: 2 drugs.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 4 Lipids
Outcome: 8 Total cholesterol: 2 drugs
Study or subgroup FDC Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CRUCIAL 2011 760 -0.45 (0.48) 657 0.02 (0.47) 33.8 % -0.47 [ -0.52, -0.42 ]
CUSP 2009 63 -0.72 (0.32) 60 0.09 (0.37) 33.4 % -0.81 [ -0.93, -0.69 ]
TOGETHER 2010 118 -1.47 (0.71) 115 0.1 (0.63) 32.8 % -1.57 [ -1.74, -1.40 ]
Total (95% CI) 941 832 100.0 % -0.94 [ -1.50, -0.38 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 159.25, df = 2 (P<0.00001); I2 =99%
Test for overall effect: Z = 3.31 (P = 0.00095)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Adherence, Outcome 1 Adherence.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 5 Adherence
Outcome: 1 Adherence
Study or subgroup FDC Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FOCUS 2014 178/350 141/345 21.9 % 1.24 [ 1.06, 1.47 ]
IMPACT 2014 208/256 119/257 23.6 % 1.75 [ 1.52, 2.03 ]
Kanyini GAP 2014 213/311 143/312 23.8 % 1.49 [ 1.30, 1.72 ]
UMPIRE 2013 829/1002 621/1002 30.8 % 1.33 [ 1.26, 1.41 ]
Total (95% CI) 1919 1916 100.0 % 1.44 [ 1.26, 1.65 ]
Total events: 1428 (FDC), 1024 (Usual care)
Heterogeneity: Tau2 = 0.01; Chi2 = 14.82, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 5.36 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Adherence, Outcome 2 Adherence: usual care as comparator.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 5 Adherence
Outcome: 2 Adherence: usual care as comparator
Study or subgroup FDC Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
IMPACT 2014 208/256 119/257 13.5 % 1.75 [ 1.52, 2.03 ]
Kanyini GAP 2014 213/311 143/312 16.2 % 1.49 [ 1.30, 1.72 ]
UMPIRE 2013 829/1002 621/1002 70.4 % 1.33 [ 1.26, 1.41 ]
Total (95% CI) 1569 1571 100.0 % 1.42 [ 1.35, 1.49 ]
Total events: 1250 (FDC), 883 (Usual care)
Heterogeneity: Chi2 = 13.32, df = 2 (P = 0.001); I2 =85%
Test for overall effect: Z = 13.68 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Adherence, Outcome 3 Adherence: comparator provision of individual drugs.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 5 Adherence
Outcome: 3 Adherence: comparator provision of individual drugs
Study or subgroup FDC Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
FOCUS 2014 178/350 141/345 100.0 % 1.24 [ 1.06, 1.47 ]
Total (95% CI) 350 345 100.0 % 1.24 [ 1.06, 1.47 ]
Total events: 178 (FDC), 141 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0087)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Discontinuation, Outcome 1 Discontinuation.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 6 Discontinuation
Outcome: 1 Discontinuation
Study or subgroup FDC Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CUSP 2009 7/66 6/64 4.1 % 1.13 [ 0.40, 3.18 ]
FOCUS 2014 14/350 13/345 8.9 % 1.06 [ 0.51, 2.23 ]
Malekzadeh 2010 24/241 15/234 10.3 % 1.55 [ 0.84, 2.89 ]
PILL 2011 44/189 33/189 22.3 % 1.33 [ 0.89, 2.00 ]
TIPS 2009 66/412 83/612 45.2 % 1.18 [ 0.88, 1.59 ]
TOGETHER 2010 15/122 11/122 7.4 % 1.36 [ 0.65, 2.85 ]
Wald 2012 0/86 2/86 1.7 % 0.20 [ 0.01, 4.11 ]
Total (95% CI) 1466 1652 100.0 % 1.24 [ 1.01, 1.51 ]
Total events: 170 (FDC), 163 (Comparator)
Heterogeneity: Chi2 = 2.40, df = 6 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.037)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Health-related quality of life, Outcome 1 EQ-5D health state.
Review: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
Comparison: 7 Health-related quality of life
Outcome: 1 EQ-5D health state
Study or subgroup FDC Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
IMPACT 2014 238 80 (17) 241 80 (17) 16.6 % 0.0 [ -3.04, 3.04 ]
Kanyini GAP 2014 304 79.2 (20.9) 305 77.5 (22.7) 12.8 % 1.70 [ -1.77, 5.17 ]
UMPIRE 2013 961 82 (17) 960 82 (16) 70.6 % 0.0 [ -1.48, 1.48 ]
Total (95% CI) 1503 1506 100.0 % 0.22 [ -1.02, 1.46 ]
Heterogeneity: Chi2 = 0.81, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Comparator Fixed-dose combination
A D D I T I O N A L T A B L E S
Table 1. Polypill content by trial
Study Polypill contents (dose) Comparator
CRUCIAL 2011 Amlodipine 5 mg to 10 mg
Atorvastatin 10 mga
Usual care
CUSP 2009 Amlodipine 5 mg
Atorvastatin 20 mg
Placebo
FOCUS 2014 Aspirin 100 mg
Ramipril 2.5 mg, 5 mg, or 10 mg
Simvastatin 40 mg
Individual components:
Aspirin 100 mg
Ramipril 2.5 mg, 5 mg, or 10 mg
Simvastatin 40 mg
IMPACT 2014 Aspirin 75 mg
Atenolol 50 mg
Lisinopril 10 mg
Simvastatin 40 mg
or
Aspirin 75 mg
Hydrochlorothiazide 12.5 mg
Usual care
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Table 1. Polypill content by trial (Continued)
Lisinopril 10 mg
Simvastatin 4 0mg
Kanyini GAP 2014 Aspirin 75 mg
Atenolol 50 mg
Lisinopril 10 mg
Simvastatin 40 mg
or
Aspirin 75 mg
Hydrochlorothiazide 12.5 mg
Lisinopril 10 mg
Simvastatin 40 mg
Usual care
Malekzadeh 2010 Aspirin 81 mg
Atorvastatin 20 mg
Enalapril 2.5 mg
Hydrochlorothiazide 12.5 mg
Placebo
OLSTA 2016 Olmesartan 40 mg
Rosuvastatin 20 mg
1. Olmesartan 40 mg,
2. rosuvastatin 20 mg, or
3. placebo
PILL 2011 Aspirin 75 mg
Hydrochlorothiazide 12.5 mg
Lisinopril 10 mg
Simvastatin 20 mg
Placebo
Soliman 2009 Aspirin 75 mg
Hydrochlorothiazide 12.5 mg
Lisinopril 10 mg
Simvastatin 20 mg
Usual care
TIPS 2009 Aspirin 100 mg
Atenolol 50 mg
Hydrochlorothiazide 12.5 mg
Ramipril 5 mg
Simvastatin 20 mg
8 other drug/drug combination groups:
1. Aspirin 100 mg
2. Aspirin 100 mg, hydrochlorothiazide 12.5 mg,
atenolol 50 mg, ramipril 5 mg
3. Hydrochlorothiazide 12.5 mg
4. Hydrochlorothiazide 12.5 mg, atenolol 50 mg
5. Hydrochlorothiazide 12.5 mg, ramipril 5 mg
6. Hydrochlorothiazide 12.5 mg, atenolol 50 mg,
ramipril 5 mg
7. Ramipril 5 mg, atenolol 50 mg, or
8. Simvastatin 20 mg
TOGETHER 2010 Amlodipine 5 mg to 10 mg
Atorvastatin 10 mg
Amlodipine 5 mg, 10 mg
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Table 1. Polypill content by trial (Continued)
UMPIRE 2013 Aspirin 75 mg
Atenolol 50 mg
Lisinopril 10 mg
Simvastatin 40 mg
or
Aspirin 75 mg
Hydrochlorothiazide 12.5 mg
Lisinopril 10 mg
Simvastatin 40 mg
Usual care
Wald 2012 Amlodipine 2.5 mg
Hydrochlorothiazide 12.5 mg
Losartan 25 mg
Simvastatin 40 mg
Placebo
aSite investigators could request dosages of amlodipine and atorvastatin 5/20 mg and 10/20 mg.
A P P E N D I C E S
Appendix 1. Search strategies 2012
The Cochrane Library
#1 MeSH descriptor Cardiovascular Diseases explode all trees
#2 cardio*
#3 cardia*
#4 heart*
#5 coronary*
#6 angina*
#7 ventric*
#8 myocard*
#9 pericard*
#10 isch?em*
#11 emboli*
#12 arrhythmi*
#13 thrombo*
#14 atrial fibrillat*
#15 tachycardi*
#16 endocardi*
#17 (sick next sinus)
#18 MeSH descriptor Stroke explode all trees
#19 (stroke or stokes)
#20 cerebrovasc*
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#21 cerebral vascular
#22 apoplexy
#23 (brain near/2 accident)
#24 ((brain* or cerebral or lacunar) near/2 infarct*)
#25 MeSH descriptor Hypertension explode all trees
#26 hypertensi*
#27 peripheral next arter* next disease*
#28 ((high or increased or elevated) near/2 (blood next pressure))
#29 MeSH descriptor Hyperlipidemias explode all trees
#30 hyperlipid*
#31 hyperlip?emia*
#32 hypercholesterol*
#33 hypercholester?emia*
#34 hyperlipoprotein?emia*
#35 hypertriglycerid?emia*
#36 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31
OR #32 OR #33 OR #34 OR #35)
#37 MeSH descriptor Drug Combinations, this term only
#38 polypill*
#39 (drug near/2 combin*)
#40 ((multi* or several) near/2 (ingredient* or component))
#41 policap
#42 quintapill
#43 (single near/2 pill* near/2 comb*)
#44 single-pill
#45 Red Heart pill*
#46 (#37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45)
#47 36 and 46, from 2000 to 2012
MEDLINE Ovid
1 exp Cardiovascular Diseases/
2 cardio*.tw.
3 cardia*.tw.
4 heart*.tw.
5 coronary*.tw.
6 angina*.tw.
7 ventric*.tw.
8 myocard*.tw.
9 pericard*.tw.
10 isch?em*.tw.
11 emboli*.tw.
12 arrhythmi*.tw.
13 thrombo*.tw.
14 atrial fibrillat*.tw.
15 tachycardi*.tw.
16 endocardi*.tw.
17 (sick adj sinus).tw.
18 exp Stroke/
19 (stroke or stokes).tw.
20 cerebrovasc*.tw.
21 cerebral vascular.tw.
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22 apoplexy.tw.
23 (brain adj2 accident*).tw.
24 ((brain* or cerebral or lacunar) adj2 infarct*).tw.
25 exp Hypertension/
26 hypertensi*.tw.
27 peripheral arter* disease*.tw.
28 ((high or increased or elevated) adj2 blood pressure).tw.
29 exp Hyperlipidemias/
30 hyperlipid*.tw.
31 hyperlip?emia*.tw.
32 hypercholesterol*.tw.
33 hypercholester?emia*.tw.
34 hyperlipoprotein?emia*.tw.
35 hypertriglycerid?emia*.tw.
36 or/1-35
37 Drug Combinations/
38 polypill*.tw.
39 (drug adj2 combin*).tw.
40 ((multi* or several) adj2 (ingredient* or component*)).tw.
41 policap.tw.
42 quintapill.tw.
43 (single adj2 pill* adj2 comb*).tw.
44 single-pill.tw.
45 Red Heart pill*.tw.
46 or/37-45
47 randomised controlled trial.pt.
48 controlled clinical trial.pt.
49 randomised.ab.
50 placebo.ab.
51 drug therapy.fs.
52 randomly.ab.
53 trial.ab.
54 groups.ab.
55 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54
56 exp animals/ not humans.sh.
57 55 not 56
58 36 and 46
59 58 and 57
60 limit 59 to yr=“2000 -Current”
Embase Ovid
1 exp Cardiovascular Diseases/
2 cardio*.tw.
3 cardia*.tw.
4 heart*.tw.
5 coronary*.tw.
6 angina*.tw.
7 ventric*.tw.
8 myocard*.tw.
9 pericard*.tw.
10 isch?em*.tw.
11 emboli*.tw.
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12 arrhythmi*.tw.
13 thrombo*.tw.
14 atrial fibrillat*.tw.
15 tachycardi*.tw.
16 endocardi*.tw.
17 (sick adj sinus).tw.
18 exp cerebrovascular disease/
19 (stroke or stokes).tw.
20 cerebrovasc*.tw.
21 cerebral vascular.tw.
22 apoplexy.tw.
23 (brain adj2 accident*).tw.
24 ((brain* or cerebral or lacunar) adj2 infarct*).tw.
25 exp Hypertension/
26 hypertensi*.tw.
27 peripheral arter* disease*.tw.
28 ((high or increased or elevated) adj2 blood pressure).tw.
29 exp Hyperlipidemias/
30 hyperlipid*.tw.
31 hyperlip?emia*.tw.
32 hypercholesterol*.tw.
33 hypercholester?emia*.tw.
34 hyperlipoprotein?emia*.tw.
35 hypertriglycerid?emia*.tw.
36 or/1-35
37 Drug Combinations/
38 polypill*.tw.
39 (drug adj2 combin*).tw.
40 ((multi* or several) adj2 (ingredient* or component*)).tw.
41 policap.tw.
42 quintapill.tw.
43 (single adj2 pill* adj2 comb*).tw.
44 single-pill.tw.
45 Red Heart pill*.tw.
46 or/37-45
47 36 and 46
48 random$.tw.
49 factorial$.tw.
50 crossover$.tw.
51 cross over$.tw.
52 cross-over$.tw.
53 placebo$.tw.
54 (doubl$ adj blind$).tw.
55 (singl$ adj blind$).tw.
56 assign$.tw.
57 allocat$.tw.
58 volunteer$.tw.
59 crossover procedure/
60 double blind procedure/
61 randomised controlled trial/
62 single blind procedure/
63 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62
64 (animal/ or nonhuman/) not human/
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65 63 not 64
66 47 and 65
67 limit 66 to yr=“2000 -Current”
ISI Web of Science
25 #24 AND #23
24 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)
23 #22 AND #14
22 #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15
21 TS=(single-pill or “red heart pill”)
20 TS=(single near/2 pill* near/2 comb*)
19 TS=(policap or quintapill)
18 TS=(several near/2 ingredient* or several near/2 component)
17 TS=(multi* near/2 ingredient* or multi* near/2 component)
16 TS=(drug near/2 combin*)
15 TS=polypill*
14 #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
13 TS=(hyperlipid* or hyperlip?emia* or hyperchlosterol* or hypercholester?emia* or hyperlipoprotein?emia* or hypertriglycerid?
emia*)
12 TS=(high near/2 “blood pressure” or increased near/2 “blood pressure” or elevated near/2 “blood pressure”)
11 TS=(hypertensi* or “peripheral arter* disease*”)
10 TS=(brain* near/2 infarct* OR cerebral near/2 infarct* OR lacunar near/2 infarct*)
9 TS=(brain near/2 accident)
8 TS=apoplexy
7 TS=(stroke or strokes or cerebrovasc* or “cerebral vascular”)
6 TS=(“sick sinus”)
5 TS=(tachycardi* or endocardi*)
4 TS=“atrial fibrillat*”
3 TS=(pericard* or isch?em* or emboli* or arrhythmi* or thromo*)
2 TS=(cardia* or heart* or coronary* or angina* or ventric* or myocard*)
1 TS=(cardio)
Appendix 2. Search strategies 2013
The Cochrane Library
#1 MeSH descriptor Cardiovascular Diseases explode all trees
#2 cardio*
#3 cardia*
#4 heart*
#5 coronary*
#6 angina*
#7 ventric*
#8 myocard*
#9 pericard*
#10 isch?em*
#11 emboli*
#12 arrhythmi*
#13 thrombo*
#14 atrial fibrillat*
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#15 tachycardi*
#16 endocardi*
#17 (sick next sinus)
#18 MeSH descriptor Stroke explode all trees
#19 (stroke or stokes)
#20 cerebrovasc*
#21 cerebral vascular
#22 apoplexy
#23 (brain near/2 accident)
#24 ((brain* or cerebral or lacunar) near/2 infarct*)
#25 MeSH descriptor Hypertension explode all trees
#26 hypertensi*
#27 peripheral next arter* next disease*
#28 ((high or increased or elevated) near/2 (blood next pressure))
#29 MeSH descriptor Hyperlipidemias explode all trees
#30 hyperlipid*
#31 hyperlip?emia*
#32 hypercholesterol*
#33 hypercholester?emia*
#34 hyperlipoprotein?emia*
#35 hypertriglycerid?emia*
#36 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31
OR #32 OR #33 OR #34 OR #35)
#37 MeSH descriptor Drug Combinations, this term only
#38 polypill*
#39 (drug near/2 combin*)
#40 ((multi* or several) near/2 (ingredient* or component))
#41 policap
#42 quintapill
#43 (single near/2 pill* near/2 comb*)
#44 single-pill
#45 Red Heart pill*
#46 (#37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45)
#47 36 and 46, from 2000 to 2013
MEDLINE Ovid
1 exp Cardiovascular Diseases/
2 cardio*.tw.
3 cardia*.tw.
4 heart*.tw.
5 coronary*.tw.
6 angina*.tw.
7 ventric*.tw.
8 myocard*.tw.
9 pericard*.tw.
10 isch?em*.tw.
11 emboli*.tw.
12 arrhythmi*.tw.
13 thrombo*.tw.
14 atrial fibrillat*.tw.
15 tachycardi*.tw.
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16 endocardi*.tw.
17 (sick adj sinus).tw.
18 exp Stroke/
19 (stroke or stokes).tw.
20 cerebrovasc*.tw.
21 cerebral vascular.tw.
22 apoplexy.tw.
23 (brain adj2 accident*).tw.
24 ((brain* or cerebral or lacunar) adj2 infarct*).tw.
25 exp Hypertension/
26 hypertensi*.tw.
27 peripheral arter* disease*.tw.
28 ((high or increased or elevated) adj2 blood pressure).tw.
29 exp Hyperlipidemias/
30 hyperlipid*.tw.
31 hyperlip?emia*.tw.
32 hypercholesterol*.tw.
33 hypercholester?emia*.tw.
34 hyperlipoprotein?emia*.tw.
35 hypertriglycerid?emia*.tw.
36 or/1-35
37 Drug Combinations/
38 polypill*.tw.
39 (drug adj2 combin*).tw.
40 ((multi* or several) adj2 (ingredient* or component*)).tw.
41 policap.tw.
42 quintapill.tw.
43 (single adj2 pill* adj2 comb*).tw.
44 single-pill.tw.
45 Red Heart pill*.tw.
46 or/37-45
47 randomized controlled trial.pt.
48 controlled clinical trial.pt.
49 randomized.ab.
50 placebo.ab.
51 drug therapy.fs.
52 randomly.ab.
53 trial.ab.
54 groups.ab.
55 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54
56 exp animals/ not humans.sh.
57 55 not 56
58 36 and 46
59 58 and 57
60 limit 59 to yr=“2000 -Current”
61 (2012* or 2013*).ed.
62 60 and 61
63 limit 62 to “core clinical journals (aim)”
Embase Ovid
1 exp Cardiovascular Diseases/
2 cardio*.tw.
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3 cardia*.tw.
4 heart*.tw.
5 coronary*.tw.
6 angina*.tw.
7 ventric*.tw.
8 myocard*.tw.
9 pericard*.tw.
10 isch?em*.tw.
11 emboli*.tw.
12 arrhythmi*.tw.
13 thrombo*.tw.
14 atrial fibrillat*.tw.
15 tachycardi*.tw.
16 endocardi*.tw.
17 (sick adj sinus).tw.
18 exp cerebrovascular disease/
19 (stroke or stokes).tw.
20 cerebrovasc*.tw.
21 cerebral vascular.tw.
22 apoplexy.tw.
23 (brain adj2 accident*).tw.
24 ((brain* or cerebral or lacunar) adj2 infarct*).tw.
25 exp Hypertension/
26 hypertensi*.tw.
27 peripheral arter* disease*.tw.
28 ((high or increased or elevated) adj2 blood pressure).tw.
29 exp Hyperlipidemias/
30 hyperlipid*.tw.
31 hyperlip?emia*.tw.
32 hypercholesterol*.tw.
33 hypercholester?emia*.tw.
34 hyperlipoprotein?emia*.tw.
35 hypertriglycerid?emia*.tw.
36 or/1-35
37 Drug Combinations/
38 polypill*.tw.
39 (drug adj2 combin*).tw.
40 ((multi* or several) adj2 (ingredient* or component*)).tw.
41 policap.tw.
42 quintapill.tw.
43 (single adj2 pill* adj2 comb*).tw.
44 single-pill.tw.
45 Red Heart pill*.tw.
46 or/37-45
47 36 and 46
48 random$.tw.
49 factorial$.tw.
50 crossover$.tw.
51 cross over$.tw.
52 cross-over$.tw.
53 placebo$.tw.
54 (doubl$ adj blind$).tw.
55 (singl$ adj blind$).tw.
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56 assign$.tw.
57 allocat$.tw.
58 volunteer$.tw.
59 crossover procedure/
60 double blind procedure/
61 randomized controlled trial/
62 single blind procedure/
63 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62
64 (animal/ or nonhuman/) not human/
65 63 not 64
66 47 and 65
67 limit 66 to yr=“2000 -Current”
68 (2012* or 2013*).em.
69 67 and 68
70 limit 69 to priority journals
ISI Web of Science
25 #24 AND #23
24 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)
23 #22 AND #14
22 #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15
21 TS=(single-pill or “red heart pill”)
20 TS=(single near/2 pill* near/2 comb*)
19 TS=(policap or quintapill)
18 TS=(several near/2 ingredient* or several near/2 component)
17 TS=(multi* near/2 ingredient* or multi* near/2 component)
16 TS=(drug near/2 combin*)
15 TS=polypill*
14 #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
13 TS=(hyperlipid* or hyperlip?emia* or hyperchlosterol* or hypercholester?emia* or hyperlipoprotein?emia* or hypertriglycerid?
emia*)
12 TS=(high near/2 “blood pressure” or increased near/2 “blood pressure” or elevated near/2 “blood pressure”)
11 TS=(hypertensi* or “peripheral arter* disease*”)
10 TS=(brain* near/2 infarct* OR cerebral near/2 infarct* OR lacunar near/2 infarct*)
9 TS=(brain near/2 accident)
8 TS=apoplexy
7 TS=(stroke or strokes or cerebrovasc* or “cerebral vascular”)
6 TS=(“sick sinus”)
5 TS=(tachycardi* or endocardi*)
4 TS=“atrial fibrillat*”
3 TS=(pericard* or isch?em* or emboli* or arrhythmi* or thromo*)
2 TS=(cardia* or heart* or coronary* or angina* or ventric* or myocard*)
1 TS=(cardio)
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Appendix 3. Search strategies 2016
CENTRAL/DARE/HTA/NHS EDD
#1 MeSH descriptor Cardiovascular Diseases explode all trees
#2 cardio*
#3 cardia*
#4 heart*
#5 coronary*
#6 angina*
#7 ventric*
#8 myocard*
#9 pericard*
#10 isch?em*
#11 emboli*
#12 arrhythmi*
#13 thrombo*
#14 atrial fibrillat*
#15 tachycardi*
#16 endocardi*
#17 (sick next sinus)
#18 MeSH descriptor Stroke explode all trees
#19 (stroke or stokes)
#20 cerebrovasc*
#21 cerebral vascular
#22 apoplexy
#23 (brain near/2 accident)
#24 ((brain* or cerebral or lacunar) near/2 infarct*)
#25 MeSH descriptor Hypertension explode all trees
#26 hypertensi*
#27 peripheral next arter* next disease*
#28 ((high or increased or elevated) near/2 (blood next pressure))
#29 MeSH descriptor Hyperlipidemias explode all trees
#30 hyperlipid*
#31 hyperlip?emia*
#32 hypercholesterol*
#33 hypercholester?emia*
#34 hyperlipoprotein?emia*
#35 hypertriglycerid?emia*
#36 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31
OR #32 OR #33 OR #34 OR #35)
#37 MeSH descriptor Drug Combinations, this term only
#38 polypill*
#39 (drug near/2 combin*)
#40 ((multi* or several) near/2 (ingredient* or component))
#41 policap
#42 quintapill
#43 (single near/2 pill* near/2 comb*)
#44 single-pill
#45 Red Heart pill*
#46 (#37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45)
#47 36 and 46, from 2013 to 2016
MEDLINE OVID
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Cochrane sensitivity-maximising RCT filter applied (Handbook 2011)
1 exp Cardiovascular Diseases/
2 cardio*.tw.
3 cardia*.tw.
4 heart*.tw.
5 coronary*.tw.
6 angina*.tw.
7 ventric*.tw.
8 myocard*.tw.
9 pericard*.tw.
10 isch?em*.tw.
11 emboli*.tw.
12 arrhythmi*.tw.
13 thrombo*.tw.
14 atrial fibrillat*.tw.
15 tachycardi*.tw.
16 endocardi*.tw.
17 (sick adj sinus).tw.
18 exp Stroke/
19 (stroke or stokes).tw.
20 cerebrovasc*.tw.
21 cerebral vascular.tw.
22 apoplexy.tw.
23 (brain adj2 accident*).tw.
24 ((brain* or cerebral or lacunar) adj2 infarct*).tw.
25 exp Hypertension/
26 hypertensi*.tw.
27 peripheral arter* disease*.tw.
28 ((high or increased or elevated) adj2 blood pressure).tw.
29 exp Hyperlipidemias/
30 hyperlipid*.tw.
31 hyperlip?emia*.tw.
32 hypercholesterol*.tw.
33 hypercholester?emia*.tw.
34 hyperlipoprotein?emia*.tw.
35 hypertriglycerid?emia*.tw.
36 or/1-35
37 Drug Combinations/
38 polypill*.tw.
39 (drug adj2 combin*).tw.
40 ((multi* or several) adj2 (ingredient* or component*)).tw.
41 policap.tw.
42 quintapill.tw.
43 (single adj2 pill* adj2 comb*).tw.
44 single-pill.tw.
45 Red Heart pill*.tw.
46 or/37-45
47 randomized controlled trial.pt.
48 controlled clinical trial.pt.
49 randomized.ab.
50 placebo.ab.
51 drug therapy.fs.
52 randomly.ab.
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53 trial.ab.
54 groups.ab.
55 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54
56 exp animals/ not humans.sh.
57 55 not 56
58 36 and 46
59 58 and 57
60 limit 59 to yr=“2000 -Current”
61 (2013* or 2014* or 2015* or 2016*).ed.
62 60 and 61
Embase OVID
Cochrane RCT filter (Handbook 2011)
1 exp Cardiovascular Diseases/
2 cardio*.tw.
3 cardia*.tw.
4 heart*.tw.
5 coronary*.tw.
6 angina*.tw.
7 ventric*.tw.
8 myocard*.tw.
9 pericard*.tw.
10 isch?em*.tw.
11 emboli*.tw.
12 arrhythmi*.tw.
13 thrombo*.tw.
14 atrial fibrillat*.tw.
15 tachycardi*.tw.
16 endocardi*.tw.
17 (sick adj sinus).tw.
18 exp cerebrovascular disease/
19 (stroke or stokes).tw.
20 cerebrovasc*.tw.
21 cerebral vascular.tw.
22 apoplexy.tw.
23 (brain adj2 accident*).tw.
24 ((brain* or cerebral or lacunar) adj2 infarct*).tw.
25 exp Hypertension/
26 hypertensi*.tw.
27 peripheral arter* disease*.tw.
28 ((high or increased or elevated) adj2 blood pressure).tw.
29 exp Hyperlipidemias/
30 hyperlipid*.tw.
31 hyperlip?emia*.tw.
32 hypercholesterol*.tw.
33 hypercholester?emia*.tw.
34 hyperlipoprotein?emia*.tw.
35 hypertriglycerid?emia*.tw.
36 or/1-35
37 Drug Combinations/
38 polypill*.tw.
39 (drug adj2 combin*).tw.
40 ((multi* or several) adj2 (ingredient* or component*)).tw.
41 policap.tw.
124Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
42 quintapill.tw.
43 (single adj2 pill* adj2 comb*).tw.
44 single-pill.tw.
45 Red Heart pill*.tw.
46 or/37-45
47 36 and 46
48 random$.tw.
49 factorial$.tw.
50 crossover$.tw.
51 cross over$.tw.
52 cross-over$.tw.
53 placebo$.tw.
54 (doubl$ adj blind$).tw.
55 (singl$ adj blind$).tw.
56 assign$.tw.
57 allocat$.tw.
58 volunteer$.tw.
59 crossover procedure/
60 double blind procedure/
61 randomized controlled trial/
62 single blind procedure/
63 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62
64 (animal/ or nonhuman/) not human/
65 63 not 64
66 47 and 65
67 limit 66 to yr=“2000 -Current”
68 (2013* or 2014* or 2015* or 2016*).em.
69 67 and 68
ISI Web of Science
RCT filter adapted from Cochrane RCT filter.
25 #24 AND #23, from 2013 to 2016
24 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)
23 #22 AND #14
22 #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15
21 TS=(single-pill or “red heart pill”)
20 TS=(single near/2 pill* near/2 comb*)
19 TS=(policap or quintapill)
18 TS=(several near/2 ingredient* or several near/2 component)
17 TS=(multi* near/2 ingredient* or multi* near/2 component)
16 TS=(drug near/2 combin*)
15 TS=polypill*
14 #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
13 TS=(hyperlipid* or hyperlip?emia* or hyperchlosterol* or hypercholester?emia* or hyperlipoprotein?emia* or hypertriglycerid?
emia*)
12 TS=(high near/2 “blood pressure” or increased near/2 “blood pressure” or elevated near/2 “blood pressure”)
11 TS=(hypertensi* or “peripheral arter* disease*”)
10 TS=(brain* near/2 infarct* OR cerebral near/2 infarct* OR lacunar near/2 infarct*)
9 TS=(brain near/2 accident)
8 TS=apoplexy
7 TS=(stroke or strokes or cerebrovasc* or “cerebral vascular”)
6 TS=(“sick sinus”)
5 TS=(tachycardi* or endocardi*)
4 TS=“atrial fibrillat*”
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3 TS=(pericard* or isch?em* or emboli* or arrhythmi* or thromo*)
2 TS=(cardia* or heart* or coronary* or angina* or ventric* or myocard*)
1 TS=(cardio)
Clinical Trials Register Searches
clinicaltrials.gov
clinicaltrials.gov/ct2/home
Advanced Search
Search Terms: polypill OR “fixed dose” OR “drug combination” OR “drug combinations”
Study Type: Interventional Studies
Conditions: cardiovascular OR hypertension OR dyslipidemia OR hyperlipidemia OR hypercholesterolemia
WHO ICTRP
apps.who.int/trialsearch/
polypill AND cardiovascular OR polypill AND hypertension OR polypill AND dyslipidemia OR polypill AND hyperlipidemia OR
polypill AND hypercholesterolemia OR fixed dose AND cardiovascular OR fixed dose AND hypertension OR fixed dose AND dys-
lipidemia OR fixed dose AND hyperlipidemia OR fixed dose AND hypercholesterolemia OR drug combination AND cardiovascular
OR drug combination AND hypertension OR drug combination AND dyslipidemia OR drug combination AND hyperlipidemia OR
drug combination ANDhypercholesterolemiaOR drug combinations AND cardiovascular OR drug combinations ANDhypertension
OR drug combinations AND dyslipidemia OR drug combinations AND hyperlipidemia OR drug combinations AND hypercholes-
terolemia
WH A T ’ S N E W
Date Event Description
12 January 2017 New search has been performed The searches were re-run on 19 September 2016.
Differences between 2014 review and 2017 update: Ti-
tle changed from cardiovascular disease to atheroscle-
rotic cardiovascular disease for greater clarity in the tar-
get disease of combinations with at least one blood pres-
sure-lowering drug and one lipid-lowering drug
6 January 2017 New citation required but conclusions have not changed Four additional trials reported in this update compared
with 2014 review
No change in the overall direction and magnitude of
effects with the addition of these additional trials. More
ongoing trials identified
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The background section has been shortened. Previous inclusion of HDL cholesterol and triglycerides as outcomes were excluded, and
subgroup analysis evaluating the comparator group as usual care versus placebo or inactive control added.
Differences between 2014 review and 2017 update
In the 2017 update, cardiovascular disease has been changed to atherosclerotic cardiovascular disease for greater clarity in the target
disease of combinations with at least one blood pressure-lowering drug and one lipid-lowering drug. We also moved discontinuation
rates from the primary outcome section, where it was reported under adverse events, to an individual secondary outcome. The rationale
for this change was two-fold: 1) investigator-defined adverse event rates did not necessarily include discontinuation rates, and 2)
discontinuation rates could not be reported when the comparator group was usual care. We included trials with active single drug
comparators but not trials comparing different fixed-dose combinations. We have also removed the dose subgroup analysis because
most fixed-dose combinations included moderate doses of either blood pressure-lowering drugs, lipid-lowering drugs, or both.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticholesteremic Agents [∗administration & dosage; adverse effects]; Antihypertensive Agents [∗administration & dosage; adverse ef-
fects]; Aspirin [∗administration&dosage; adverse effects]; Blood Pressure [drug effects]; CardiovascularDiseases [mortality; ∗prevention
& control]; Cause of Death; Cholesterol [blood]; Drug Combinations; Placebo Effect; Platelet Aggregation Inhibitors [∗administration
& dosage; adverse effects]; Randomized Controlled Trials as Topic
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MeSH check words
Female; Humans; Male; Middle Aged
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